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The combination of severe ocular and distal limb malformations is rare. 
Ophthalmo-acromelic syndrome (OAS; MIM 206920) is characterised by anophthalmia 
with lower limb oligodactyly.  To date <40 cases of this autosomal recessive disorder 
have been reported. Genome-wide analysis of ~10,000 SNPs typed on two apparently 
unrelated families - comprising a total of three affected individuals, four unaffected 
siblings and their consanguineous parents - identified a large region of overlapping 
autozygosity on chromosome 14q.  Adding data from a third consanguineous family 
gave a combined LOD score of >5 with no evidence of locus heterogeneity.  
Collaborative data from a further 6 individuals refined the critical interval to a 3.4 Mb 
region on chromosome14:69,652,605-73,059,612  Mb.  To sequence all 19 known 
protein-coding genes in the region, the 238 exons were ranked by evolutionary sequence 
conservation and divided equally between the Edinburgh and Nijmegen groups. 
Complete sequence coverage has been obtained for 61% of the “Edinburgh” exons but 
no potentially causative mutations have been identified.  Further mutation analysis of the 
OAS locus is on-going. 
 
Mice homozygous for the X-ray induced Mp mutation were reportedly 
anophthalmic with hind limb oligodactyly and thus represented a potential model for 
human OAS. This line was rederived in Edinburgh and phenotypic analysis of Mp/Mp 
homozygotes showed runting, malformed pinnae with microphthalmia but not 
anophthalmia.  The apparent hind-limb oligodactyly was due to osseous syndactyly.  Mp 
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heterozygotes had milder microphthalmia and pinnae deformities, but lacked the 
syndactyly.  In both heterozygotes and homozygotes the eye malformations were fully 
penetrant, pan-ocular and characterised by failure of both the ciliary apparatus and 
vitreous body to form and abnormal retinal lamination.   
 
Genome-wide microsatellite marker analysis showed linkage of the Mp 
phenotype to chromosome 18.  Fbn2 mapped within the linkage interval and was a good 
candidate for Mp based on the finding of hind limb osseous syndactyly in Fbn2-null 
mice.  However, Fbn2-null mice have no eye phenotype.  3’-RACE identified that Mp 
was as a 660 kb inversion affecting the 3’-regions of Fbn2 and the adjacent gene Isoc1. 
This created two aberrant reciprocal fusion transcripts: Fbn2 exons 1-63 are fused to 
Isoc1 exon 5; and Isoc1 exons 1-4 are fused to Fbn2 exons 64-65. This predicts 
nonsense-mediated decay of the Isoc1 Mp transcript and production of a truncated Fbn2 Mp 
protein. 
 
Ocular development was analysed in homozygote and wild type embryos to 
define the basis of the “worse than null phenotype” seen in Mp mice.  RNA in situ 
hybridisations (ISH) failed to detect expression of Isoc1 in the embryonic eye. In 
contrast, normal expression of Fbn2 in the ciliary body and retina was consistent with 
the Mp phenotype.  A combination of EM and immunocytochemistry showed that 
truncated Fbn2 (Fbn2Mp) was retained within the ER. Fbn2Mp co-localised with markers 
of ER stress: Grp78 expression and UPR-specific  Xbp1 splicing. Signalling by Wnt2b is 
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thought to be critical for ciliary development and Lef1, a Wnt-responsive transcription 
factor, showed increased and ectopic ocular expression in the region affected by ER 
stress.  Sox2 is a direct transcriptional target of Lef1 and we observed apparent ectopic 
expression of Sox2 in the ciliary body.  Throughout the developing retina in mutant 
embryos we also observed individual cells that were ectopically expressing the 
transcription factor Chx10 and other cells expressing the apoptotic marker Activated-
Caspase-3.  The apoptotic marker did not specifically co-localise with Fbn2Mp.  
 
Taken together, these findings suggest that the ocular malformations in Mp are a 
direct result of the ER stress induced by Fbn2Mp in a specific group of cells in the early 
ciliary body.  The ER stress presumably halts post-translational modification of a 
developmentally critical signaling molecule, possibly Wnt2b, which happens to be 
expressed in the same cells.  We have termed the resulting pathological mechanism a 
synodiporic effect (synodiporia = the ones walking the street together or fellow 
travellers).   Such effects may have significant implications for human genetic disease 
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2. Introduction 
2.1. Anophthalmia and microphthalmia 
Anophthalmia (absence of the eye) and microphthalmia (small eye) are 
congenital structural abnormalities that are typically associated with significant loss of 
vision that have a prevalence rate of 0.2 and 1.7, respectively, per 10,000 live births 
(Stoll et al., 1997). Clinically, anophthalmia is heterogeneous and refers to a complete 
absence of the globe in the presence of normal ocular adnexa (eyelids, conjunctiva and 
lacrimal apparatus). Classification can be separated into true or primary anophthalmia, 
secondary anophthalmia, or apparent or clinical anophthalmia. In true primary 
anophthalmia, there is no evidence of tissues derived from the optic vesicle; in 
secondary anophthalmia the orbits of the eyes may contain some remnants derived from 
the optic vesicles. For the criteria for these classifications to be met, scanning by CT or 
MRI, or post-mortem is required. Therefore, the generally accepted classification is the 
clinical one, which refers to the apparent absence of an eyeball from examination at 
birth. Microphthalmia is classified as a small ocular globe that is less than two standard 
deviations below the mean for that age (Bardakjian, 2007). This is typically <21mm in 
adult eyes, and generally requires scanning for diagnosis. 
 
However, the classification of severe ocular malformations can also be based on 
the developmental programme that is interrupted and is more clinically robust than 
categorisation solely on the basis of eye size. Under this schema, anophthalmia results 
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from a disruption to events surrounding formation of the optic vesicle and the lens 
placode, whereas microphthalmia is more likely to result from aberrant processes that 
occur after these early events, and which coincide with a failure in correct retinal 
differentiation, lens-surface ectoderm separation, and closure of the optic fissure 
(Fitzpatrick and van Heyningen, 2005).  
 
Thorough knowledge of the major morphological processes determining early 
stages of normal eye development, complimented with identification and understanding 
of the genetic pathways and factors that are critical for these events, is required to 
further our understanding of anophthalmia/microphthalmia pathogenesis.  One useful 
method of identifying critical genetic factors involved in human development is to study 
rare mendelian syndromes. For example, understanding of the diverse functions of cell 
cilia during development has been enhanced through identification of the multiple gene 
loci mapped by studies of the genetically heterogeneous Bardet Biedl syndrome (MIM 
#209900), which in turn have lead to an increased understanding of the developmental 
pathways involved (Badano et al., 2006). This thesis describes genetic and molecular 
studies of a unique human anophthalmia syndrome, and a complementary mouse model, 
to advance our understanding of severe ocular disease. 
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2.2. Introduction to Ophthalmo acromelic syndrome 
Ophthalmo–acromelic syndrome (OAS) (MIM 206920) is a rare inherited 
disorder characterised by the association of severe ocular malformations, most 
commonly bilateral anophthalmia, with symmetrical and distinct distal limb 
abnormalities in the 4th and 5th rays of the hands and, more severely, the 5th ray of the 





Figure 2.2.1 Clinical features of OAS. OAS patients characteristically present with 
anophthalmia but normal external ocular features (A).  Forelimbs (B & C) display fused 
metacarpals [arrows], while hindlimbs (D) are lacking the entire fifth rays (arrows). 
Images used and adapted with permission from Garavelli et al., 2006.  
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The inheritance pattern is clearly autosomal recessive (see below) but the genetic 
basis of the condition is unknown. Waardenburg (Waardenburg, 1961) first described 
the condition as the “association of anophthalmia with anomalies of hands and feet” in 
two families. Subsequent reports of individuals with very similar phenotypic features led 
Traboulsi (Traboulsi et al., 1984) to suggest the name “Waardenburg Anophthalmia 
Syndrome” to describe the entity. Le Merrer (and later Al Gazali)  (al Gazali et al., 1994; 
Le Merrer et al., 1988) argued that the title “ophthalmo-acromelia” is more appropriate 
as the pattern of limb malformations is very specific and, with the anophthalmia, is a 
defining feature of this condition. Both terms are used in the literature but in this thesis 
the term Ophthalmo-acromelic syndrome (OAS) is the term of choice. The total number 
of cases known to us is 37.  
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2.3. Detailed OAS phenotype description 
A table of the phenotypes for all OAS cases published is presented (Table 1.2). 
In the first family described by Waardenburg (Waardenburg, 1961), there were two 
sisters with unilateral anophthalmia, one with a retinal coloboma in her cognate eye. 
Both had bilateral absence of the 5th ray of the foot with soft tissue syndactyly, and 
synostosis of the 4th and 5th metacarpals. 6/7 of their other siblings were normal, one 
brother had the same limb involvement but with no ocular phenotype and was thus 
considered as having mild OAS. The second family Waardenburg described consisted of 
a girl with bilateral anophthalmia, lower limb oligdactyly missing the 5th ray in both of 
her feet, short fingers bilaterally, and mental handicap. A younger sister was reportedly 
normal.  These first described cases of OAS illustrated the specificity of the limb 
anomalies, affecting the distal-most rays of both hands and feet, while also 
demonstrating the severity and range of the ocular malformations.  
 
The penetrance of ocular defects in all subsequent OAS cases published is 
particularly striking: 100% of 26 index cases reported (i.e. probands described in 
original publications) had a severe ocular phenotype, of which 20 (77%) were bilaterally 
anophthalmic. Anophthalmia is the most common ocular presentation in cases (88%), 
however some cases have been reported with a microphthalmia phenotype, and also in 
some multiplex families, affected sibs with limb malformations but no eye involvement 
have been reported. This represents a wide range in the penetrance of the ocular 
phenotype and suggests that although the eyes may be affected throughout the 
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developmental process, in the majority of cases there is a failure in formation of the 
optic vesicle. However, identification of optic nerve structures on scanning in some 
cases suggests an arrest in development after optic vesicle formation possibly coinciding 
with or immediately prior to lens induction. The cases with microphthalmia suggest a 
later defect; possibly due to aberrant proliferation of retinal progenitor cells. Coloboma 
has been reported in only one OAS case so far (Waardenburg, 1961). In this individual it 
unilateral and was associated with contralateral anophthalmia. There have been no 
further reports of colobomas in OAS patients since.1 
 
The limb phenotype is variable in severity but shows a consistent pattern with 
significant pathology most commonly restricted to the 4th and 5th rays of the hands and 
feet. Of the 26 index cases all had lower limb involvement, with the majority of these 
being 5th-ray oligodactyly (81%). Oligodactyly was generally reported as associated with 
cutaneous syndactyly of the 2-3rd toes, and with a “sandal” gap present between the 1st 
and 2nd toes. Talipes equinovarus was reported in two OAS cases from separate families 
(Kara et al., 2002; Richieri-Costa et al., 1983), and 4 cases had tibial bowing (Kara et al., 
2002; Le Merrer et al., 1988; Richieri-Costa et al., 1983; Suyugul et al., 1996). 
Involvement of the upper limb was reported in 23 (85%) cases, mostly with osseous 
synostoses between the proximal metacarpals of the 4th and 5th rays. This was often 




All of the cases studied in this thesis (Table 1.2), and the reported cases that are 
included in the review of clinical features, have been reviewed by Dr David FitzPatrick, 
a consultant in clinical genetics with an interest in dysmorphology. Anophthalmia and 
involvement of the 4th and 5th digital rays are considered cardinal features and both 
should be present in an affected sibship.  Two cases with severe eye malformations that 
were reported as OAS were excluded from further consideration as they are probably 
misdiagnoses; one case reported with ectrodactyly and polydactyly (Quarrell, 1997) and 















Neurological developmental abnormalities have been described in 10 OAS cases 
(38%), ranging from severe psychomotor retardation and very poor communication 
skills to slightly delayed motor development in comparison to an unaffected sib.  The 
data on neurocognitive impairment in OAS should be considered preliminary as many 
cases have been only examined during infancy, when accurate assessment of cognition is 
difficult. Another feature of this condition is early post-natal death, which has been 
reported to occur in 12% of index cases and 8 siblings retrospectively diagnosed with 
OAS, together totalling 29 % of all OAS cases. Most OAS deaths occurred as infants 
(less than 1 year old) with the causes of deaths largely unspecified further than as: 
“sudden” (e.g. after feeding time) (Le Merrer et al., 1988) or from a “failure to 
thrive”(Richieri-Costa et al., 1983), while others died as a result of apparently treatable 
infections. There is also a report of stillbirths occurring in 2 OAS siblings (Richieri-
Costa et al., 1983), and further reports of multiple early-miscarried pregnancies in 
families with OAS cases. Low birth weight (<p25) was reported in 50% and growth 
delay (<p25) was observed in 35% of OAS cases. 
 
A characteristic facial appearance has been suggested with a prominent forehead; 
short or slanting palpebral fissures, flat maxillary regions, long and wide philtrum, flat 
nasal bridge, thick-lobed and angulated ears, and flared nostrils. Some of these are 
secondary to the anophthalmia and are not specific. Isolated cleft palate has been 
described in a single patient. 
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Moderate deafness and two cases of mutism have been reported. Large incisors 
have been noted as has an absent prepuce. Recently diagnosed patients have had 
additional features, including: horseshoe kidney, absence of interior vena cava, a single 
umbilical artery, cervical fusion and spinal deformities.  
 
2.4. Inheritance of OAS 
An autosomal recessive pattern of inheritance for OAS has been suggested on the 
basis of definite or probable consanguinity in 17/19 families (89%). Many individuals 
had affected sibs within the same generation and no vertical transmission has been 
observed. This pattern of inheritance is also supported by the lack of any reported 
cytogenetic abnormalities where karyotypes have been analysed (n=13) and also by the 
observation that both males (n=15) and females (n=11) were similarly affected. There 
have been no reports of maternal illness, substance abuse, or exposure to teratogens, 
pathogens or radiation during pregnancy, and pregnancies have been generally described 
as ‘uneventful’.  
 
The reported cases are from a limited number of ethnic backgrounds, with the 
majority being either Turkish (n=9, 7 families) or from Arabic countries (n=7, 4 
families). There have also been three families from Italy (n=4), two from the 
Netherlands (n=3), two from Brazil (n=2), and one from Argentina (n=1).  
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2.5. Differential Diagnosis of OAS 
 Anophthalmia and microphthalmia have a combined birth incidence of ~1 
per 10,000 (Morrison et al., 2002).  Associate malformations are relatively common in 
severe eye abnormalities; however, distal limb anomalies and specifically post-axial 
oligodactyly are very rare.  Thus OAS is a relatively easy condition to diagnose and 
there are few conditions that can be considered in a differential diagnosis. 
 
Oculodentodigital dysplasia syndrome (ODDD) (MIM#164200) is characterized 
by microphthalmia or microcornea with upper limb cutaneous postaxial syndactyly. A 
common feature of ODDD is hypoplasia or aplasia of the middle phalanx of those toes 
that normally have three phalanges (digits 2-5). Nasal and dental dysmorphisms are 
characteristic in this condition.  
Lenz microphthalmia syndrome (LMS) (MIM 309800) is an X-linked recessive 
disorder presenting anophthalmia and microphthalmia, but also involving mental 
handicap, urogenital abnormalities, microcephaly, external ear, cardiac, dental and 
skeletal anomalies. However, there are currently no reports of syndactyly or oligodactyly 
in LMS.  
Isolated postaxial tetramelic oligodactyly (MIM 176240) is a yet unmapped 
autosomal dominant, non-syndromic congenital abnormality where the 5th metatarsals 
and metacarpals are absent.  
In Ulnar-Mammary Syndrome (MIM #181450), postaxial limb defects range 
from hypoplasia of the terminal phalanx of the 5th digit to total absence of forearm and 
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hand. UMS can be caused by mutations in the TBX3 gene (Bamshad et al., 1999), but no 
ocular deformities have so far been reported.  
Miller syndrome cases (MIM %263750) present with post-axial oligodactyly of 
both hands and feet, together with cleft palate, retrognathia and renal anomalies, features 
which overlap with the clinical spectrum of OAS. Nevertheless, there are no ocular 
phenotypes associated so far with this autosomal recessive syndrome. 
Another syndrome affecting the post-axial rays is Pallister-Hall syndrome, 
caused by loss of function mutations in the GLI3 gene (Kang et al., 1997). Postaxial 
polydactyly is a defining feature of this condition and ocular anomalies are not generally 
reported.   
In Tukel syndrome (MIM %609428), mapping to chromosome 21q22, patients 
have postaxial oligodactyly highly similar to the oligodactyly seen in the feet of OAS 
patients, namely the complete absence of postaxial rays. However, they do not present 
with a hind limb phenotype and furthermore the ocular findings are mild, with 
ophthalmoplegia and blepharoptosis (ocular muscle failure and droopy eyelids, 
respectively) the main features. 
Therefore, the association of severe ocular malformations with postaxial 
oligodactyly is extremely rare and it is the association anophthalmia with such a 
consistent and distinctive distal limb abnormality, bilateral postaxial foot oligodactyly, 
which is particularly intriguing in OAS, suggesting there are common pathways or 
genetic mechanisms in the development of the two distinct fields and that the genetic 
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lesion(s) in OAS patients contributes significantly to both developmental programmes. 
This condition therefore warranted genetic and molecular investigation. 
 
2.6. Utility of mouse models for human developmental diseases 
 Although the human genome project is now complete, the developmental 
function of many genes remains largely unknown. Additionally, many human 
developmental abnormalities have not been ascribed to mutated genes or genomic 
lesions. These situations are mainly associated with the general rarity of many 
interesting developmental diseases, a paucity of tissue samples and problems gaining 
sufficient DNA quantities for effective mapping strategies. In addition, there is a lack of 
in situ molecular information as a result of appropriate ethical constraints of working 
with human samples and subjects.   Nevertheless, human genetic analysis of individuals 
and families segregating severe eye and limb malformations has identified mutations in 
several developmentally regulated genes that have furthered our understanding of their 
underlying developmental processes. Inevitably however, much of our knowledge of the 
mechanisms involved in embryonic development has come from animal models, with 
the laboratory mouse contributing vast amounts of data and often the model of choice 
for understanding the molecular mechanisms in vertebrate eye and limb development. 
Human and mouse eyes are very similar, and share many structural and functional 
similarities in their ocular systems throughout both development and adulthood.  
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In both species, genes share common interacting partners at the protein level and 
are located in homologous chromosomal segments, with most genes being highly 
conserved at the sequence level due to similar selection pressures. In addition, the mouse 
provides other benefits to research of genetic diseases: inbred strains of the laboratory 
mouse are available to facilitate genetic mapping strategies using identical genetic 
backgrounds behind the disease locus; animals can be kept under uniform conditions to 
reduce the effects of environment of gene expression; tissue samples can be easily 
collected, stored, processed and manipulated; large pedigrees can be generated over 
short periods of time; and of huge importance, a wealth of genetic and molecular 
information is already available to researchers, while genes can also be specifically 
inactivated or can be non-specifically targeted by various different types of mutation 
screens.   
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2.7. The Mp mouse as a model for human OAS 
 The Mp mouse line (MGI 97070; Micropinna Microphthalmia) was 
generated in a screen for radiation-induced mutations at Oak Ridge National Laboratory 
by X-ray irradiation. It was described (Phipps, 1964) as: 
“Dominant mutation affecting eyes, external ears and feet. This mutation 
appeared in the offspring of an irradiated male. Heterozygotes invariably have 
Microphthalmia and often, in addition, reduced pinnae. Homozygotes appear to be 
eyeless and have oligodactyly of the hind feet (usually 3 toes, occasionally 4).  They are 
of very small size and most die around 12 days of age; none has survived to weaning. 
The pinnae is pesent and probably reduced in size, but, because of the early death, no 
accurate comparisons to heterozygotes can be made in this respect.” 
 
 The phenotypic features of this line overlap with human OAS, namely 
apparent anophthalmia or microphthalmia associated with hindlimb oligodactyly. This 
line was not being managed as active colonies and samples of sperm had been stored 
from affected heterozygote males. Therefore, the Mp mouse line was rederived for 
mutation and phenotype analysis in Edinburgh for the present study for genetic mapping 
and molecular analysis.  
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2.8. Vertebrate eye development 
2.8.1. Key morphogenetic events during eye development 
Mammalian ocular development can be divided into five distinct morphological 
events: (i) formation and outgrowth of the optic vesicle, (ii) lens induction and optic cup 
invagination, (iii) lens and retinal differentiation, (iv) anterior chamber formation and (v) 
formation of the periocular structures.  
 
Around the end of the third gestational week in human development and ~E8.0-
9.0 in the mouse, bilateral and symmetrical evaginations of neuroepithelium appear on 
the lateral aspects of the anterior prosencephalon and grow towards the overlying 
surface ectoderm of the primitive head. These structures, the optic vesicles, make 
contact with the surface ectoderm in regions that are visible externally as the optic 
eminences at around Carnegie Stage 12 (CS12 & ~E9.5 in mouse). Contact between the 
neural ectoderm and surface ectoderm results in a local thickening of the surface 
ectoderm to form the lens placode.  The placode begins to invaginate forming the lens 
pit, which is visible at the surface ectoderm, and then finally separates from the surface 
ectoderm to form the lens vesicle at CS15, or E11.5.  A simultaneous conformational 
change in the underlying optic vesicle forms the optic cup. This is the result of 
invagination of the optic vesicle occurring primarily in medial and ventral regions, with 
these tissues destined to become neural retina and optic nerve, respectively. The dorsal 
optic vesicle will become the outer layer of the optic cup, which develops into the 
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retinal-pigmented epithelium (RPE) distally and proximally will envelop the optic nerve 
after closure of the optic fissure along the proximal-distal axis of the developing eye. 
Lens and retinal differentiation occur concomitant with closure of this fissure. The 
primitive lens buds off from the surface epithelium to form an independent hollow 
vesicle structure. The cells within the vesicle undergo differentiation into lens-specific 
cells and the vesicle is then filled-in by the elongation and maturation of lens cells. 
Cellular organelles are then cleared from the lens cells to create the clear and functional 
lens. The highly organised multilayered mature retina containing the photoreceptors and 
their auxiliary cells develops from the region of neural retina that was in intimate contact 
with the placodal surface ectoderm at CS12-14. Dividing mitotic cells are maintained in 
their progenitor state in the morphologically developing optic cup to create sufficient 
cell numbers to supply all of the layers required in the mature retina. Periodically, the 
environment of intrinsic and extrinsic factors is mutually convivial for subsets of these 
cells to undergo specific differentiation, a process that ultimately provides the retina 
with the full complement of cell types. 
 
Further development of ocular structures such as cornea, anterior chamber, iris, 
and the ciliary processes occurs at later stages and is dependent on contributions from 




2.8.2. Genes involved in early optic development and implicated in major ocular 
malformations 
 Mutations in various genes have been identified as causative for 
anophthalmia and microphthalmia (Table 2.3). All of these genes encode transcription 
factors and the successful activation or repression of their transcriptional targets requires 
the cooperation of multiple binding partners to facilitate either an inductive or repressive 
response. They are expressed in many ocular tissues throughout the various stages of eye 
development, often within overlapping domains. Additionally, they probably operate as 
critical components of a complex network involving multiple feedback loops to ensure 
exquisite control of their own and each-others expression in a spatially and temporal 
specific manner.  





PAX6 11p13 Haploinsufficient Aniridia/ Peter’s anomaly  EF; OV; LP; LV; NR; CN 
SOX2 3q26 Haploinsufficient Anophthalmia/ Microphthalmia LP; LV; NR; CN 
RX 18q21 Recessive Anophthalmia/ Microphthalmia EF; OV; NR 
OTX2 14q21 Haploinsufficient Anophthalmia/ Microphthalmia/ Retinal defects 
OV; RPE; 
NR 
CHX10 14q24 Recessive Microphthalmia/ cataracts/ Iris abnormalities OV; NR 
MAF 16q23 Dominant Microphthalmia/ Lens, Iris & Anterior Segment abnormalities LV; LP 
BCOR Xp11 X-linked/ Dominant 
Lenz Microphthalmia Syndrome / 




Table 2.3. Genes involved in severe ocular malformations. CN, cornea; EF, eye field; 




Therefore the exact embryopathological mechanisms for severe ocular 
pathologies involving these genes are obscured. Superficially, it could be assumed that 
disruption to the function of those genes expressed at early stages, such as in the eye 
field or in the optic vesicle or lens placode, results in the most severe disorders of 
anophthalmia or microphthalmia. However, expression of mutant genes within the 
proliferating or differentiating retina, or in the RPE or developing lens vesicle, may also 
lead to equally severe malformations. The genes so far implicated in anophthalmia or 
microphthalmia are discussed below. 
  
OTX2 is a homeodomain containing transcription factor of the bicoid class, 
whose expression precedes expression of other eye transcription factors (Chow and 
Lang, 2001).  Although OTX2 expression disappears from the eye field, expression in 
the anterior neural plate prior to gastrulation suggests a role in neural induction. OTX2 
expression is subsequently activated in the dorsal region of the optic vesicle, then 
becoming refined to the developing RPE. Heterozygous loss-of-function mutations 
result in a range of severe ocular malformations, ranging from anophthalmia and 
microphthalmia to retinal defects, often associated with learning disability and brain 
defects (Ragge et al., 2005). Impaired retinal function is a universal phenotype in OTX2 
mutations, and suggests a major role in retinal differentiation, which may be the cause of 
anophthalmia if ablated during early stages (Fitzpatrick and van Heyningen, 2005). 
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The paired box gene 6, PAX6, has multiple roles in the development of the 
vertebrate eye and was the first gene to be identified as disrupted in human 
anophthalmia (Glaser et al., 1994). Subsequently, Pax6 has been described as the master 
regulator for eye development, with Pax6 expression and transcriptional targets 
identified in a wide range of tissues and processes; in the establishment and outgrowth 
of the eye field, patterning the optic vesicle and the presumptive neural retina, in RPE 
development, neural retina layer specification and differentiation, and in the formation 
of the lens pit, placode, vesicle and mature lens. Biallelic mutations in humans are rarely 
found in PAX6 as they are anophthalmic but lethal, however haploinsufficiency results 
in the highly penetrant Aniridia and Peter’s Anomaly, both significant ocular defects 
(van Heyningen and Williamson, 2002). Loss of Pax6 in the mouse causes the small eye 
(Sey) phenotype in heterozygotes (Hill et al., 1991) and anophthalmia with lethality in 
Sey/Sey homozygotes (Grindley et al., 1995).  
 
RX (or RAX) is another homeodomain-containing transcription factor and is the 
first retinal patterning gene to be expressed during eye development where it specifically 
marks the eye field in the anterior neural plate. Continual expression is observed in the 
optic vesicles and the neural retina throughout ocular development. Human 
haploinsufficiency for Rx has results in anophthalmia or microphthalmia (Voronina et 
al., 2004) and recessive loss of function in the mouse results in bilateral anophthalmia, 
as a result of failure to form optic vesicles (Mathers et al., 1997).  Loss of Rx in the 
 46 
mouse eye field results in a failure of Pax6 expression, indicating Pax6 is downstream of 
Rx and is dependent of Rx expression (Chow and Lang, 2001).  
 
Heterozygous loss of function mutations in SOX2, a HMG domain-containing 
transcription factor, have been reported as the cause of between 10-20% of human 
anophthalmia and severe microphthalmia cases, with most cases presenting with 
bilateral anophthalmia (Fantes et al., 2003; Ragge et al., 2005). These are commonly 
deletions, translocations and point mutations, consistent with haploinsufficiency for the 
SOX2 protein during ocular development, where either loss of function mutations or the 
presence of a single allele result in the same phenotype. 
In mice, a gene-dosage allelic series of Sox2 mutations has confirmed the 
requirement for Sox2 during eye development (Taranova et al., 2006). SOX2 
synergistically activates the expression of other eye-development genes in different 
regions of the eye anlagen, depending on the binding partner. In the developing chick 
lens, Sox2-Pax6 binding activates developmental expression of crystallin genes 
(Kamachi et al., 2001), while the cooperative binding of Sox2 to Otx2 at a conserved 
non-coding sequence upstream of the Rx promoter can synergistically activate Rx gene 
expression (Danno et al., 2008). 
  
CHX10 is expressed in the neural retina in development and in the inner nuclear 
layer in adult eyes. Specific expression in the presumptive neural retina during contact 
of the optic vesicle with the lens placode contributes to the proliferation of retinal 
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progenitor cells. Recessive loss of function resulting from missense changes in the 
homeodomain of this transcription factor cause human microphthalmia, cataracts and 
abnormal iris development (Ferda Percin et al., 2000). In the mouse, mutations in Chx10 
cause the ocular retardation phenotype (or), characterised by blindness, 
microphthalmia, cataracts and an absence of the optic nerve (Burmeister et al., 1996).  
The poorly differentiated retina in the or mouse is explained by a reduction in the 
proliferation of retinal precursor cells. Mutations in mouse and human CHX10 therefore 
reflect the potential for retinal dysgenesis after the optic vesicle stage to cause 
microphthalmia.  
 
The BCOR gene is a key transcriptional regulator during early embryogenesis 
and mutations result in Lenz microphthalmia and Oculofaciocardiodental syndromes, 
both X-linked pattern of inheritance and characterised by severe ocular malformations 
(Ng et al., 2004). Knock-down of the Bcor orthologue in zebrafish caused 
developmental anomalies consistent with these syndromes. In the developing mouse eye, 
Bcor expression is not obvious until after E11.5, where it is identified in the retina and 
lens tissues (Wamstad and Bardwell, 2007), temporally coinciding with the 
differentiation of these tissues. 
 
Mammalian MAF genes are involved in lens induction and differentiation and 
loss of function by a point mutation in a DNA binding domain in the mouse results in 
defective lens formation and microphthalmia (Lyon et al., 2003). MAF genes are 
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expressed in lens placode, lens vesicle and within the differentiating lens. Distant 
translocations affecting genomic control regions of the MAF locus in humans are 
associated with microphthalmia, together with other ocular deformities affecting the 
lens, anterior segment and iris, which can also arise from dominant intragenic missense 
mutations (Jamieson et al., 2002).  
Most of these transcription factors continue to be expressed within the 
neuroectoderm as the optic vesicles grow and come into contact with the overlying 
surface ectoderm and then differentiate into optic stalk, RPE and neural retina structures.  
 
2.8.3. Patterning within the optic vesicle 
The highly organised laminar structure of the mature retina is closely dependent 
on the correct position and organisation, and therefore the subsequent differentiation and 
migration of different cell types during neural retina development. Additionally, the RPE 
and optic stalk must be specified in the dorsal and ventral regions of the optic vesicle, 
respectively. Formation of a correctly oriented and patterned optic vesicle is therefore 
fundamental to normal ocular development. This process requires permissive gradients 
of morphogens to pattern the optic vesicle along opposing axes and the localised 
expression domains and boundaries of specific transcription factors to specify the 
neuroectoderm to differentiate into distinct regions of RPE, optic stalk and neural retina. 
Understandably, failure in this process can result in severe ocular malformations. 
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Ventral morphogenic signals, such as Sonic hedgehog (Shh), retinoic acid and 
noggin act to pattern the optic stalk through transcription factors Vax2 (ventral anterior 
homeobox 2), Pax2 (paired box like transcription factor 2), whereas Pax6 expression in 
the presumptive RPE and neural retina is a consequence of dorsally expressed Bmp4 
(Chow and Lang, 2001).  
 
Vax2 is almost exclusively expressed in the ventral part of the optic vesicle 
during early mouse and human ocular development and is vital for dorsal-ventral axis 
determination in the optic vesicle  (Barbieri et al., 1999; Kim and Lemke, 2006). Vax2 
overexpression in Xenopus optic vesicle leads to a ventralisation of the eye, including an 
expanded optic stalk, and a dorsalisation of Pax2 expression with a reduction in dorsal 
markers (Barbieri et al., 1999). No human ocular malformations have yet been described 
linked to mutations in Vax2. Human loss of function mutations in Pax2 cause optic 
nerve colobomata, a failure of correct optic fissure closure, while in mice, a range of 
mutations cause various optic nerve abnormalities (Barbieri et al., 1999; Favor et al., 
1996; Torres et al., 1996). Additionally, the optic nerve closure defect colobomata 
occurs in SHH mutations, indicating an upstream role in Pax2 expression regulation 
(Schimmenti et al., 2003) 
 
An opposing gradient of Bmp4, a member of the transforming growth factor beta 
family of signaling molecules, emanating from the dorsal-distal optic vesicle, determines 
a Pax6-positive region encompassing future RPE (dorsal) and neural retina (central). 
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Overexpression of Bmp4 in the optic vesicle expands the Pax6 expression domain at the 
expense of repressed Pax2. Phenotypically, this results in the extension of RPE into the 
presumptive forebrain regions and an absence of the optic stalk (Sasagawa et al., 2002). 
Additionally, expression of the constitutively active nuclear form of Vax2 in optic 
vesicles repressed Pax6 expression and resulted in eyeless chick embryos (Mui et al., 
2005).   
 
2.8.4. Lens induction and development 
The vertebrate lens develops from surface ectoderm in a process triggered by its 
intimate contact with optic vesicle. Initially, all head surface ectoderm is thought to be 
competent for lens development, but with a subsequent reduction to the areas over the 
outgrown optic vesicles. The surface ectoderm and optic vesicle both thicken at their 
respective regions of contact, with the presumptive lens region becoming a “placode” of 
tissue specific for lens fate. This represents the first morphologically identifiable stage of 
lens development and is visible by the end of the fourth week (CS12; ~ E9.0-9.5 in 
mouse).  
 
The presumptive lens begins to invaginate and initiates the process of lens-
specific cell differentiation. It buds off from the surface ectoderm, leaving a discrete 
hollow lens vesicle beneath the now intact surface ectoderm (the future cornea). Cells at 
the proximal pole of the lens, closest to the neural retina, differentiate into primary lens 
fibre cells and elongate to fill the entire lens lumen, while epithelial cells at the 
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equatorial region, or lens bow, simultaneously differentiate and elongate into the 
secondary lens fibres, migrating inwardly and increasing the size of the lens. The 
anterior cells in the lens vesicle persist as a single layer of undifferentiated stem cells 
that ‘feed’ the secondary lens cell population throughout this lens growth and throughout 
adult life.  
 
2.8.5. Molecular aspects of early lens development 
Pax6 is essential to lens induction and functions throughout lens development 
and its expression in the SE is necessary for lens development in vertebrates (Chow and 
Lang, 2001). Initially Pax6 is expressed throughout the head ectoderm during the period 
of lens forming bias, but then becomes spatially restricted to the region overlying the 
OV during the period of initial contact between the two tissues (Grindley et al., 1995). 
This initial pre-placodal Pax6 expression is followed by a second wave of expression, 
apparently via autoregulation.  Pax6 expression, together with expression of the Meis 
family of transcription factors, Bmp7, and Fgf signaling, define the pre-placodal stage of 
lens induction (Lang, 2004). Sox2 is expressed in the pre-placodal ectoderm, but at very 
low levels. Up-regulation of Sox2 expression is achieved through action of Bmp4 
(Furuta and Hogan, 1998). Its activation is required for the expression of crystallin genes 
later in the lens anlage by forming a complex with its DNA-binding partner, Pax6 
(Kondoh et al., 2004). 
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The presence of Sox2 and Pax6 proteins together in the nuclei of surface 
epithelial cells defines the placodal stage of lens development. Their combined presence 
is necessary for the expression of crystallin genes, which is a characteristic feature of 
this stage of lens development. Crystallin genes are vital for lens development and 
function, with mutations often the cause of lens opacities (Graw, 2003).  
 
Placodal Pax6 up-regulation enhances the already increased expression of Sox2 
in the lens placode (Chow and Lang, 2001). The cooperative binding of Pax6 to its 
binding partners regulates the expression of lens-specific differentiation genes. Such 
binding is both sufficient and necessary to produce lens differentiation in the placode 
(Kondoh et al., 2004). Although the delta crystallin gene is not present in mouse, the 
alphaA-crystallin promoter is composed of multiple Pax6 and Maf binding sites and its 
activation is regulated by recruitment of these factors, while disruption of these sites 
results in reduction of promoter activity in lens cells (Yang and Cvekl, 2005).  
 
Other transcription factors vital for lens development are expressed in the 
developing lens; Six3 is expressed in the presumptive lens in mouse and chick and 
persists in epithelial cells during differentiation stages. Mice that do not express Pax6 
are deficient in Six3 expression. MAF transcription factors are also expressed in the lens 
placode, the lens vesicle and, later, in the primary lens fibres, and are important for the 
expression of Crystallins. Mutations in MAF1 have been associated with opacities in the 
lenses of both humans and mice (Graw, 2003; Lyon et al., 2003).  The forkhead family 
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gene FoxE3 is expressed in the presumptive lens SE throughout lens induction. FOXE3 
mutations in humans cause anterior chamber malformations. Analysis of the enhancer 
element in the chick delta-crystallin gene identified that, in addition to Sox2, Sox1 can 
also form a complex with Pax6 and bind to the control region of DNA, resulting in the 
initiation of crystallin expression. Sox1 is expressed in the developing lens in both 
mouse and chick. It is active in the developing lens pit and its deletion in mouse causes 
microphthalmia, consistent with an important role in lens development, perhaps through 
vesicle closure (Nishiguchi et al., 1998). 
2.8.6. Differentiation of the neural retina 
The fully differentiated adult retina is a highly organised and laminated structure 
of photoreceptors, auxiliary neurons and glial cells. The molecular mechanisms and 
temporal sequence of events involved in retinal differentiation appear to be well 
conserved among vertebrates, beginning in the mouse at around E13.5-14.5 and 
continuing until approximately postnatal day 21 (Chow and Lang, 2001; Hatakeyama 
and Kageyama, 2004). In humans, the differentiation process in the neural retina begins 
to occur at around week 6 and continues until the first month after birth.  
 
For correct retinal development, neuroectoderm of the primitive neural retina in 
the optic vesicle becomes directly apposed to the lens placode and neuroblastic cells 
begin to proliferate. This region of multipotent cell proliferation is highly positive for 
Sox2 and Chx10 expression. The contact between lens placode and optic vesicle triggers 
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invagination of the optic cup and the development of the neural retina distinct from the 
optic stalk and the RPE (Chow and Lang, 2001).  
 
Correct differentiation of the multipotent retinal progenitors involves the 
interaction of specific homeodomain transcription factors with basic helix-loop-helix 
(bHLH) transcriptional regulators to establish temporal and spatial microenvironments 
of permissive factors for specific cell-type differentiation (Hatakeyama and Kageyama, 
2004). Repressive bHLH inhibit bHLH activators to maintain retinal progenitors, while 
bHLH activators interact with homeodomain factors to promote differentiation into the 
required cell type. Each retinal cell type therefore has a unique bHLH and transcription 
factor combinatorial code.  
 
Initially, SOX2 expression maintains proliferation in the ventricular zone of the 
neural retina and is widely expressed in neural progenitors. Closely related SOX 
transcription factors are markers for neural progenitors throughout the vertebrate CNS 
where they prevent the differentiation of neural progenitors by counteracting the effects 
of the proneural bHLH factors (Bylund et al., 2003; Graham et al., 2003). Hypomorphic 
mutations in mouse Sox2 result in the loss of RGCs and cause disrupted cell lamination 
within the neural retina. The decreased levels of Sox2 are associated with reduced 
expression of anti-proneural genes, while bHLH activators are up regulated, 
concomitantly with Pax6 expression (Taranova et al., 2006). As retinal progenitors 
begin to differentiate, Sox2 is down regulated, with the only cells that retain Sox2 
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expression in the fully differentiated retina being displaced amacrine cells within the 
GCL (Taranova et al., 2006).  
 
Within the differentiating INL, multiple transcription factors define the layer 
specification, while the expression of specific combinations of bHLH genes defines the 
neuronal cell type within that layer. Chx10 is required for bipolar cell fate, while 
horizontal cells require Pax6 and the forkhead-family transcription factor, Foxn4 (Li et 
al., 2004), and the combined expression of Pax6 and Six3 is required for amacrine cell 
differentiation (Inoue et al., 2002). Muller glial cells are the last to differentiate and are 
characterised by the continued expression of bHLH repressors until ~P10 in the mouse 
(Hatakeyama and Kageyama, 2004). In the outer nuclear layer (ONL), rod and cone 
photoreceptors require the combined expression of Crx and Otx2. Crx is necessary for 
normal cone and rod function and is implicated in human photoreceptor degeneration 
and Leber’s Congenital Amaurosis (LCA; MIM#602225). It binds to the promoter 
sequences of several additional photoreceptor-specific genes. In mice, Crx expression is 
observed in both developing and mature photoreceptor cells and in Crx-null mice, 
abnormal photoreceptors are formed (Morrow et al., 2005). Otx2 can also promote 
photoreceptor development (Hatakeyama and Kageyama, 2004) and is essential for 
photoreceptor cell fate determination. Deficiency of Otx2 leads to a conversion of 
differentiating photoreceptors to amacrine-like neurons (Nishida et al., 2003). 
Additionally, binding sites for Otx2 are found in the mouse Crx promoter, and Otx2 
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transactivates Crx (Nishida et al., 2003), providing evidence that Otx2 is a direct 
upstream regulator of Crx and thus a key regulator of photoreceptor development. 
2.8.7. Development & developmental function of the RPE 
The developing RPE is essential for the correct morphogenesis of the neural 
retina and is important in maintaining the organization of neural cell layers during later 
stages of development. Disruption of the RPE in early developmental stages results in 
disorganization of the neural retina and an arrest of eye development causing 
anophthalmia or severe microphthalmia (Raymond and Jackson, 1995). Microphthalmia 
associated transcription factor, Mitf, a basic helix-loop-helix leucine zipper family gene, 
is expressed in the future RPE in both mouse and chick. Missexpresion studies in both 
species result in aberrant RPE phenotypes (Martinez-Morales et al., 2004), while 
mutations in Mitf cause microphthalmia in the mouse mi mutant, resulting from defects 
associated with the RPE layer of the optic cup (Graw, 2003).  
 
2.8.8. The importance of ciliary body development 
The ciliary body has become of great recent interest in the field of eye 
development. Not only is it vital as a foundation for the correct formation of iris, 
trabecular meshwork and the zonules connecting the ciliary muscles to the lens, but also 
it is thought to synthesise the major constituents of the vitreous body (Bishop et al., 
2002; Ihanamaki et al., 2004). Additionally, further focus has been warranted due to the 
identification of retinal stem cell population within the non-pigmented ciliary body in 
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various organisms (Kubo and Nakagawa, 2008). Finally, an additional role as a signaling 
centre to promote and maintain correct lamination of the neural retina during 
development and growth has also been identified (Cho and Cepko, 2006; Nakagawa et 
al., 2003).  
 
2.8.9. Development of the ciliary body 
At the distal most edge of the adult retina, and directly apposed to the lens, is the 
ciliary body. It has three main functions during development and adult life: (i) secretion 
of aqueous humour; (ii) maintenance of intraocular pressure; and (iii) accommodation of 
the lens. The ciliary body is composed at its interior of ciliary muscles and stroma, while 
at the exterior are the pigmented and unpigmented layers of the ciliary epithelium. The 
pigmented layer lies between the RPE and the outer iris. The non-pigmented ciliary 
epithelium is continuous with the neural retina and the iris stroma, and secretes the 
aqueous humour constituent molecules. The aqueous humour then exits the eye through 
the trabecular meshwork, which is positioned in the ‘angle’ of the eye at the junction 
between cornea and iris. This process is vital for the maintenance of intraocular pressure. 
At the region adjacent to the lens, the ciliary epithelium is extensively folded in to create 
the ciliary processes. At the tips of these processes are the zonular fibres, suspensory 
ligaments connected to the lens, which facilitate the process of lens accommodation in 
conjunction with the action of the ciliary muscles.  
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The ciliary epithelium differentiates from the two layers of neuroepithelial cells 
at the distal rim of the optic cup (Beebe, 1986). The optic cup ‘rim’ is created by the 
inward folding of the neural retina that forms the inner and outer layers of 
neuroectoderm destined to become neural retina and RPE, respectively. The 
differentiation of the ciliary body is a relatively late event in eye development, with 
morphologically identifiable structures not developing until E18.5 and continuing until 
postnatal stages in the mouse. However, specification and patterning occur much earlier 
in development. Failure in correct development of the ciliary body may result in ocular 
malformations, possibly resulting in microphthalmia if dysgenesis occurs early during its 
development (Beebe, 1986). 
 
Molecular aspects of ciliary body development are now beginning to be 
understood.   While the rest of the neural retina undergoes separate differentiation 
programmes, repression of neuronal differentiation in the presumptive ciliary epithelium 
is maintained by elements of the Wnt/beta-catenin pathway (Cho and Cepko, 2006; de 
Iongh et al., 2006; Kubo et al., 2005). Canonical Wnt activity was identified in the 
peripheral retina in mice, and Wnt2b was identified as the likely ligand (Liu et al., 
2003). Specifically, in chick embryos, Wn2b is identified in the distal optic cup and 
determines peripheral fates (ciliary body and iris) in the eye. Wnt2b and Lef1 expression 
are not typically identified in the central neural retina, however activation of canonical 
Wnt signaling by a constitutively active beta-catenin induced expression of ciliary 
markers collagen IX and Bmp7 and inhibited neuronal differentiation (Cho and Cepko, 
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2006). Ectopic expression of mouse Wnt2b in central chick retina resulted in folding 
reminiscent of ciliary epithelium, associated with the inhibition of retinal markers 
Notch1 and NF-M, and the expression of the ciliary markers collagen type IX and Pax6 
(Cho and Cepko, 2006; Kubo et al., 2003). Additionally, inhibition of Wnt signaling in 
the peripheral retina resulted in precocious differentiation into retinal ganglion cells, 
whereas in wild types, cells in the presumptive ciliary region proliferate over longer 
periods than cells in the central retina (Cho and Cepko, 2006; Kubo et al., 2003).  
 
Expression of the signaling molecules Bmp4; Bmp7, together with the 
transcription factors Msx1 and Otx1 are also specifically identified in the normal 
developing ciliary epithelium. Otx1 null mice fail to develop ciliary body (Acampora et 
al., 1996), and the expression of these transcription factors are responsive to changes in 
Bmp signaling (Zhao et al., 2002).  However, evolutionary conserved signals emanating 
from the lens are also thought to be vital for differentiation within the ciliary epithelium 
and induced removal of lens signals results in inhibition of iris and ciliary body 
formation (Beebe, 1986). It has been shown that the lens produces currently unknown 
instructive signals that induce the development of iris and ciliary body (Thut et al., 
2001). Fgfs are good candidates for this effect (Dias da Silva et al., 2007). Inhibition of 
Bmp signaling in the ciliary epithelium, from transgenic noggin expressed in the lens, 
prevents normal ciliary formation and promotes differentiation of retinal ganglion cells. 
This phenotype can be reversed by over-expression of ciliary Bmp7 (Zhao et al., 2002).  
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Together, this data suggests that canonical Wnt and Bmp signaling, combined 
with specific combinations of transcription factor expression and function, demarcates 
the presumptive ciliary cells of the peripheral retina, supports ciliary specific 
differentiation and prevents neuronal cell fates.  
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2.9. Limb Development relevant to OAS 
In tetrapods such as humans and mice, primordia for two pairs of limbs originate in 
four specific areas of the flanks of the early embryo. Increased rates of cell division in 
comparison to those outwith the limb fields, generate outgrowth of the limb primordia, 
or ‘limb-buds’ from the ventrolateral body wall. These limb buds are therefore 
composed of proliferating mesenchymal cells pocketed by an ectodermal sheath. Limb 
buds appear at around CS13 in the human embryo, and at around E9.5 in the mouse. In 
both cases, the appearance of the forelimb slightly precedes that of the hindlimb and this 
staggered developmental pattern continues throughout embryogenesis.  
 
2.9.1. Organising centres control development along different limb axes  
As the limb bud becomes visible, an organising centre is created at distal-most 
region of the SE, the apical ectodermal ridge (AER). The AER is a collective of cells at 
the midline of the limb bud running along the anterior to posterior (A-P) axis and is 
essential for limb outgrowth and patterning via reciprocal interactions with cells of the 
underlying mesenchyme and expression of FGFs, and the continued outgrowth of the 
limb bud requires this FGF signaling to be maintained. The fate of cells in the growing 
limb bud depends on the time spent in the progress zone (PZ), a region of highly 
proliferating mesenchymal cells immediately proximal to the AER, and thus exposure to 
AER signals, with those residing longest becoming more distal elements of the limb. 
Thus, the AER controls development in the proximodistal axis.  
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The autopod skeletal elements are formed in a posterior-first order, where the 
metatarsals and metacarpals of the feet and hands, respectively, are formed before the 
phalanges. This fits the PZ model of limb bud development and differentiation.  
 
A separate organising centre in the developing limb is the zone of polarizing 
activity (ZPA), positioned in the posterior mesenchyme of the developing limb bud and 
crucial for defining patterning across the anterior-posterior (A-P) axis. Signals coming 
from the ZPA help delineate the formation of separate digits with distinct morphologies 
organised across the autopod (Capdevila and Izpisua Belmonte, 2001; Tickle, 2006). 
Patterning along the A-P axis is principally achieved through the action of the highly 
conserved signaling molecule Sonic Hedgehog (Shh)(Riddle et al., 1993), emanating 
from the ZPA (Riddle et al., 1993).  
 
2.9.2. Determining digit identity 
Shh is thought to be vital for determining both digit number and identity. This 
process involves modification of Shh-responsive Gli proteins, which positively and 
negatively mediate the patterning effects of Shh. For example, high amounts of Gli3R 
(repressor) are present in anterior regions of the limb bud where Shh is unable to diffuse, 
while the activator form, Gli3A, is predominant in posterior regions in close proximity 
to the ZPA. This mediates the response to the Shh morphogen gradient across the A-P 
axis of the limb bud, which contributes to the creation of permissive and inhibitory 
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domains for the expression of target genes, and ultimately leads to the correct 
specification of digit number and identity required for distal limb development. In the 
absence of Shh (e.g. in Shh-/- mutant mice), Gli3R prevails throughout the limb bud 
resulting in the loss of digits (Tickle, 2006).  
 
In addition to the morphogen gradient model of anterior-posterior patterning of 
digits whereby concentration of SHH determines digit identity, the length of exposure to 
SHH may also be important (Tickle, 2006). In this model, the posterior-most digit 5 is 
exposed to SHH for the greatest length of time and concentration, whereas digits 4, 3, 
and 2 have reducing lengths and intensities of exposure, respectively. In accordance with 
this model, in the posterior-most digits it is the temporal element that is most critical 
(Scherz et al., 2007). However, whether or not Shh itself determines digit identity is not 
clear.  
 
Individual digit morphologies are controlled by endogenous signals from the 
interdigital mesenchyme, possibly mediated through Bmp signaling (Dahn and Fallon, 
2000), although this is currently controversial (Bandyopadhyay et al., 2006). However, 
Bmp2 is expressed posteriorally in limb buds and can be induced in response to ectopic 
Shh doses, where it can posterioralize duplicated digits (Drossopoulou et al., 2000). 
 
The targets of such signals (Bmps and Shh) remain unknown (Tickle, 2006), 
however Bmps act in part through the T-box transcriptional repressors, expressed in the 
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posterior region of the limb and likely to be important for posterior digit morphology 
and identity. One target is the T-box gene transcription factor Tbx3. Tbx3 mutations have 
been identified in the human condition Ulnar Mammary Syndrome (UMS; MIM 
#181450), which has phenotypes of posterior (ulnar or postaxial) upper limb defects 
ranging from hypoplasia of the terminal phalanx of the fifth finger to complete loss of 
forearm and hand. Additionally, the 5’Hoxd-genes are expressed across the anterior-
posterior axis in the developing limb bud and are likely to be important in determining 
digit identity. Hoxd13 has the most posterior expression domain, and mutations in 
humans can result in Synopolydactyly (MIM #186000), a condition of soft-tissue 
syndactyly and rudimentary extra digits affecting the posterior rays of the hands and feet 
(Muragaki et al., 1996).  
 
2.9.3. Chondrogenesis & apoptosis for formation of digits & interdigital regions 
Within the developing autopod, mesenchymal cells are specified to undergo two 
opposite fates: forming skeletal elements of the digits, or becoming interdigital tissue 
that will be removed by programmed cell death (PCD). To form the digits, mesenchymal 
cells aggregate to form precartilagenous condensations. These are subsequently replaced 
by bone through the process of endochondral ossification, where mesenchymal cells 
differentiate into osteoblasts. In the interdigital regions, tissue is removed to free the 
individual digits by apoptosis. The exact mechanisms for the contrasting fates of these 
mesenchymal cells remains obscure, however the specific location and levels of growth 
factors and their receptors appears crucial (Capdevila and Izpisua Belmonte, 2001). 
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Bmps are expressed throughout the developing autopod and therefore have roles as 
inducers of PCD and cartilage fate. In the prechondrogenic digit regions, the combined 
expression of TGF-β2 and BmpR-1b determines digital development, together with the 
expression of the Bmp antagonist noggin. In the interdigital regions, however, 
expression of BmpR-1a and the absence of TGF-β2expression induces PCD. An 
additional role is played by Fgf signals emanating from the AER, whose function 
appears to be to protect cells in the PZ from PCD (Capdevila and Izpisua Belmonte, 
2001). Once a chondrogenic fate has been determined, expression of the HMG-domain 
containing transcription factor Sox9 is up-regulated. This occurs throughout the embryo 
in regions of endochondral ossification during mesenchymal cell condensation and 
cartilage formation (Wright et al., 1995). 
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2.10. Genetic mapping 
The aim of genetic mapping is to identify disease genes that segregate with 
affected individuals. The principle of genetic mapping for any trait is therefore 
straightforward and is centred on identifying chromosomal regions that have shared 
features among affected individuals, usually family relatives, but differ from unaffected 
individuals. Once a genetic localisation is identified, genes within the region are 
considered as potential candidates to effectuate disease by virtue of their position. 
Occasionally, genes within identified regions may offer themselves as candidates based 
on previously known function alone, or by being the sole gene within that region.  
 
2.10.1. Methods available for mapping 
Often the first step taken in disease gene identification is cytogenetic analysis to 
identify chromosomal rearrangements, duplications or deletions. However such methods 
are useful only for low-resolution identification of genetic lesions and are thus not 
always successful in mapping genetic diseases. Typically, for smaller mutations, use is 
made of genetic markers: loci that have more than one allele and thus display 
polymorphism within populations. Microsatellite markers such as simple-tandem 
repeats, e.g. (CA)n generally have multiple alleles and are highly informative between 
individuals. Such markers can be analysed rapidly by PCR, using the unique flanking 
sequences for specific primer annealing, and can be tagged with fluorescent probes to 
enable multiplex reactions and accurate, high throughput computational analysis. 
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However, the use of microsatellite markers is limited in that many markers are required 
for whole genome mapping, and (CA)n repeats are predicted to occur only once every 30 
kb (Stallings et al., 1991) and hence can only be used in mapping to restricted 
resolutions.  
 
2.10.2. SNPs and autozygosity mapping 
Single nucleotide polymorphisms (SNPs) occur at least once every 250 base 
pairs (NCBI assembly 36). Due to this high density and their known locations, together 
with their diallelic nature being amenable to full automation, they have been utilised in 
microarray chips to analyse many thousands of SNPs simultaneously in a single 
experiment.    Sufficiently high numbers of informative markers results in large genetic 
power for screening whole genomes for linkage. 
 
Autozygosity mapping is a powerful tool for the discovery of autosomal 
recessive gene loci in consanguineous families (Lander and Botstein, 1987).  
In such families, there is a high probability that an affected individual has inherited both 
copies of a disease gene, one from each parent, which originated from a recent common 
ancestor. These alleles are generally inherited with regions of flanking genomic DNA 
sequence and together, these whole regions are referred to as being identical by descent 
or autozygous. Thus, autozygosity mapping seeks regions of homozygosity in affected 
individuals from consanguineous families. Recent strategies for autozygosity mapping 
incorporate SNP-chip data for thousands of SNPs. 
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2.10.3. Genetic mapping in mice 
Mouse genetics has the advantage over human studies of being able to plan and 
select matings to facilitate linkage analysis. If a mutation has arisen on a particular strain 
background, and the heterozygous phenotype of interest is fully penetrant, multiple 
crosses to a separate inbred, or tester strain, (back- or outcrosses) can be set up, 
segregating phenotypic animals. The choice of tester strain depends on the availability of 
different alleles from the mutant strain that can be readily genotyped at multiple loci. 
The carrier parent is thus heterozygous for the mutant, or target loci and the mating 
partner is fully homozygous for all the tester strain loci. F1 progeny from the first 
outcross will therefore have one homologous chromosome from either parent. Meiotic 
recombination events in subsequent crosses will increase the amount of tester strain 
background, but by segregating heterozygotes for further outcrosses the original strain 
background close to the target loci will be retained. Hence, further crosses of phenotypic 
progeny with the tester strain will refine the target loci and facilitate whole genome 
mapping with markers informative between tester and target strains.  
 
2.10.4. Genetic linkage in mapping 
Linkage mapping has been essential for mapping the locations of genes that 
cause genetic disease. Loci on the same chromosome are connected physically and 
therefore usually segregate together during meiosis. However, the greater the distance 
between two loci on the same chromosome, the greater the chance of non-sister 
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chromatids crossing over during meiosis between loci, the process of meiotic 
recombination. Conversely, recombination occurs less frequently between two loci close 
together on the same chromosome. Linkage occurs when recombination events between 
two markers is identified as occurring less than 50% of the time, thus indicating the 
markers are close to each other on the same chromosome. Linkage analysis tests whether 
the recombination fraction (θ, the ratio of recombinant progeny to the total progeny) 
observed between markers differs from 0.5 and can be used to test the null hypothesis of 
no linkage when 5 out of 10 (θ= 0.5) meioses are recombinant.  
 
In most families or pedigrees however, it is impossible to assign recombination 
fractions unambiguously. The overall likelihood of a pedigree can be calculated by using 
the alternative assumptions that loci are linked (θ= 0 <θ <0.5) or not linked (θ= 0.5), 
where a range of values for θ within a given data set of loci for defined pedigrees 
(Strachan & Read). The ratio of these two likelihoods is the odds ratio, and the log10 of 
the odds ratio is the LOD score, Z. LOD scores are therefore statistical likelihood tests 
used to determine linkage between a two loci, or a particular trait and a marker (Morton, 
1955). In reality, computational analyses of pedigrees, gene frequencies and genotypes 
are now routinely used to calculate LOD scores for individuals and can also be used to 
calculate linkage across multiple families, where cumulative LOD scores can be added 
up. The currently used critical values for accepting and rejecting linkage in simple 
mendelian traits in humans are Z ≥ 3.3 and Z ≤ -2, respectively, for significance levels of 
0.05 (Lander and Kruglyak, 1995; Morton, 1955).  
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3. Materials and Methods 
3.1. Materials and methods for the OAS project 
3.1.1. Mapping OAS using Affymetrix 10K array 
DNA was collected from families with OAS by collaborative clinicians and sent 
to Dr. David FitzPatrick at the MRC Human Genetics Unit (Edinburgh, UK). Samples 
were quantitated and checked for quality using a NanoDropTM 1000 (Thermo Scientific) 
and agarose gel electrophoresis, respectively. DNA samples were sent to RZPD (Berlin, 
Germany) for analysis using the Affymetrix GeneChip® Human Mapping 10K Array 
Xba 131 platform. Primary chromosomal SNP raw data was produced in Excel 
spreadsheets from the output Affymetrix GeneChip® DNA Analysis Software (GDAS). 
For each affected individual, the data was sorted by chromosome and genetic distance 
and was then analysed for genome wide linkage using ExludeAR spreadsheets 
(http://leedsdna.info/science/Autozygozity/spreadsheets.htm).  Linkage was tested using 
ALOHOMORA, a data conversion software tool to facilitate genome-wide linkage 
studies. The linkage analysis programme Allegro (v1.2c) was used to undertake a 
genome-wide multipoint linkage analysis of linked regions. Gene data within the 




3.1.2. Whole genome amplification of sample genomic DNA 
OAS patient and family genomic DNA samples were limiting and therefore 
whole genome amplification reactions were required to facilitate a PCR-based 
sequencing strategy. The GenomiPhiDNA Amplification Kit (Amersham) was used to 
generate large volumes of DNA for template in PCR-sequencing reactions from patient 
DNA according to the manufacturers instructions. Amplified DNA samples were diluted 
to 100 ng/µl in RNAse and DNAse free Ultrapure water.  
  
3.1.3. Development of oligonucleotide primers for an OAS sequencing strategy 
The physical coordinates for the critical interval linked to OAS were used to 
extract all coding exons from the Ensembl database using the Biomart tool 
(http://www.ensembl.org/biomart/martview//def0f0e79955dcf569528e09fd74245f) on 
ensembl v38 (April 2006).  In order to evaluate a general level of evolutionary 
conservation in the coding regions, a table available from the UCSC table browser 
website (http://genome.ucsc.edu/cgi-bin/hgTables) was downloaded that displayed the 
critical region with a measure of evolutionary sequence conservation across 17 
vertebrates including mammalian, amphibian, avian, and teleost species. This data was 
generated using PhastCons17way, based on a hidden Markov model, PhastCons (Siepel 
et al., 2005). The table contained a single score per base pair reflecting the level of 
conservation in all the species: 1 being the maximum score and 0 denoted a non-
conserved element. In house scripts were then used to parse the information from the 
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conservation table and to generate oligonucleotide primers for each exon using the 
EMBOSS eprimer3 script. For the primer design, all of the exons in the region were 
downloaded with the flanking 100 bp of genomic sequence on both sides, with the 
positions of the coding regions defined. Changes to standard parameters for eprimer3 
primer design were as follows: GC clamp = 1 nt; Optimum Tm= 60oC; Minimum Tm = 
57oC; Maximum Tm = 63oC; and optimum primer size = 19 nts. Exon details, together 
with sequence conservation and the generated primers sequences were shared between 
the Edinburgh (Dr. D. FitzPatrick & Joe Rainger, MRC Human Genetics Unit, 
Edinburgh, UK) and Nijmegen  (Drs. H. Brunner & H. van Bokhoven, Radbound 
University Nijmegen Medical Genetics, Department of Human Genetics, Nijmegen, The 
Netherlands) collaborating groups for this project and are in Appendix 6.1.  These 
primers were purchased from various suppliers throughout the project and were 
synthesised with no modifications and were desalt-purified.  
 
3.1.4. PCR based sequencing of exons for OAS patients  
Oligonucleotides were rehydrated to stock solutions and 10 µM working 
solutions were set up, containing both forward and reverse primers in each primer-pair. 
PCR reactions were set up with reagents as described below, with the exception that 2 µl 
of WGA DNA (20 ng/µl) was added to 25 µl reactions at a final concentration of 1.6 
ng/µl and the final dilution of primers was 0.4 µM. PCR reactions were run on DNA 
Engine Tetrad™2 (BioRad, CA, USA).  Agarose gel electrophoresis was used to analyse 
success of PCR reactions. Sequencing reactions were performed by the Technical 
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Service Department at the MRC Human Genetics Unit. Sequence analysis was 
performed with Mutation Surveyor™ Software (SoftGenetics® LLC, PA, USA) or 
Sequencher™4.8 (GeneCodes Corp. MI, USA). 
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3.2. Materials and methods for the Mp project 
 
3.2.1. Genetic background and breeding schedule of the Mp mouse line 
The Mp (micropinna microphthalmia) line was produced by exposing 
spermatogonia of an F1 male (101/R1 x C3H/R1) to a total of 7 x 200 cGy doses of X-
ray irradiation over 7-day intervals at a dose rate of ~ 90 cGy/min at Oak Ridge Nuclear 
Laboratory (Phipps, 1964). The irradiated male was bred to a multiple-recessive tester 
(T-stock) female and offspring were crossed once to mice of Bl10 background. Further 
crosses were made to inbred background strains 101 and C3H a total of 37 times. Sperm 
was isolated and cryogenically stored from Mp affected males. Mutant sperm was used 
to perform intra-cytoplasmic sperm injection (ICSI) using oocytes from a donor female 
F1 (CBA x C57Bl/6). Generation-0 (G0) affected offspring from this dam were 
intercrossed for gross mutant phenotype analysis of progeny and also outcrossed to a 
genetically distinguishable inbred strain (C57Bl/6) to facilitate genetic mapping. A total 
of four backcrosses (to C57Bl/6) followed this initial outcross, selecting for 
heterozygous phenotype, to generate informative recombinants within chromosomal 
regions from the original mutagenised background (C3H/101) co-segregating with the 
Mp phenotype.  
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3.2.2. Gross phenotyping and penetrance analysis of Mp Mouse line 
 
The Mp mutation phenotype has been described (Phipps, 1964). Phenotypes were 
classified grossly at, or as close to, post-natal day 21. Heterozygote animals were 
identified by small eyes with/ or without reduced pinnae size. In contrast, ocular absence 
(demonstrated by failure in opening of the palpebral fissures) in combination with distal 
limb oligodactyly or syndactyly was used to identify homozygote animals. For 
penetrance analysis, records of each perceived genotype were accumulated for each 
backcross generation in out-crosses to both C57Bl6/j and CD1 strains, and calculated as 
each phenotype percentages and ratios for comparison to expected numbers. 
3.2.3. Skeletal analysis 
Animals at various ages were culled with lethal intravenous doses of Euthatal 
(Merial Animal Health Ltd. Essex, UK) and were washed in 70% Ethanol. Animals were 
weighed for weight comparisons between genotypes and then completely eviscerated 
with abdominal tissues and organs removed. Carcasses were then placed in 95% ethanol 
for 24 hours, followed by 72 hours in 100% acetone, at least 3 days in stain solution (1 
part 0.3% alcian blue in 70% ethanol; 1 part 0.1% alazarin red in 95% ethanol; and 1 
part acetic acid, in 17 parts 70% ethanol); followed by 3 days clearing in 1% potassium 
hydroxide (KOH); 3 days in 1% KOH/30% glycerol; and two 24 hour periods in 1% 
KOH/50% glycerol; in 1% KOH/70% glycerol and finally were stored in 100% glycerol. 
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3.2.4. Mouse Eye processing for histology and immunohistochemistry  
Eye tissue was dissected from culled animals at recorded stages and periocular 
tissues removed to reveal globes and optic stalks, taking care to remove as much 
extraocular tissue as possible. Eyes were rinsed in cold PBS and then fixed in 4% PFA 
overnight at 4oC; rinsed again in PBS, and dehydrated in serial dilutions of 30%; 50%; 
70% ethanol for 1 hour each at room temperature. They were then either stored at 4oC in 
70% ethanol, or paraffin embedded. Paraffin embedding was performed by sequential 15 
min rinses in each of 85%; 95% and 100% ethanol, followed by 2x 30 min in xylene, the 
second of which was at 50 oC. Xylene was then replaced by 1x 30 min wash in 50oC 
paraffin and then manually embedded in fresh paraffin at 50oC for cutting in either 
sagittal, coronal or transverse planes. Sectioning was done on a manual microtome set to 
cut at either 4 µm or 6 µm. Dewaxing of slides was performed by serial washes of 5 min 
in xylene (3x washes) and 100% ethanol (3x washes), followed by 2 min washes each in 
90%; 70%; 50% and 30% ethanol and finally rinsed in dH2O. 
 
3.2.5. Karyotype analysis of Mp pro-metaphase chromosomes 
(Adapted from protocol at jax.org/cyto/blood_preps.html) Para-cardiac blood 
samples (0.05–0.1 ml) were collected from 11-week old phenotypically heterozygous 
male Mp animals, and supplemented with heparin to 500 USP units/ml. Samples were 
added directly to 0.95 ml RPMI media (Gibco) with 1% penicillin/streptomycin; 1% L-
glutamine; and 0.5% MOPS (1.25 M); supplemented with 0.15 ml PHA (0.01% v/v); 0.1 
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ml LPS (750 µg/ml); and 0.15 FCS. Samples were cultured in 15 ml falcon tubes at 37oC 
with regular, light agitation. At 43 hours incubation, 7.2 µl Colcemid (Gibco; 10 µg/ml) 
was added to cultures and incubated for 15-20 min.  Cultures were centrifuged at 400 x g 
for 10 min and supernatants removed. Cultures were gently resuspended in 2-3 ml of 
pre-warmed (37oC) KCl (0.56%; 0.075 M) and further incubated for 15 min at 37oC. 
Cells were harvested by centrifugation at 500 x g for 10 min and supernatants removed 
without removal of Buffy layer. Cell pellets were resuspended in 3:1methanol:glacial 
acetic acid fixative and left overnight at 4oC. Cells were centrifuged at 400 x g and 
resuspended in fixative a total of three times with final resuspension in 0.25-0.5 ml 
fixative. Cell suspensions were dropped on slides pre-cleaned with fixative and rapidly 
dried to facilitate spreading of chromosomes. Chromosome preparations were mounted 
in Vectashield (Vector Laboratories) containing DAPI fluorescent stain at 0.1 µl/ml and 
visualised by fluorescence microscopy as described below. Karyotype analysis was 
performed using SpectraVysion software (Vysis, Illinois USA).  
 
3.2.6. Brightfield and fluorescent microscopy 
For fluorescence imaging, the imaging system comprised a Coolsnap HQ CCD 
camera (Photometrics Ltd, Tucson, AZ) Zeiss Axioplan II fluorescence microscope with 
Plan-neofluar objectives, a 100W Hg source (Carl Zeiss, Welwyn Garden City, UK) and 
Chroma #83000 triple band pass filter set (Chroma Technology Corp., Rockingham, 
VT) with the excitation filters installed in a motorised filter wheel (Ludl Electronic 
Products, Hawthorne, NY). For brightfield colour imaging, colour additive filters 
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(Andover Corporation, Salem, NH) installed in a motorised filter wheel (Ludl Electronic 
Products, Hawthorne, NY) were used sequentially to collect red, green and blue images, 
that were then superimposed to form a colour image. Image capture and analysis were 
performed using in-house scripts written for IPLab Spectrum (Scanalytics Corp, Fairfax, 
VA). 
3.2.7. Morphometric eye measurements 
Embryos were dissected at E15.5 and the heads removed. They were then rinsed 
in cold PBS and then fixed in 4% PFA overnight at 4oC; rinsed again in PBS, and placed 
in 30% Sucrose/PBT O/N at 4oC. Heads were then dehydrated in serial dilutions of 30%; 
50%; 70% ethanol each for 3 h at room temperature, or O/N at 4oC. They were then 
processed for Optical Projection Tomography (OPT) as follows: heads were mounted in 
1% agarose, dehydrated in methanol and then cleared overnight in BABB solution (1 
part Benzyl Alcohol: 2 parts Benzyl Benzoate). The sample was then imaged using a 
Bioptonics OPT Scanner 3001 (Bioptonics, UK) using brightfield to detect the LacZ 
staining and for tissue autofluorescence (with wavelengths for excitation set to 425nm, 
and emission set to 475nm) to capture the anatomy (Sharpe et al., 2002).  The resulting 
images were reconstructed using Bioptonics propriatory software (Bioptonics, MRC 
Technology, Edinburgh, UK), automatically thresholded and merged to a single 3D 
image output using Bioptonics Viewer software. Scans were analysed with Amira 4.1.2 
(Visage Imaging, CA, USA) with measurements taken for head lengths and widths, eye 
depth and width, and lens depth and width, all in Voxels. Measurement data was then 
processed in Excel worksheets.  
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3.2.8. DNA extraction from mouse tissues 
Tail tips were taken and incubated in 500 µl tail lysis buffer (100 mM Tris-HCl, 
pH8.5; 5 mM EDTA; 0.2% SDS; 200 mM NaCl) with 10 µl Proteinase K (10 mg/ml) 
and incubated overnight at 50oC. Samples were centrifuged at 13,000 rpm for 30 min at 
4oC. Supernatants were transferred to fresh tubes and 1/8th volume Sodium Acetate (3 M; 
pH8) and 2x volume of (-20oC) 100% ethanol were added and mixed. Samples were 
stored at -20oC overnight and centrifuged at 13,000 rpm for 30 min at 4oC. Pellets were 
washed twice with 70% ethanol and air-dried. DNA was resuspended in sdH2O.  
3.2.9. RNA extraction from mouse tissues and cell cultures 
 RNA was isolated from tissues collected from animals culled as 
described above, or from cultured mouse embryonic fibroblast (MEF) cells. For cells, 
media was removed and cells were washed once in sterile PBS. Accutase (Innovative 
Cell Technologies, Inc., CA) was used, according to the manufacturers instructions, to 
remove monolayers from tissue-culture flasks. Cells were then centrifuged at 1200 rpm 
for 5 min, the supernatants were removed and cells were resuspended in TRIzol® 
Reagent (Invitrogen, 15596-026). For RNA isolation from tissue, fresh tissues were 
dissected and frozen on dry ice, and then stored at -80oC prior to, or homogenised 
immediately in TRIzol Reagent. RNA was extracted by following the manufacturers 
instructions, with the slight modification of mixing a fifth volume of 
Phenol:chloroform:isoamyl (25:24:01) alcohol (Sigma, P3803) to the 
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TRIzol/homogenised tissue, instead of chloroform. The aqueous phase was collected and 
RNA was precipitated, washed and resuspended in sterile ultrapure H2O and stored at -
80oC. RNAs were run on agarose gels (1% in TBE) to check for quality, degradation and 
genomic contamination, and yield was calculated with a NanoDropTM 1000 (Thermo 
Scientific). 
 
3.2.10. Single-stranded cDNA synthesis & RT-PCR 
 RNA was used for single-stranded cDNA synthesis by reverse 
transcription. The 1st Strand cDNA Synthesis Kit for RT-PCR (AMV) (Roche, Cat. No. 
1 483 188) was used according to the manufacturers instructions using oligo-dT primers 
and with various RNA input quantities. Controls were set up for each sample without 
enzyme to identify genomic contamination. Reverse transcriptase (RT)-PCR with 
primers specific for the 18s ribosomal subunit (18sRNA_Fwd & 18sRNA_Rev) was used 
to check cDNA for genomic contamination. These primers produced a single amplicon 
of ~500 bp in the presence of cDNA alone, but also produced an additional amplicon of 
~1 kb if genomic contamination is present.  
 
3.2.11. Polymerase chain reaction (PCR)  
All PCR reactions (including non-quantitative RT-PCRs) were carried out using 
Faststart Amplitaq Gold enzyme (Roche Applied Science) at a final reaction 
concentration of 0.06 U/µl in reaction mixes with PCR buffer containing MgCl2 (Roche 
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Applied Science, Product no. 12 032 945 001) and 0.4 mM dNTPs (Abgene, diluted 
1/10 in sdH2O). Oligonucleotide primers were diluted to working solutions containing 
10 µM of both forward and reverse primers in sterile dH2O, and were diluted to a final 
reaction concentration of 0.2 µM. Total DNA input for PCR reactions varied within the 
range 40-200 ng, with the reaction volumes being 10-50 µl, respectively, giving a 
general DNA reaction concentration of 4 ng/µl. Mastermixes were made up where 
multiple reactions were performed, with all reaction mixed prepared on ice, with DNA 
and primers generally added last to avoid contamination.  Filter tipped pipettes were 
used where possible in dedicated, clean, PCR set-up areas. Specific reaction cycle 
conditions are listed in Appendix, however a general programme was used for all 
oligonucleotide primer pairs as a first-pass attempt: 95oC x 3 min, followed by 30x 
cycles of 95oC x 30 s; 58oC x 45 s; 72oC x 45 s, followed by a single extension of 10 min 
at 72oC and final holding at 4oC, with the thermal cycler lid tracking at 5oC each stage 
temperature. Details of primers and cycles used are in Appendix. All products were run 
on agarose gels (1% in TBE with 0.5 % TBE running buffer) with either 100 bp or 1 kb 
molecular DNA size markers (Invitrogen, Product Nos. 15628-050 and 15615-016, 
respectively).  
 
3.2.12. DNA preparation for Whole Genome 768 SNP Panel Array for Mp mapping 
Genomic DNA was extracted from tails of 8x phenotypically heterozygous 
animals as described above from the 2nd outcross to C57Bl6/j, together with parental G0 
and F1 genomic DNAs. DNAs were quantitated and checked for quality by recording 
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their 260/280 nm absorbances using a NanoDrop 1000 spectrophotometer (NanoDrop 
Technologies, DE, USA) and by running samples on 1% agarose gel to check for 
degradation. All had 260/280 ratios >1.80 and were undegraded and therefore were 
considered of good enough quality for the array analysis. 4 µg total DNA was sent for 
each sample to be analysed on the 768 SNP genotyping panel (Moran et al., 2006).  
 
3.2.13. Genome-wide mapping of Mp using fluorescently tagged microsatellite 
markers 
PCR amplifiable microsatellite markers were used for mapping using tail-tip 
DNA samples from heterozygous Mp animals from the 3rd generation of outcrosses to 
C57Bl6/j. DNAs were quantitated, and checked for quality by recording their 260/280 
nm absorbances, using a NanoDrop 1000 spectrophotometer (NanoDrop Technologies, 
DE, USA). Markers were selected according to whether their oligonucleotide primers 
were held in the laboratory of Professor Ian Jackson (MRC Human Genetics Unit) and if 
so, whether they were informative between the background strains C3H and 101 and 
C57Bl6/j, according to details publicly available on an annotated electronic database: 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=unists. Primers specific for those markers 
selected were used in PCR reactions with positive control DNAs collected from C3H 
and C57Bl6/j mice. The PCR-products were run on agarose gels (1% TBE with 0.5% 
TBE running buffer) to check for presence and the specificity of product(s) and were 
then run on an ABI PRISM® 310 Genetic Analyzer. This single-capillary genetic 
analyser ran 3 different coloured markers concomitantly, together with a size marker in 
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each single lane. Hence, microsatellite-specific oligonucleotide primers were conjugated 
with FAM, TET, or HEX dyes and used for amplicon fragment analysis. In total 73x 
markers were selected that were informative between C3H and C57Bl6/j alleles. The 
markers used, their fluorescent tag and chromosomal location, and peak sizes for each 
allele are listed below.  Genomic DNA was collected from 30x wild type and 38x 
heterozygote animals from the 3rd outcross. Samples were quantitated and checked for 
DNA quality as described above and then diluted to 50 ng/µl. Equal amounts (20 µl) of 
these equilibrated samples were then pooled together and used to create two samples 
containing DNA from either wild type or heterozygote samples only.  The heterozygous 
and wild type pooled DNAs were then used separately as templates for PCR reactions, 
using the reagents and quantities described above, for each of the selected markers 
(Table 3.1) and run on the ABI PRISM® 310 Genetic Analyzer. The PCR cycle 
conditions for all markers was: 94oC x 3 min; 30x cycles of (i) 94oC x 30 s; (ii) 55oC x 
45 s; (iii) 72oC x 1 min, followed by a single step of 72oC x 2 min and holding at 4oC. 
Oligonucleotides were used at a final concentration of 0.5 µM. PCR reactions were 
removed from the thermal cycler and run on agarose gels to check for PCR success. 2 µl 
of each PCR product was mixed with 4 µl sdH2O and mixed well. Samples were then 
diluted with 14 µl Genescan-350 TAMRA® (ABI PRISM) molecular 
markers/formamide mix (1:28) and denatured at 95oC for 5 min and cooled on ice prior 
to loading onto the ABI PRISM® 310 Genetic Analyzer. When completed, data was 
removed from the Genetic Analyzer and organised in Excel worksheets. Peak heights for 
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each allele were recorded and the ratios of C57Bl6/j:C3H peak heights were calculated 
and presented graphically.  
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Table 3.1. Informative markers per chromosome used for whole genome mapping 
panel. 
 
Chromosome Size (Mb) Number of markers 
Average Density 
(Mb/marker) 
1 195.1 4 48.8 
2 181.8 5 36.4 
3 158.9 4 39.7 
4 154.7 4 38.7 
5 150.3 4 37.6 
6 150.2 5 30.0 
7 139.7 5 27.9 
8 127.9 4 32.0 
9 124.1 3 41.4 
10 130.3 4 32.6 
11 121.8 4 30.5 
12 115.8 4 28.9 
13 114.7 4 28.7 
14 118.9 3 39.6 
15 103.6 4 25.9 
16 97.4 2 48.7 
17 92.9 4 23.2 
18 90.3 4 22.6 
19 60.6 2 30.3 
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3.2.14. Fine mapping of Mp using non-fluorescent microsatellite markers 
Using the same principle as for the whole genome mapping of Mp written above, 
fine mapping was performed around the chromosome 18 and 11 regions identified as 
candidate loci for Mp. In these case, in addition to some markers being tested using the 
ABI PRISM® 310 Genetic Analyzer, other marker alleles were PCR amplified and 
products were run on resolving 4% agarose gels (4% agarose in 0.5% TBE with 0.5% 
TBE running buffer) to discriminate between background alleles. The microsatellite 
markers used for fine mapping the chromosome 18 locus are listed in table 3.1.The 
primer pairs used, and the nucleotide sequences, are listed in the primer list in Appendix 
6.4.1.  
 
Table 3.2. Microsatellite markers on chromosome 18 and their amplicon sizes used 
for haplotype analysis of heterozygotes from 3rd outcross to C57Bl6/j. 
 
Marker Physical position (Mb) 
C3H size 




D18 MIT 94 38 124 141 Gel 
D18 MIT 149 45 116 136 Fluorescence 
D18 MIT 74 53 184 220 Gel 




3.2.15. 3’-End cDNA amplification using RACE  
Rapid Amplification of cDNA Ends (RACE) was used for the identification of 
the 3’-end of the Fbn2 transcript in the Mp mouse. An adaptor oligonucleotide primer 
(3’-RACE_d(T): see table in appendix for primer sequences) with 17x 3’-thymine residues 
was used as the only primer in separate reverse transcription reactions with RNA 
extracted from phenotypically mutant and wild-type animals as described above, using  
1st Strand cDNA Synthesis Kit for RT-PCR (Roche) with standard conditions. The 
single-stranded cDNA species (cDNA) were then used in gene-specific PCR reactions 
with an adaptor-only primer (3’-RACE_adaptor) and the Fbn2-specific primer 
(FBN2cDNA10_Fwd). Products from these separate reactions were then gel 
electrophoresed and analysed for the presence of different bands between the wild-type 
and mutant samples. Candidate bands were excised and purified from the gel and TA-
cloned into the pGEM-Easy vector system (Promega), according to the manufacturers 
instructions, for sequence analysis using T7 and SP6 vector-specific primers (T7_Fwd & 
SP6_Rev). The sequences obtained were analysed using Sequencher Version 4.8 (Gene 
Codes Corp. MI, USA) and then used as query sequences in BLAT search alignments 
against the mouse genome (http://genome.ucsc.edu/cgi-bin/hgBlat). 
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3.2.16. Long-range PCR for Fbn2 breakpoint mapping 
The regions between the last 3’-exons of the Fbn2 gene were amplified with 
primers listed as Fbn2 3’-exon primers in Appendix 6.4.2 & 6.4.3. The Roche Expand 
Long Template PCR kit (Roche, IN, USA) with buffer 1 was used as per the 
manufacturers guidelines with genomic DNA from heterozygote, homozygote and wild 
type animals.  
 
3.2.17. PCR-based genotyping assay 
Based on the genomic rearrangement identified at the Mp locus, it was possible 
to devise a PCR-based genotyping assay to genetically distinguish heterozygous, 
homozygous and wild type embryos and neonates. Primers Fbn2_FineMap_Fwd, 
Fbn2_FineMap_Rev and Isoc1Ex5_4_Fwd2 were used in multiplex PCR reactions using 
DNA isolated from mouse tail-tip samples. The Fbn2-specific primers produced an 
amplicon of 956 bp, indicative of the wild-type allele, whereas the Fbn2_FineMap_Rev 
and Isoc1Ex5_4_Fwd2 specific primers will produce an amplicon of 500 bp, signifying 
the presence of an Mp allele. The presence of both amplicons indicated heterozygote 
animals, whereas a single upper band or a single lower band signified wild types or 
homozygotes, respectively. Thus separation of these amplicons with 1% agarose gel 
electrophoresis (1% in TBE with 0.5% TBE running buffer) was used to identify 







Figure 3.2.1. PCR-based genotyping assay for Mp. Agarose gel electrophoresis 
indicating the different amplicons produced using wild type (Wt), heterozygote (Mp/+) 
and homozygote (Mp/Mp) input genomic DNA as templates for the genotyping-PCR 
reaction described with the Fbn2 and Isoc1-specific primers described above (M = 100 
bp molecular weight marker).  
 
 
3.2.18. Strong fix protocol for Transmission-Electron Microscopy (TEM) 
For sample preparation, tissues (epidermis, perichondrium and tendon from hind 
limbs, ears and eyes) from culled neonates was collected and placed into sterile serum-
free Dulbecco’s modified eagles media (DMEM) for immuno-EM and into strong-fix for 
regular EM. For Strong-fix (1.5 % Glutaraldehyde/ 1.5 % Paraformaldehyde in 0.1 M 
Sodium Cacodylate/ 0.05 % Calcium Chloride/ 0.05 % Tannic Acid), tissue samples 
were fixed for 3 h at RT, followed by 3x rinses in Cacodylate buffer (0.1 M Sodium 
Cacodylate/ 0.05 % Calcium Chloride). Tissues were shipped on ice in serum-free 
DMEM or Cacodylate buffer for immuno-EM and regular-EM, respectively. EM 
analysis was performed by Doug Keene and Sara Tufa (Shriners Hospitals for Children, 
Oregon Health and Sciences University, Portland, Oregon). Briefly, for immuno-EM, 
tissues were rinsed briefly in DMEM and then immunolabeled en bloc by immersing in 
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primary antibody diluted 1:5 in DMEM overnight at 4°C. They were then rinsed 
extensively in DMEM and immersed in 5-nm secondary gold conjugate (Amersham) 
diluted 1:3 in DMEM, rinsed again in DMEM.  The immuno-labelled tissues were fixed 
in 1.5% glutaraldehyde/1.5% paraformaldehyde containing 0.05% tannic acid in DMEM 
followed by 1% buffered OsO4 and then rinsed, dehydrated, and embedded in Spurrs 
epoxy.  Tissues were examined in a Philips EM410 transmission electron microscope. 
For regular EM, tissues were examined on a Philips EM410 transmission electron 
microscope following fixation in 1.5% paraformaldehyde/1.5% glutaraldehyde with 
0.05% tannic acid and osmium tetroxide, dehydration in ethanol and embedding in 
Spurrs epoxy. 
 
3.2.19. Primary MEF cultures 
 Primary Mouse Embryonic Fibroblast (MEF) cultures were established 
for RNA and immunocytochemistry analysis. Embryos were collected at E13.5 and 
separated into individual wells of a tissue culture plate and held in culture media: 
DMEM with 20% foetal calf serum; 1% penicillin/streptomycin. Tail-tips were removed 
for genotyping (as described above) and the abdominal cavity, and head, of each embryo 
was removed and discarded, or processed for sectioning, respectively. The limbs and 
skin from each embryo were then finely chopped with a sterile scalpel in 1 ml of culture 
media, passed several times through a pastette and then carefully injected into a 25 ml 
tissue culture flask (T25) and gently spread to cover the greatest amount of area 
possible. Flasks were then inverted and incubated upside-down at 37oC/ 5% CO2 for 3 h, 
 91 
then returned to right-side-up and cultured overnight. Flasks had media removed and 
replaced after 48 h and were checked for growth of fibroblast colonies. Large pieces of 
tissue debris were removed after cultures were established with large areas of fibroblast 
cells. When cultures were 80% confluent, they were passaged at a ratio of 1:2 by 
washing cultures once with PBS, incubating with Accutase (Innovative Cell 
Technologies, Inc., CA) at 37oC/ 5% CO2 for 5-10 min, and then centrifugation at 1200 
rpm for 5 min. Cell pellets were resuspended in culture media and separated evenly into 
two T25 flasks. These cells were then cultured as described above, and allowed to reach 
80% confluence. They were passaged in the same way, or alternatively the entire 
contents of a single T25 flask was used to seed a 75 ml culture flask. In addition, some 
cells were used to seed 16 mm glass coverslips placed into 6-Well tissue culture plates 
for immunocytochemistry analysis, using the same culture conditions described above.   
 
3.2.20. Tunicamycin assay 
 2x separate MEF cultures for each genotype were grown in 6-well tissue 
culture plates for 72 h with normal media and conditions. Culture media was removed 
and replaced with normal media containing the carrier substance DMSO (Sigma) at 0.05 
% with Tunicamycin (Manufacturer) at either 0 µg/ml; 0.5 µg/ml or 5.0 µg/ml doses for 
30 min. The experimental media was removed and replaced with normal culture media. 
Plates were then cultured under normal conditions and RNA was extracted after 24 h as 
described above.  
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3.2.21.  Xbp1 splicing assay 
The alternatively spliced  Xbp1transcripts were differentially identified using 
RT-PCR and the ABI PRISM® 310 Genetic Analyzer. A FAM-labelled forward (Xbp-
1_Fwd_FAM: 5’-[6FAM]-TTACGGGAGAAAACTCACGGCC-3’) and an unlabelled 
reverse ( Xbp1_Rev: 5’-GGGTCCAACTTGTCCAGAAT-3’) oligonucleotide primer 
specific for generating amplicons that covered the splicing region of the  Xbp1 transcript 
were used in PCR reactions with single stranded cDNA produced as described 
previously from RNA isolated from MEF cultures and dissected E16.5 eyes. In this 
assay, an unspliced  Xbp1 transcript will amplify a 289 bp product, while a spliced 
transcript will produce a 263 bp amplicon, and if both transcripts were present then both 
amplicons should be amplified. The ABI PRISM was used to identify peak heights for 
each splice-form of the  Xbp1 transcript from samples of different genotypes, and the 
ratios of peak heights were then calculated and displayed graphically. Relative 
quantitation of Fbn2 and  Xbp1 transcripts was analysed using QuantiTect SYBR Green 
RT-PCR (QIAGEN, CA, USA) according to manufacturers instructions, with the same 
RNA samples as were used for the 1st-strand synthesis in the Xbp-1 splicing assay. 
Primer pairs for specifically amplifying Fbn2,  Xbp1 and Hprt cDNA were used to 
generate ct values for each sample in triplicate. The averages ct values were used to 
generate ∆ct values for Fbn2 and  Xbp1 normalised to Hprt expression, and then ∆∆ct 
values were subsequently calculated for each of the samples for  Xbp1 expression 




 Cells were cultured on 16 mm glass coverslips in 6-well culture plates as 
described above and analysed for Fbn2 protein localisation with the rabbit polyclonal 
anti-Fbn2 antibody PAb-868. Cultures were grown for 72 hours and media was removed 
and cells were fixed with 3.7% formaldehyde at RT for 5 min. Cells were then washed 
3x in PBS and were either stored or processed immediately. Cells were permeabilised in 
PBS + 0.5% Triton-X-100 (Sigma) for 5 min. Coverslips were then blocked in PBS + 
10% foetal calf serum for at least 30 min at room temp, or overnight at 4oC. Fbn2 
antibody was diluted 1:150 in blocking solution and coverslips were incubated for 1 h at 
RT, then washed 3x in PBS + 0.1% Tween-20 (Promega). Secondary antibody (goat 
anti-rabbit Fab’ Alexa Fluor® 488, Invitrogen) in blocking buffer for 1 h at RT. 
Coverslips were then washed 3x in PBS followed by PBS + 0.1% Tween-20 and then 
mounted in Vectashield (Vector Laboratories) containing DAPI fluorescent stain at 0.1 
µl/ml to visualize cell nuclei and inverted onto glass microscope slides, sealed and 
stored at 4oC in dark conditions. A list of antibodies used is presented in table 3.3. 
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3.2.23. Immunohistochemistry  
 Slides with paraffin sections (cut at 4-7 µm) were de-waxed as described 
above. Antigen retrieval was carried out to reveal epitope sites by boiling in 0.1 M 
Citrate buffer (pH 6.0), boiled prior to application, and then brought back to the boil and 
left to cool for 20 min at RT. Slides were then rinsed twice in PBS and once in PBT. 
Slides were blocked for 1 hr at RT in buffer containing 10% sheep serum (heat 
inactivated at 60oC for 1 hr); 1% BSA; 0.1% Tween-20; 0.05% Triton-X-100, all in 
PBS. Slides were then rinsed 2x PBS. Primary antibodies were applied diluted in 
blocking buffer (for dilutions and antibody details, see table below), and incubated 
overnight at 4oC. The sections were then washed as above and then incubated in the 
relevant fluorescent conjugated secondary antibody, either Alexa Fluor® 488  Fab’ 
fragment or Alexa Fluor® 594 Fab’ fragment (Invitrogen) in blocking buffer for 1 h at 
RT (for reactive species used, see table below). Sections were washed extensively in 
PBS followed by PBT and then mounted in Vectashield (Vector Laboratories) 
containing DAPI fluorescent stain at 0.1 µl/ml to visualize cell nuclei. For Lef1 primary 
antibody, the manufacturer’s immunohistochemistry protocol (paraffin) was followed up 
to the point of incubation in blocking solution. Instead, blocking solution was made up 
according to the vectastain® ABC-AP kit protocol (Rabbit IgG; Vector Labs, 
Switzerland, product ID: AK-5001), which was followed from the blocking stage to 
completion. The substrate used was BM-Purple AP Substrate Solution (NBT/BCIP) 
(Roche) and slides were mounted in Vectashield (Vector Laboratories). A list of 
antibodies used is presented in table 3.3. 
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Antigen Dilution Species Manufacturer/ Reference Secondary Antibody  
Fbn2 1:150 Rabbit anti-mouse (PAb) 
L. Sakai, Portland, 
OR Goat anti-rabbit 
Sox2 1:1000 Rabbit anti-mouse (PAb) Chemicon AB5603 Goat anti-rabbit 
Pax6 1:20 Mouse (MAb) 
V. v Heyningen, 
MRC HGU Goat anti-mouse 
Lef1 1:1000 Rabbit MAb Cell Signaling 
#2230 Goat anti-rabbit* 
A-Caspase-3 1/500 Rabbit MAb BD Pharminogen 
#559565 Goat anti-rabbit 
Rhodopsin 1/2000 Mouse (MAb) Abcam ab5417 Goat anti-mouse 
GFAP 1/500 Mouse (MAb) Sigma G3893 Goat anti-mouse 
Calbindin 1/1000 Rabbit anti-mouse (PAb) Millipore AB1778 Goat anti-rabbit 





Millipore AB9014 Rabbit anti goat 
Table 3.3. Details of antibodies used. * Colourmetric reaction used for Lef1 antibody 
(see above). 
 
3.2.24. RNA In Situ Probe Synthesis 
Probe synthesis was performed with cDNA prepared as described above. 2-4 µL 
cDNA template was mixed with 10x PCR buffer (Roche, Faststart Amplitaq); 1.0 µl 
dNTP mix (10 mM each dNTP); 0.6 µl Amplitaq polymerase enzyme; 1.0 µl 
Oligonucleotide mix (see appendix 6.4 for the sequences of individual primers); with the 
total reaction mix made up to 50 µl. Reaction conditions were as follows: 94oC x 3 min; 
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35 cycles of: 94oC x 30s; 57oC x 40s; and 72oC x 1 min 25 s; followed by a single step of 
72oC x 10 min. PCR products (5 µl) were run on 1% agarose gel containing ethidium 
bromide to visualise the presence of specific amplicons of correct size and were then 
purified (QiaGen PCR Purification Kit) according to the manufacturers instructions. 
Purified PCR product (~150 ng) was incubated for 37oC for 2 h in a 20 µl reaction 
containing: 2 µl transcription buffer; 1 µl RNase inhibitor (Roche); 2 µl DIG RNA 
labelling mix; T7 RNA polymerase; and ultra-pure H2O. An additional 1 µl T7 RNA 
polymerase enzyme was added after 1 hr incubation to increase yield. Transcription of 
probes was confirmed by running 1 µl product on an agarose gel (1% TBE with 0.5% 
TBE running buffer) containing ethidium bromide. 10 Units of DNaseI were added to 80 
µl ultra-pure H2O, which was subsequently added to the probe reaction to remove 
template DNA, and together the mix was incubated for 10 min at 37oC. RNA probe was 
then precipitated with 10 µl sodium acetate (3 M; pH5.4) and 250 µl ethanol (pre-cooled 
to -20oC) on dry ice for 1 h and centrifuged at 13,000 x rpm for 30 min at 4oC. RNA 
pellets were washed once in 500 µl 70% EtOH (DEPC-treated H2O) and air-dried before 
rehydrating in 50 µl ultrapure H2O, quantifying on a NanoDrop, and then stored at –
40oC. 
 
3.2.25. Section In Situ Hybridisation 
For section in situs, tissues were dissected and processed as described for 
immunohistochemistry, with the exception that PBS or graded dilutions of ethanol were 
prepared in 0.1% DEPC-treated water. For section in situs, all solutions were made 
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using 0.1% DEPC-treated sterile water or PBS for all pre-hybridisation stages. Washes 
and incubations were carried out at RT, unless otherwise stated, in 4h baked glassware 
free of RNases, and paraffin sections were cut at 6 µm. Solutions were generally made 
up to 50 ml in Falcon tubes and numbered accordingly for convenience. Coplin jars were 
used as vessels for each wash or incubation stage, unless stated otherwise. The steps for 
this procedure are listed in tables 3.4 and 3.5. 
 
Table 3.4. Slide preparation and hybridisation for section In Situ hybridisation 
(Note: *TEA treatment requires vigorous agitation for the first min of each stage) 
 
Step Solution Temperature Incubation time 
1 Xylene RT 1 h 
2 Xylene RT 15 min 
3 100% EtOH RT 15 min 
4 100% EtOH RT 5 min 
5 100% EtOH RT 5 min 
6 90% EtOH RT 5 min 
7 70% EtOH RT 5 min 
8 50% EtOH RT 5 min 
9 30% EtOH RT 5 min 
10 PBS RT 5 min 
11 PBS RT 5 min 
12 4% PFA RT 20 min 
13 PBS RT 5 min 
14 PBS RT 5 min 





16 4% PFA RT 10 min 
17 PBS RT 5 min 
18 PBS RT 5 min 
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19 0.2 M HCl RT 10 min 
20 PBS RT 5 min 
21 PBS RT 5 min 
22 0.1 M TEA RT 1 min* 
23 0.1 M TEA + acetic anhydride RT 5 min* 
24 0.1 M TEA + acetic anhydride RT 10 min* 
25 PBS RT 5 min 
26 PBS RT 5 min 
27 30% EtOH RT 2 min 
28 50% EtOH RT 2 min 
29 70% EtOH RT 2 min 
30 90% EtOH RT 2 min 
31 100% EtOH RT 2 min 
32 100% EtOH RT 2 min 
 
Slides were then air-dried in the Coplin jar for 10 min while the hybridisation 
chamber was prepared by soaking Whatmann paper with humidity solution (5x SSC pH 
4.5/50% Formamide) and laying cut pastette shafts adjacently to raise slides and keep 
them horizontal). Aliquots of hybridization buffer were preheated to 85oC for 15 min 
and then probe was added at concentration of ~500 ng/µl, allowing for 200 µl total 
hybridisation mix per slide, and incubated for a further 10 min 85oC and then placed on 
ice. Hybridisation mix was added to each slide and then covered neatly with cut parafilm 
to prevent evaporation. Slides were placed in hybridisation chamber and incubated at 
55oC for 16-20 h. Proteinase K (10 mg/ml) was added to PBS for a final concentration of 
20 µg/ml (100µl to 50 ml PBS). For 0.2 M HCl: a 1:5 dilution of 1 N HCl was prepared 
(9 ml concentrated HCl; 241 ml H2O). For TEA (0.1 M), 6.7 ml of 98% Triethanolamine 
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(Sigma) was added to 500 ml sterile ultrapure H2O and filtered. 125 µl acetic anhydride 
(Sigma) was then added to 50 ml TEA (0.1 M) for washes 23 & 24. Hybridisation buffer 
(50 ml) was made using 25 ml distilled formamide; 12.5 ml 20x SSC (DEPC) pH 4.5; 
2.5 ml 20% SDS; 250 µl yeast tRNA (50 mg/ml); 125 µl Heparin (20 mg/ml); and 10 ml 
ultrapure H2O. 
Table 3.5. Post-hybridisation steps for section In Situ hybridisation. (Note: 
*Blocking and antibody incubation steps were carried in post-RNase humidity chambers 
prepared as before but by substituting 5xSSC/50% formamide with ddH2O. ** TBST-
Levamisole treatment required agitation) 
 
Step Solution Temperature Incubation time 
1 5x SSC (to remove 
parafilm) 
60oC 5 min 
2 2x SSC/50% formamide 60oC 20 min 
3 TNE RT 10 min 
4 TNE 37oC 10 min 
5 TNE + RNase A 37oC 35 min 
6 TNE RT 10 min 
7 TNE RT 10 min 
8 2x SSC 60oC 15 min 
9 2x SSC 60oC 15 min 
10 0.2x SSC 60oC 15 min 
11 0.2x SSC 60oC 15 min 
12 1x TBST RT 15 min 
13 Dry slides - - 
14 1x Blocking Reagent RT 1 h* 
15 Anti-DIG-AP (1:2000) RT 1 h* 
16 1x TBST + Levamisole RT 15 min** 
17 1x TBST + Levamisole RT 15 min** 
18 APB Buffer RT 15 min** 





Reactions were stopped by 3x 5 min washes in ddH2O, followed by dehydration in 
3x 2 min washes in 100% EtOH and 4x 2 min washes in Xylene. Slides were then 
mounted in Permount and covered with a coverslip and air-dried in a fume-hood. 
Dilutions of SSC were made from 20x stock SSC. TNE buffer was made using 100 ml 
of 5 M NaCl; 5 ml of 1 M Tris HCl (pH 8.0); and 1 ml of 0.5 M EDTA, adding 
deionised H2O to 500 ml. 120 µl RNase A (10 mg/ml) was added to 50 ml TNE buffer. 
A stock solution of 10x Blocking reagent (Roche) was made in 1 M Maelic acid and 
stored in aliquots at –20oC and working solutions (1x) were made by adding 5 ml to 45 
ml TBST. Anti-DIG-AP (Roche) was diluted 1:2000 in 1x blocking reagent, allowing ~ 
500 µl per slide. Levamisole (800µl of 125 mM) was added to 50 ml TBST to a final 
concentration of 2mM. APB buffer (50 ml) was made from 0.5 ml Tween-20; 1 ml 5 M 
NaCl; 2.5 ml Tris-HCl (pH 9.5); 800µl of 125 mM Levamisole; 12.5 ml of 200 mM 
MgCl2 and 32.5 ml deionised H2O.  BM-Purple AP Substrate Solution (NBT/BCIP) 
(Roche) was applied liberally until colour development and rinsed off with sdH2O. 
Slides were mounted in Vectashield (Vector Laboratories).  
 
3.2.26. Whole mount In Situ hybridisation 
Embryos were dissected as described for immunohistochemistry. All solutions 
were made from RNase-free, DNase-free sterile Ultrapure dH2O. Dissected embryos 
were washed 2x in PBS and fixed in 4% PFA in PBS overnight at 4oC. The steps for this 
procedure are listed in tables 3.6 and 3.7. 
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Table 3.6. Pre-hybridisation steps for whole mount In Situ hybridisation. 
Step Solution Temperature Incubation time 
1 PBT  RT 2x 5 min 
2 25% Methanol:PBT RT 5 min 
3 50% Methanol:PBT RT 5 min 
4 75% Methanol:PBT RT 5 min 
5 100% Methanol RT 5 min 
6 100% Methanol RT 10 min 
Optional 100% Methanol -20oC Storage < 2 months 
7 75% Methanol:PBT RT 5 min 
8 50% Methanol:PBT RT 5 min 
9 25% Methanol:PBT RT 5 min 
10 PBT RT 10 min 
11 6% H2O2 in PBT RT 1 h 
12 PBT RT 3x 5 min 
13 10 µg/ml Proteinase K RT E10.5=20 min; E11.5=25 min; 
E13.5=30 min 
14 2 mg/ml Glycine in PBT RT 5 min 
15 PBT RT 2x 5 min 
16 Pre-hybridisation buffer Pre-warmed 65oC Until embryos sink 
17 Pre-hybridisation buffer Pre-warmed 65oC O/N 
 
 Hybridisation buffer for whole mount In Situs is the same as for section In Situs, 
and aliquots were preheated to 85oC for 15 min. Riboprobes were added at concentration 
of ~500 ng/µl and cooled immediately on ice. Hybridisation buffer with riboprobe mixes 
was added to embryos and together were incubated 2x O/N.  
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Table 3.7. Post-hybridisation and detection steps for whole mount In Situ 
hybridisation. 
 
Step Solution Temperature Time 
1 Solution A 65oC 5 min 
2 50:50 solution 65oC 5 min 
3 2x SSC; 0.1% CHAPS 65oC 2x 30 min 
4 0.2x SSC; 0.1% CHAPS 65oC 2x 30 min 
5 Cool on bench RT 5 min 
6 TBST RT 3x 5 min 
7 TBST 4oC 72 hr 
8 10% Sheep serum in TBST RT 6 h (rocking) 
9 1:2000 Anti-DIG 1
oAb in 1% sheep 
serum in TBST RT 1 min 
10 1:2000 Anti-DIG 1
oAb in 1% sheep 
serum in TBST 4
oC O/N 
11 TBST 4oC 3x 5 min 
12 TBST RT 5x 12 min 
13 TBST 4oC O/N 
14 Repeat steps 11-13 - - 
15 NTMT RT 1 min 
16 NTMT RT 3x 10 min 
17 BM-Purple with Levamisole RT Colour development 
18 NTMT RT 2x 10 min 
19 PBS (pH  5.5) 1% Triton-X-100 RT 10 min 
20  4% PFA/ 0.1% Glutaraldehyde RT 20 min 
21 1% PFA or PBS 4oC Store 
 
Solution A contained 5x SSC (pH 8.0), 0.1% Triton-X-100, 0.5% CHAPS, 50% 
Ultrapure Formamide.  Anti-DIG-AP (Roche) antibody was diluted 1:2000 in blocking 
buffer, which has the same ingredients as for section in situs NTMT buffer contained 
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0.1% Triton-X-100, 100 mM NaCl, 100 mM Tris, 50 mM MgCl2. Levamisole (125 mM) 
was added to BM-Purple Substrate (Roche) to a final concentration of 0.5 mM.
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4. Results 
4.1. Genetic mapping and analysis of the OAS locus 
4.1.1. DNA was obtained from two separate OAS families  
DNA was obtained with consent from affected patients, unaffected sibs and 
parents from two separate families containing a total of three OAS patients (figure 
4.1.1A & B). No further pedigree information was available for these families to 
illustrate the nature of the consanguineous relationships 
Family C was an unpublished multiplex OAS family, of Turkish origin and was a 
1st-cousin marriage. There were five sons, two of whom were affected with OAS. The 
first proband (Family_C; severe) had bilateral anophthalmia, oligodactyly of both feet 
affecting the fifth rays, syndactyly of both feet, severe mental retardation, horseshoe 
kidney and cleft palate.  The other affected brother (Family_C; mild) had syndactyly of 
toes 3-5 and 4 & 5 on the right and left feet, respectively, and horseshoe kidney. He did 
not have an eye phenotype. Two of the other brothers had horseshoe kidney but no 
features of OAS and the other boy was normal. The presence of horseshoe kidney in this 
family may extend the phenotype range of OAS. Indeed, another case from a separate 
family (Garavelli et al., 2006) described a male patient with bilateral anophthalmia and 
hindlimb oligodactyly who also inherited horseshoe kidney. Renal ultrasounds of the 
parents were normal.  There are no other reports of kidney abnormalities in any other 
reported cases, however this may reflect that only 5 other OAS reported patients 
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received a renal ultrasound examination.  Horseshoe kidneys are the most common type 
of fused kidneys and can be inherited as isolated, or associated with other syndromic 
disorders  (van Allen, 1993). In the case of the two boys who have horseshoe kidney but 
no OAS features in the family recruited for this study, this poses the possibility that 
these boys either have non-penetrant OAS, or that the kidney anomaly is a separately 
inherited condition. For the purpose of this study these two boys were classified as being 
unaffected and no further investigation of horseshoe kidney was undertaken. 
 
Family_140 (al Gazali et al., 1994)was from a 1st cousin Syrian marriage with 
one boy of twins presenting with OAS and the other boy was normal. The OAS case had 
unilateral microphthalmia, bilateral oligodactyly of the fifth toes, fusion of 4th and 5th 
metacarpals and a slight delay in motor development.  
 
DNA from patients, parents and affected sibs was used for 10k Array analysis. 
The autozygosity mapping was performed using data from affected individuals only.  
 
4.1.2. 10K SNP arrays identified an OAS candidate interval on chromosome 14 
DNA from these individuals was used for SNP genotyping analysis with the 
Affymetrix GeneChip® Human Mapping 10K Array Xba 131 platform. This array 
contains approximately 11,500 SNPs tiled on a single array with an average 
heterozygosity rate of 0.37 and an average distance of 210 kb between SNPs. Primary 
chromosomal SNP raw data was produced in Excel spreadsheets from the output 
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Affymetrix GeneChip® DNA Analysis Software. For each affected individual, the data 
was sorted by chromosome and genetic distance and was then analysed for genome wide 
linkage using ExludeAR spreadsheets. The output was listed as the 10x largest runs of 
homozygous SNPs by physical distance, including the genomic coordinates, the number 
of consecutive homozygous SNPs and the numbers of ‘no-calls’ contained in the run.  
 
For analysis of a single patient, a run of 46 consecutive homozygous SNPs 
would appear by chance less than 1 in 1000 times, for two sibs, this would be 23 SNPs, 
and additionally the same probability is assigned to a run of 10 consecutive, 
homozygous and concordant SNPs in the analysis of 2 siblings and 1 unrelated 
individual.   For both OAS affected individuals in Family_C, an overlapping run of 72 
consecutive homozygous SNPs was identified on chromosome 14. This region was 
within the proximal and distal boundaries of a larger run of 194 consecutive, 
homozygous SNPs identified on chromosome 14 in the OAS patient of Family_140. 
These were the only significant regions of overlapping autozygosity detected. Combined 
together as data from 2 siblings and 1 unrelated individual, this constitutes a highly 
significant run of 72 consecutive, homozygous and concordant SNPs. The physical 
distances of these regions are defined by the genomic locations of the first flanking 
heterozygous SNPs of each run. For Family_140 these are at 53,193,709-99,862,235 bp, 
for Family_C (mild) 53,596,965-75,862,258 bp, and for Family_C (severe): 51,074,896-
75,862,258 bp (figure 4.1.1C). Thus, chromosome 14: 53,596,965-75,862,258 bp was a 
22.3 Mb candidate interval for OAS. 
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Figure 4.1.1. Patients overlap for regions of extended autozygosity on 
human chromosome 14 to define a 4.2 Mb critical interval for OAS.  
Pedigrees for two families (A & B) recruited for mapping study by this research group 
(Edinburgh). (A) Family C (unpublished) is the product of a Turkish consanguineous 
marriage and contains five boys examined during childhood, two of which have the 
OAS phenotype. One boy is severe for OAS (II5; filled box), while another is mildly 
affected (II4; grey box). Two boys had isolated horseshoe kidney but do not have OAS 
phenotype (II1 & II2). The other boy is normal (II3). (B) Family 140 (al Gazali et al., 
1994) contains one OAS boy (II2; filled box), examined at both and 8 months old, of 
twins from a 1st cousin Syrian marriage. The other boy is normal (II1). (C) DNA from 
OAS families from the Edinburgh cohort was analysed for regions of extended 
autozygosity in affected individuals using Affymetrix 10K SNP arrays. All three 
affected individuals overlapped at a region on chromosome 14 between 53,596,965-
75,862,258 bp. By including similar analyses of data from a collection of OAS patients 
gathered by collaborators in Nijmegen, The Netherlands, this interval was reduced to 4.2 
Mb, between 69,652,605-73,892,603 bp on chromosome 14. No other regions of overlap 
were observed and this interval was referred to as critical interval 1. 
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4.1.3. Data from OAS patients analysed by Collaborators reduced the 
chromosome 14 interval to 4.2 Mb 
Similarly analysed data from 6x OAS patients from 4x separate families (2x 
multiplex families: sibs 20384 & 20386 and sibs 15781 & 15782; 2 simplex families: 
patients 18176 and 15124. Patient 15124 from non-consanguineous parents, all other 
patients were from marriages of 1st-cousin parents) belonging to collaborators from 
Radbound University Nijmegen Medical Genetics, Department of Human Genetics, was 
added to the Edinburgh OAS cohort. These additional OAS cases also mapped to the 
same region on chromosome 14 and refined this interval to 69,652,605-73,892,603 bp 
(figure 4.1.1C). This 4.2 Mb region was defined as OAS critical interval 1, and using the 
Ensembl BioMart application to extract all coding genes, there were a total of 36 genes 










Figure 4.1.2. The 4.2 Mb critical interval for OAS contains 36 known coding 
genes.  
Using Ensembl to mine the critical interval, 36 known coding genes were identified in 
this region and are listed according to their genomic location.  
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4.1.4. SNP data from another OAS family reduced the critical interval to 3.6 Mb 
 Recruitment of a third family to the collection of OAS families in the 
Edinburgh cohort enabled further genetic mapping. This family contained an OAS-
affected boy and a normal younger sib, the products of an Italian gipsy 2nd-cousin 
marriage (Figure 4.1.3A). No further pedigree information was available for this family. 
 
The proband had bilateral anophthalmia, fused 4th-5th metacarpals bilaterally, and 
fifth-toe oligodactyly with 2nd and 3rd toe syndactyly on both feet, and horseshoe kidney. 
Affymetrix GeneChip® 10k Array analysis using the ExcludeAR software revealed a 
region of autozygosity in the OAS child on chromosome 14:69,652,605-73,059,612 bp 
(Figure 4.1.3B). This overlapped with critical interval 1 and refined it distally by 830 kb 
to 3.6 Mb, creating OAS critical interval 2.  
 
Linkage analysis was performed using SNP data from the four affected OAS 
patients from the three Edinburgh families. Exported SNP data was converted into 
conventional linkage format, together with pedigree files that were generated for each 
family, allele frequencies for the Caucasian ethnic group and the required SNP marker 
data, to enable the running of ALOHOMORA, a data conversion software tool to 
facilitate a genome-wide linkage study of the data. Following error removal, the linkage 
analysis programme Allegro (v1.2c) was then used to undertake a genome-wide 
multipoint linkage analysis, based on a recessive model of inheritance and using a 
disease allele frequency of 0.0001. A LOD score of Z=5.3 was obtained between 
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14q22.3-24.2 (Figure 4.1.3C) with the genomic position 53.156-71.254 cM, delimiting 
an OAS critical interval between 53.60-72.22 Mb. This further reduced the critical 
interval for OAS. The calculated LOD score for this region exceeded the threshold of 
Z=3.3 set for parametric analysis recommended by Lander and Krugylak (Lander and 
Kruglyak, 1995) and was therefore considered as statistically significant. Linkage 








Figure 4.1.3. The OAS critical interval was refined to 3.4 Mb and linkage 
was calculated.  
A third family was added to the Edinburgh cohort. (A) This was a 2nd-cousin gipsy 
marriage containing two boys, one of whom had severe OAS. The other was unaffected. 
(B) Analysis by 10k Xba 131 SNP array identified a region of autozygosity on 
chromosome 14, between 69,425,921-73,059,612 bp. This mapping region overlapped 
with the other cases and reduced the critical interval distally by 830 kb to chromosome 
14:69,652,605-73,059,612 bp. This refined interval was referred to as Critical Interval 2. 
(C) The overlapping regions of autozygosity from the four affected individuals from the 
separate consanguineous families of the Edinburgh cohort achieved a significant LOD 
score of Z=5.3 following parametric multipoint linkage analysis using Allegro (v1.2c) 
and the ALOHOMORA data conversion software. The significance level for parametric 
linkage analysis is set to Z=3.3.  
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4.1.5. A PCR-based sequencing strategy was employed to identify coding changes 
in OAS patients 
 The Ensembl application BioMart identified there were now only 19 
known coding genes in critical interval 2 (figure 4.1.4A). A PCR-based sequencing 
strategy was designed to identify genetic mutations within the critical interval. Genes 
were divided into individual exons, which were ranked according to degree of 
evolutionary sequence conservation using PhastCons17. This programme calculated 
sequence similarity as a measure of evolutionary conservation across 17 vertebrates 
including mammalian, amphibian, avian, and teleost species (Siepel et al., 2005).  
Oligonucleotide primers were designed for sequence analysis using a modified script of 
Primer3 (http://frodo.wi.mit.edu/). This bioinformatics work was carried out by Phillipe 
Gaultier (MRC Human Genetics Unit) 
 
Exons were divided equally between the two collaborative groups and PCR-
based sequencing was performed using unamplified and whole-genome amplified 
genomic DNA samples from 8x OAS patients (Figure 4.1.4B). Using 8x patients 
allowed for high-throughput strategy using 96-well PCR plates with primer pairs for 12x 
exons. The final status of this project was that 61% of all exons in the Edinburgh cohort 
were successfully sequenced for ≥4 patients and a further 11% of exons were either 
partially completed (i.e. for large exons), or had full-exon sequence for between 1-3 
patients. Only 28% of exons had no sequence data generated (figure 4.1.4C).  The status 







Figure 4.1.4. Sequencing of all exons within the refined 3.4 Mb critical 
interval was attempted for a panel of 8 patients.  
(A) Using Ensembl to mine the critical interval, 19 known coding genes were identified 
in this region and were listed according to their genomic location. The exons in these 
genes were ranked according to their sequence conservation across 17 species 
(PhasCons17) and were divided up equally between collaborators for DNA sequencing. 
(B) Table with information for patient DNA samples used in the panel for sequencing. 
(C) Progress of sequencing for Edinburgh cohort, where completed exons refers to those 
where good quality sequence data was produced for the whole exon in four or more 
patients. Partial coverage was applied for exons either with less than four, but more than 











Figures 4.1.5 & 4.1.6. Sequencing coverage for the coding regions of each 
gene.  
Genes that had sequence data generated for the patient panel in the Edinburgh cohort are 
displayed graphically. Green indicated full coverage for that exon and patient, yellow 
was partial coverage for an exon for each patient, whereas red indicated there was no 
sequence data for that exon and patient. Note there is no sequence data for any region of 
genes SYNJ2BP, RGS6, WDR21A, and HEATR4 due to PCR or sequencing failure and 
the majority of exons within these genes belonging to the Nijmegen data set. Green 
indicated complete sequence for that exon, yellow was for incomplete coverage for that 
exon and red was for no coverage due to sequencing failure. X = Identification of 
missense changes not previously reported.  
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4.1.6. The sequencing strategy identified numerous coding and non-coding 
changes in patient DNA 
 For those exons that have been successfully sequenced in the Edinburgh 
data set, many nucleotide changes have been identified (figure 4.1.7). Silent changes, 
defined as not creating a difference in the encoded amino acid at that location, and 
changes in non-coding regions were identified throughout the critical interval (figure 
4.1.7A). There were 14 known polymorphic SNPs identified, of which 8 were within the 
ADAM21 gene. Additionally, this gene contained 2x silent changes not previously 
reported. There were also silent changes noted in PCNX, MAP3K9, SIPA1L1, ZFYFE1, 
and PSEN. Previously reported non-synonymous missense changes were identified in 
the ADAM21, MED6, DPF3, ZFYFE1, and PAPLN genes (figure 4.1.7B), with ADAM21 
containing 3 missense changes alone. Additionally, there were 4x missense changes 
identified in the ADAM21 gene that had not been previously reported (F129C, V158L, 
I161V, AMD V216M; figure 4.1.7C) and a novel non-synonymous change in PCNX 
(T471A). These were all of the nucleotide changes identified in the Edinburgh 










Figure 4.1.7. Nucleotide changes identified in the OAS patient panel in the 
Edinburgh cohort.  
(A) Silent changes, including previously identified SNPs, indicating case number, SNP 
ID or genomic position if not previously recorded, gene ID, nucleotide change and 
Refseq nucleotide for that position. (B) Missense changes identified were all previously 
published and were presented with gene ID, AA change and Refseq nucleotide for that 
position. (C) Predicted missense changes identified in the Edinburgh OAS panel that 
were not already listed as SNPs, presented with gene ID, AA change and Refseq 
nucleotide for that position. Note the absence of data for patient A and C for some 
changes due to PCR or sequencing problems.  
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4.2. Establishing Mp phenotypes for genetic mapping of the Mp locus 
4.2.1. The first generations of Mp displayed eye, limb and ear phenotypes 
The first generation born (G0) from ICSI IVF using the Mp sperm produced a 
litter of five pups. Brendan Doe, formerly of MRC Human Genetics Unit, expertly 
performed the ICSI IVF for this line. Four of these animals, three females and one male, 
were identified as heterozygous for the Mp phenotype, based on the described phenotype 
of combined inheritance of small, flattened ears and microphthalmia. At six weeks of 
age, intercrosses were set up between the affected male and affected females from the 
G0 litter to produce homozygous offspring. 
  
All progeny from the first heterozygote x heterozygote intercrosses were 
analysed (n=21). In contrast to the described phenotype, we noted no mortality in 
homozygotes. At 35 days old (P35) the homozygous Mp phenotype was noted in three 
animals that displayed apparent anophthalmia with complete failure of palpebral fissure 
opening, an event that should usually occur between P12-P15 in laboratory strain mice. 
All of these animals also displayed small, unfolded pinnae and had hind-limb 
oligodactyly (Figure 4.2.1A-F). Animals born with the heterozygous microphthalmia 
phenotype did not display distal limb anomalies. We were thus able to categorise 





Figure 4.2.1 Macroscopic phenotypes of Mp homozygote and 
heterozygote mice  
Gross phenotype analysis illustrated ocular, limb and external ear abnormalities in Mp 
mice (A-F). From analysis of external head features, Mp/Mp animals were identifiable 
by a failure of the palpebral fissures to open (C). In contrast, the palpebral fissures of 
both the heterozygote (B), and the wild type (A) were opened and revealed the presence 
of eyes. In addition, homozygote and heterozygote animals displayed smaller and less 
complex folding of the pinnae (arrowheads), in comparison to wild-type animals. Gross 
analysis of external limbs illustrated hindlimb oligodactyly in homozygote animals (F), 
with digits missing in the axial region of the foot. Heterozygotes (E) did not display a 
hindlimb phenotype and were comparable to the wild type (D). Wild-type forelimbs (G) 
and hindlimbs (I) displayed five rays. In contrast, homozygote hindlimbs displayed 
oligodactyly (J), with osseous fusions between phalanges 2-3-4 in their axial digits. 
Homozygote forelimbs were normal (H). Analysis of embryonic limbs (K & L) during 
development revealed that hindlimb oligodactyly was an embryonic phenotype, and was 
identifiable in the homozygote (L) at E13.5. No obvious ocular defect was noted by 
morphological analysis during embryogenesis.  A graded reduction in the size of 
dissected ocular globes was noted in Mp genotypes at P35 (M), with homozygote and 
heterozygote eyes appearing considerably smaller than wild type, and with the 
homozygote most severely affected (Scale bar = 3.0 mm). Heterozygotes had lens 
cataracts, identifiable at P15 (N). No cataracts were observed in wild types (O). Asterix 





4.2.2. Mp/Mp hindlimbs had osseous oligodactyly and were identifiable during 
embryogenesis 
Skeletal analysis of mutant hindlimbs (Figure 4.2.1G-J) indicated that 
oligodactyly was a result of osseous fusion between mid-axial phalanges, and that 
metatarsal bones remained unaffected. The fusions affected rays 2 and 3; or 3 and 4; or 
2, 3 and 4, but did not ever affect rays 1 or 5.  
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 Macroscopic analysis of embryonic development in mutant litters 
revealed that the homozygous hindlimb oligodactyly was unequivocally evident from 
E13.5 (figure 4.2.1L & K), with large and irregular condensations, consistent with the 
osseous fusion of several digits, present in the central digital regions of the developing 
footplate, which clearly differed from the discrete, regular digits seen in the wild type at 
equivalent stages.  
 
4.2.3. Dissection revealed mutant eyes were microphthalmic 
 
Dissection of eyes from adult mice showed that Mp/Mp were not anophthalmic 
but had markedly reduced eye size, i.e. were microphthalmic. A graded reduction in size 
was seen from wild type, to heterozygote to homozygote (Figure 4.2.1M), with the 
mutant eyes appearing considerably smaller than the wild type.  
 
4.2.4. Mp/Mp neonates were runted 
 
 Animals were weighed to analyse the runted phenotype of the 
homozygote mutants described previously. In intercrosses between heterozygotes, 
homozygous progeny at P21 or younger showed a significant reduction in weight 
compared to the other phenotypes, with the mean weight of homozygotes less than half 
that of heterozygote and wild-type animals (Figure 4.2.2A). In contrast, there was no 
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significant difference observed between the weights of wild-type animals and 
heterozygotes in this age range. In outcrosses of heterozygotes to wild-type C57Bl6/J 
animals, where only adult heterozygote and wild-type progeny weights were analysed, 
there was no significant difference noted between the weights of these phenotypes 
(figure 4.2.2B). The weighing of animals for these analyses was performed by Margaret 







Figure 4.2.2  Homozygous Mp mice were runted.  
Average weights of animals were recorded from both intercrosses (A) and outcrosses 
(B) of the Mp line.  (A) Weights from the three genotypes recorded between post-natal 
days 14-22 shows there to be no significant weight difference between heterozygotes 
and wild-types, but that homozygotes have significantly lower weighs than both of these 
classes. (Wt, n=19; Mp/+, n=51; Mp/Mp, n=7). (B) Weights for heterozygotes and 
wild-types show no significant difference at age ranges P30-60, and P60 and older (n 
values are: Wt=41; Het=20 and Wt=14; Het=24, for P30-60 and P60+, respectively). For 
both analyses, confidence intervals of 95% were used. 
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4.2.5. Sufficient phenotype information was therefore established for genetic 
mapping Mp 
Taken together, these phenotypic features were sufficient to differentiate 
between wild-type mice and those homozygous or heterozygous for Mp. Therefore, to 
develop a genome mapping strategy to identify the disease locus, these features were 
used to phenotypically analyse all offspring from post-natal day 21 onwards.
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4.3. Analysis of the Mp ocular phenotype 
 
4.3.1. Adult Mp eyes displayed pan-ocular malformations 
 
Histological analysis of the Mp ocular phenotype was begun with animals at P15 
using Haematoxylin & Eosin (H&E) staining (Figures 3.2.3 & 3.2.4). At this stage, the 
Wt cornea, ciliary body, anterior segment and iris were formed normally. Vitreous body 
physically separated the central lens from the retina, the lens is mature and all retinal 
layers are present (Figure 4.2.3A). In contrast, mutant animals at the same stage 
appeared to lack vitreous body and had disruptions to the laminar structure of the retina 
(Figure 4.2.3B & C), indicated by the presence of abnormal folding of the cell layers and 
circular, rosette-like structures composed of cells and their processes interrupting the 
normal uniform lamination of the retina. In addition, the Mp/Mp eye displayed a 
thickened and abnormal cornea, and the lens appeared structurally abnormal and 
regionally displaced the retina (Figure 4.2.3C). These additional phenotypic features 
were not seen in Mp/+ eyes (Figure 4.2.3B). The extension of RPE in the mutant to 
between lens and cornea was an artefact due to the plane of sectioning in this specimen 










Figure 4.2.3 Histological analysis revealed Mp mice display a severe  pan-
ocular phenotype.   
Haemotoxylin & Eosin (H&E) analysis of full eye composites from paraffin-embedded 
coronal sections at post-natal day (P)15 indicated gross structural malformations. In the 
Wt eye (A) the cornea (C), iris (I), anterior-segment (AS), and RPE were fully formed, 
and the vitreous body (VB) separated the lens (L) and retina (R). In contrast, the space 
occupied by VB between lens and retina was missing in heterozygotes (B) and 
homozygotes (C). In addition, mutant retinas displayed disorganisation in the normal 
lamination of cell types and were folded, or had rosettes, in discrete regions, as indicated 
by white arrowheads (B & C). The retinal phenotype was more severe in the 
homozygote, with increased folding than heterozygote, and was associated with 
increased corneal thickness and a structurally malformed lens, which had dorsally 
displaced the retinal tissue in this sample. These features were not seen in the 
heterozygote eye. The RPE continuation across the lens in the anterior region of the 
homozygote was an artefact of planar deviation on sectioning. 
 
 
4.3.2. Mp retina layers were abnormally patterned and presented with rosette 
structures 
Higher magnification analysis of retinas revealed major differences between wild 
type and mutant retinas (figure 4.2.4A-C). The rosettes observed in the heterozygote 
retina affected cells from both the inner and outer layers and their associated plexiform 
layers (Figure 4.2.4B). The homozygote retina (Figure 4.2.4C) was more severely 
disrupted than the heterozygote and individual cell layers were not easily identified, 
although homozygous rosettes appeared to be composed only of cells from the outer 
nuclear and plexiform layers. In addition, homozygote retinas appeared to have reduced 
numbers of ganglion cells.  
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4.3.3. Mp/Mp eyes displayed additional abnormalities in cornea, lens and ciliary 
body 
Macroscopic analysis of lenses, corneas and anterior segments (Figure 4.2.4D-F) 
revealed that in the homozygote, stromal cells of the cornea were not correctly organised 
into the linear configuration seen in Wt and heterozygotes. Additionally, the lens of the 
homozygote did not have the normal stratified appearance of both the wt and 
heterozygote lenses.  Instead the homozygote lens appeared globular in structure and 
displayed various vacuoles. Furthermore, there were disruptions to the anterior segment 
of heterozygote and homozygote animals, with the complete loss of ciliary processes in 
homozygotes and only rudiments of these processes present in the heterozygote.  







Figure 4.2.4  Higher magnification analysis of mutant eyes revealed severe 
retinal and anterior-eye abnormalities.   
Higher magnification analysis revealed the rosettes were possibly composed of cellular 
projections from the outer nuclear layer in the heterozygote (B) but in the homozygote 
(C), the severity of the folding inhibited the identification of particular cell types of the 
rosettes. Some ganglion cells were identifiable in the inner-most region of the 
homozygote retina, whereas in both heterozygote and homozygote the outer segment 
was only present between RPE and outer nuclear layer in certain regions and was not 
continuous (arrowheads). Enlarged images of the anterior ocular regions (D-F) reveal a 
graded disruption to ciliary processes (arrows), with none identifiable in the homozygote 
(F & inset), and a reduced structure in the heterozygote (E), compared to the Wt (D). In 
addition, the cornea of the homozygote is disrupted in the stromal layer, with a loss of 
normal layer organisation and vacuolar spaces between some cells (filled arrowheads), 
resulting in a thickened corneal structure overall. GCL, ganglion-cell layer; INL, inner 
nuclear layer; ONL, outer nuclear layer; IPL, inner plexiform layer; OPL, outer 




4.3.4. Rosettes in the retinas of mutant eyes were predominantly composed of 
disorganised rod-photoreceptor cells 
Paraffin embedded eye sections from adult (P56) wild type, heterozygote and 
homozygote mice were analysed by immunofluorescence using primary antibodies as 
markers for specific retinal cell types. Although I prepared these samples,  this 
immunostaining work was performed by Dr. Sebastien Mella (MRC Human Genetics 
Unit). 
The anti-Rhodopsin primary antibody is a recognised general marker for rod 
photoreceptors and stains cytoplasmic regions within the outer segment (OS) and outer 
nuclear layer (ONL) of the wild type retina (figure 4.2.5A), consistent with the 
distribution of rod cells within the proximal layers of the retina. The distribution of 
Rhodopsin in the heterozygote (figure 4.2.5B) retina was similar to the wild type in 
ONL and OS, however it was noted that there was no region of non-staining between the 
proximal-most nuclei of the ONL and the Rhodopsin-positive OS, a region which was 
clearly defined in the wild type. The homozygote retina showed severe disruption to the 
distribution of Rhodopsin staining (figure 4.2.5C). There was no outer segment visible, 
and there were large foci of intense staining that were spatially and morphologically 
consistent with the retinal rosettes previously seen with H&E staining. Adjacent to these 
regions were cell nuclei with perinuclear Rhodopsin staining, similar to those seen in the 
heterozygote and wild type rods of the ONL, suggesting that rosettes were composed of 
rod photoreceptor cells that were disorganised in orientation. Regions of inner nuclear 
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layer (INL) and ONL, as well as outer plexiform layer (OPL) were indistinguishable in 
the homozygote.  
 
4.3.5. Mutants had increased retinal levels of the astrocyte and retinal stress 
marker, Gfap but showed reduced horizontal cell numbers by Calbindin staining 
Antibodies to the astrocyte marker and indicator of retinal stress; Glial fibrillary 
protein (Gfap), and the horizontal and amacrine marker; Calbindin, were used to 
examine the spatial distribution of these cells in Mp mutants. Wild type Gfap was 
observed adjacent to the ganglion cell layer (GCL), possibly within the inner limiting 
membrane of the retina, with some projections penetrating the IPL (figure 4.2.5D). No 
signal was detected elsewhere in the retina. In both of the mutants (figure 4.2.5E & F), 
Gfap signal was identified throughout the INL and the number of projections into the 
IPL was considerably increased compared tot the wild type. Additionally, there was a 
substantial and graded increase in the levels of Gfap signal adjacent to the GCL in the 
heterozygote and homozygote.  
 
Calbindin signal was identified within the inner nuclear layer and inner 
plexiform layer of wild type retinas (figure 4.2.5D), but the strongest signal was 
observed in the outer plexiform layer (OPL). In heterozygote (figure 4.2.5E) and 
homozygote (figure 4.2.5F) retinas, this distribution was unchanged, however there was 
an obvious and graded decrease in the numbers of positive foci within the OPL in 
heterozygotes and homozygotes. Nevertheless, there were positive cells present in the 
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homozygote, and these cells provided a possible landmark to spatially differentiate the 
INL and ONL. 
4.3.6. Staining for Chx10 and Pkc∝  revealed a reduced INL in homozygote retinas 
Bipolar cells located in the INL were identified with co-immunofluorescence 
using antibodies specific for Chx10 and Pkc∝ (rod-bipolar cells). In wild type (figure 
4.2.5G), heterozygote (figure 4.2.5H) and homozygote (figure 4.2.5I) retinas, co-
localisation was observed within nuclei of the proximal INL, while there were Chx10-
only positive nuclei within central regions of the INL. There was an additional region of 
ILN that was non-staining for either marker, and that appeared to contain an equal 
number of cell nuclei to the positive staining INL. A further Pkc∝-positive domain was 
identified in the distal-most region of the IPL, immediately adjacent to the CGL. In this 
region the protein localisation was cytoplasmic.  
 
There was a general reduction in positive staining nuclei for both markers within 
the homozygote INL, and additionally there were fewer non-staining nuclei in the distal 
INL. Staining of both markers in the heterozygote was equivalent to the wild type. 
Therefore, there were no clear differences in the distribution of these proteins between 
the genotypes (figure 4.2.5G-H), and although bipolar cells are not specifically affected, 






Figure 4.2.5 Immunofluorescence analysis of adult eyes revealed multiple 
retinal abnormalities in Mp.  
Adult eyes (at P56) were analysed by immunofluorescence with antibodies to Rhodopsin 
(A-C), by co-immunofluorescence for Glial Fibrillary Protein (Gfap) and Calbindin (D-
F), and by co-immunofluorescence for Protein Kinase C-alpha (Pkc∝) and the 
homeobox protein Chx10 (G-I). DAPI was used to counterstain cell nuclei. Rhodopsin 
specifically stained rod photoreceptor cells (red) and in the wild type (A), signal was 
seen in cytoplasmic regions of both the outer segment (arrows) and the outer nuclear 
layer (arrowheads) consistent with projections of rod cells. The heterozygote (B) 
Rhodopsin distribution was comparable to wild type in the ONL (arrowheads) and in the 
outer segment of rod cells (arrows); however, there was reduced space between outer 
segment staining and the nuclei of the ONL, indicating loss of the inner segment (white 
arrowheads).  The homozygote (C) had no outer segment staining (white arrowheads) 
and displayed perinuclear cytoplasmic signal (arrowheads); presumably these were cells 
of the ONL based on the morphological similarity to ONL cells of wild type and 
heterozygote. In addition, homozygotes displayed large and dense foci of signal (arrows) 
consistent with central regions of rosettes and which displayed similarity to the staining 
seen in outer segments of heterozygote and wild type. Regions of INL and ONL, as well 
as OPL were indistinguishable in the homozygote. In the wild type retina (D) Gfap (red) 
stained astrocytes at the region of the inner limiting membrane (arrows), with some 
projections into the IPL. Calbindin (green signal) stained horizontal cell and amacrine 
cell projections in both the OPL and IPL (arrowheads), with strongest staining in the 
OPL. In both mutants (E & F), there was a considerable increase in Gfap signal and the 
spatial distribution was markedly different, with signal found among cells of the 
internal-most layer of nuclei in homozygote (F) and INL of the heterozygote (E; 
arrows). In contrast, Cabindin signal was reduced in the OPL of the heterozygote, while 
in the homozygote; some signal was visible within the central region of the internal mass 
of nuclei (arrowheads), indicating a possible boundary between nuclei of INL and ONL. 
In both mutants, signal in the IPL remained comparable to wild type.  Pkc∝ (red 
signal) and Chx10 (green signal) were mostly distributed in the proximal layers of nuclei 
(arrows) in the INL in wild type retina (G), with some Pkc∝ observed in the IPL 
adjacent to ganglion cells (arrowheads). There was additionally a layer of Chx10-only 
positive nuclei in the central region of the INL, which was apposed to a region of non-
staining cells of the distal-most region of INL. Although the number of cells in the INL 
that positively stained for both markers, and Chx10-only were reduced in the 
homozygote (I), they were spatially comparable to both wild type (G) and heterozygote 
(H) (arrows). Additionally, there was no clear difference between genotypes for Pkc∝ 
staining in IPL regions directly adjacent to the GCL (arrowheads). RPE, retinal 
pigmented epithelium; OS, outer segment; IS, inner segment; ONL, outer nuclear layer; 
INL, inner nuclear layer; IPL, inner plexiform layer; OPL, outer plexiform layer, GCL, 
ganglion cell layer. 
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4.4. Histological examination of the developing Mp eye 
 
4.4.1. Embryonic stages E13.5 to E15.5 
 
Histological staining with Haematoxylin and Eosin was used on sections cut 
from paraffin-embedded embryos and post-natal eyes. Initial analyses were performed 
on eyes from E13.5 embryos (figure 4.2.6A). In all genotypes (wt, Mp/+ and Mp/Mp) 
the major components of the ocular system, the lens; retina; RPE; periocular 
mesenchyme; optic stalk; and neural crest cells within the vitreous were present and 
appeared normal, strongly suggesting that early embryonic developmental processes, 
pathways and events were not perturbed in the Mp mouse eye. 
 
As no phenotype was identified in either Mp/+ or Mp/Mp at this stage, further 
analyses were applied to later embryonic stages, beginning at E15.5 (figure 4.2.6B & C). 
By this stage there was an apparent difference in total ocular size noted in the mutants 
compared to the wild type, especially in the homozygote (figure 4.2.6B). Otherwise the 
eyes of the different genotypes displayed comparably normal histological features. It 
was noted that there were aggregates of cells within the developing vitreous body of 
both mutants. These were larger in the homozygote than in the heterozygote and there 
were none initially seen in the wild type. However, further analysis of other animals 
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revealed similar collections in wild types (inset) and that in some mutant eyes they were 
absent. Higher magnification of the developing ciliary body for the different eyes 
identified an apparent difference in the homozygote, compared to the heterozygote and 
wild type (figure 4.2.6C): there were fewer nuclei present and the structure did not 
extend towards the distal lens. This was noted as a possible phenotypic difference but 
with the caveat that it may have been due to slight differences in angle of section.
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Figure 4.2.6  Early ocular developmental events appear normal in Mp at 
E13.5 but phenotype presents at E15.5.  
The lens, retina, RPE, peri-ocular mesenchyme, vitreous and optic stalk were present 
and appeared to have been normally developed in Mp/+ and Mp/Mp eyes at E13.5 by 
histological examination (A) Scale bar = 100 µm. Similarly, by E15.5, the major ocular 
structures were present and appeared normal (B), however the mutant appeared reduced 
in size in comparison to the wild type. There was a also suggestion of persistent neural 
crest cells in the vitreous of mutant eyes, however these were not always found in 
mutants and also were found in some wild type eyes (arrowed in inset) Scale bar = 200 
µm. Additionally, higher magnification analysis revealed possible under-development of 
the ciliary body in the homozygote, with fewer nuclei present and an apparent truncation 




4.4.2. The Mp eye had a growth phenotype identifiable by stage E15.5 
 
 Further investigation of the apparent difference in eye size was carried 
out using OPT (Sharpe et al., 2002) analysis of whole heads from embryos at E15.5. 
Crosses were set up between heterozygotes on the CD1, non-pigmented strain 
background. Litters were collected and embryos were genotyped, dehydrated and 
processed for OPT analysis. Measurements were taken of head length and head width 
(figure 4.2.7A) using Amira software (Amira 4.1.2, Visage Imaging, Carlsbad CA, 
USA) on virtual sections in the horizontal plane running through the centre of both eyes 
(figure 4.2.7B). Measurements were in Voxel units and averages were plotted for each 
genotype (figure 4.2.7C). No significant difference was observed for either average head 
length or width (95% confidence limits, wt, n=5; Mp/+, n=17; Mp/Mp, n=8), however it 
was noted that there was a slight reduction in the average head width sizes from wild 
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type to heterozygote to homozygote. Similarly, measurements were taken for each eye 
for the genotypes (figure 4.2.7D). These were: eye width (taken as the distance between 
lateral edges of retina at the widest point, measurement B), eye length (taken as a sum of 
the lens depth and vitreous measurements at the widest point, measurements A and D) 
and lens diameter (the means of measurements A and C). For each genotype, n values 
were double those for the head measurements, on the basis that each embryo had two 
eyes. The plane of the horizontal virtual section is shown in figure 4.2.7E. All sections 
were aligned so the optic stalk was simultaneously visible for both eyes in each sample. 
The homozygote average eye width measurements were significantly different from 
those of the wild type and heterozygote. Although none of the other measurements 
showed significant differences, there was a graded reduction in both average eye length 
and average lens diameter, indicating that the overall eye size in mutant animals is 
reduced at E15.5, with the homozygotes more severely affected. This result reflects the 
semi-quantitative histological findings seen in this chapter and defines an ocular 
phenotype for Mp at E15.5. 
 
Although I performed the dissections of embryos and eyes, and initial sample 
preparation, OPT analysis and morphometrics were performed by Mr Harris Morrison 








Figure 4.2.7.  Morphometric analysis of embryos at E15.5 revealed a 
graded reduction in ocular size in mutant animals.  
Using length and width measurements (A) taken in the plane of section running through 
the centre of the eye in the horizontal plane (B), there was no overall difference seen 
between genotypes in head lengths (C). However, there was a suggestion of a graded 
reduction in head width sizes, although no level of significance was reached. 
Measurements of ocular sizes, including total eye width, eye length, and lens diameter 
(D) taken from the horizontal plane through the midline of the eye (E). (Note the eye 
length measurements were the sum of measurements A + D from the distal lens to the 
distal retinal edge and did not include the thickness of the proximal retina due to lack of 
clarity of many scans). For all measurements, there was a graded reduction in eye size 
from wild type to heterozygote to homozygote (F).  There was significant difference 
between the eye width of homozygotes to both heterozygotes and wild types, however 
none of the other measurements reached significance. Nevertheless, the trend of eye size 
reduction in mutants is consistent for all three measurements analysed. For (C): n=5 
[wt]; n=17 [Mp/+]; n=8 [Mp/Mp]; for (F): n=10 [wt]; n=34 [Mp/+]; n=16 [Mp/Mp]. 
Averages were calculated from measurement readings recorded in Voxel units using 
Amira software (Amira Release 4.1.2, Visage Imaging, Carlsbad CA, USA). 
Original images were captured by OPT analysis set at a constant magnification. All error 
bars set to confidence limits of 95%. 
 
 
4.4.3. Mutant eyes display defects to vitreous, ciliary body and neural retina 
 Gross histological examination of homozygote versus wild type eyes at 
E16.5 (figure 4.2.8A & B) corroborated the reduction in eye size observed at E15.5, but 
did not reveal any major differences other than a reduction in vitreous body size in the 
mutant. In these samples, the lens, cornea, outer and inner retinal layers and anterior 
segment all appeared normal. Additionally, the pupillary membrane is clearly visible in 
the mutant eye in the anterior chamber extending from iris to lens. Although the angles 
of section were not identical in these sections, a different section through the same eye 
(inset) reveals the optic stalk (arrow) yet maintained the reduction in vitreous. 
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Heterozygote eyes were not analysed at E16.5 and later stages as it was thought that the 
initial ocular phenotype in Mp may be too subtle to identify and therefore comparison 
between homozygote and wild types would be sufficient to identify clues towards the 
pathogenic mechanisms in this mutant line. Higher magnifications in the region of the 
ciliary body (figure 4.2.8C & D) showed thinning in the unpigmented region of the 
mutant ciliary body compared to in the wild type. However, the pigmented region of the 
ciliary, as well as mesenchymal cells of the future iris and cells of the lens and cornea, 
all appeared normal in mutants. Analysis of retinas in equivalent regions between 
mutants and wild types identified the presence of cells with abnormal morphology 
within the neuroblastic region of mutant retinas. These cells resembled the differentiated 
ganglion cells of the inner region of the retina and were seen throughout mutant retinas 
and may therefore be ectopic retinal ganglion cells. Additionally the orientation of the 
cytoplasmic projections of the normally positioned ganglion cells in the mutant was 
more disorganised than in the wild type, where they were oriented in a strict apical-basal 






Figure 4.2.8.  E16.5 Mp/Mp mice display phenotype in multiple ocular 
components.  
Gross histological examination of wild type (A) and Mp/Mp (B) eyes at E16.5 revealed a 
reduction in overall eye size in the mutant with an absence of vitreous body. However, 
the main structures of the eye (lens, retina, cornea and RPE) were present and appear 
grossly normal. The planes of section are not equivalent for these, however a different 
section from the same mutant eye indicates the presence of optic stalk (arrowed in inset). 
Higher magnification images identified the developing ciliary body as being thinner and 
less extended in the mutant (D) than in the wild type (C), consistent with analysis of 
E15.5 mutant eyes (Figure 4.2.6). It was also noted in these magnifications that the lens 
and lens-fibre cells, iris stroma and cornea appeared normal. Retinal examination of 
mutant retina (E) identified the presence of ectopic rounded, darker-staining cells 
(arrows) in the neuroblastic layer, with similar appearance to the inner-layer 
differentiated ganglion cells. In addition, the pink-stained cytoplasmic projections 
(arrowheads) from ganglion cell nuclei appeared to lack the linearly arranged, apical to 
basal orientation of the equivalent cells in the wild type retina (E). Scale bar = 150 µm. 
C, cornea; CB, ciliary body; G, ganglion cell layer; I, retinal inner segment ; Ir, iris 
stroma; L, lens; O, retinal outer segment; OS, optic stalk; R, retina; RPE, retinal 




4.4.4. Late embryonic and newborn developmental stages were perturbed in the 
Mp eye.  
In the E18.5 eye the retina is thinner and there is no apparent vitreous in the 
mutant compared to the wild type (figure 4.2.9A & D). However, the other main features 
of the developing eye appear normal, e.g. lens, cornea, RPE, and retinal layers. Close up 
views of the ciliary body (figure 4.2.9B & E) showed a thinner non-pigmented ciliary in 
the mutant, which was not undergoing the folding seen in the wild type. In this respect, 
now both pigmented and non-pigmented ciliary body development was affected in Mp. 
Higher magnification views of the retina in both samples identified the ectopic cells in 
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the neuroblastic outer layer of the neural retina, but that otherwise the development of 
retinal layers appeared to be normal. 
 
 Consistent with at E18.5, mutant eyes analysed at one day after birth (P1) 
had no vitreous, a thin neural retina, and an obvious disruption to the ciliary body 
(Figure 4.2.9J). Nevertheless, lens cornea, anterior segment, and retinal layering 
appeared grossly normal and comparable to wild type (figure 4.2.9G). Although these 
samples were from non-pigmented animals, it was visible that the wild type had begun 
the complex folding process of both ‘pigmented’ and ‘unpigmented’ ciliary body, and 
that the iris stroma had extended towards, and reached the lens (figure 4.2.9H). In the 
mutant (figure 4.2.9K), there were remnants of the ‘unpigmented’ ciliary apposed to the 
lens capsule and severely disrupted. There were loose cells visible between the 
‘pigmented’ ciliary, which was also abnormally arranged, while the iris had not 
extended towards the lens. No ectopic cells were identified in the mutant retina although 
the ganglion cells maintained their cytoplasmic processes with disturbed orientation 
compared to wild types (figure 4.2.9I & L).  
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 Figure 4.2.9. 
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Figure 4.2.9.  Severe malformations are present at E18.5 and P1 in 
Mp/Mp eyes.  
At E18.5, the Mp/Mp eye (D) was smaller, had a thinner retina and lacked vitreous body 
in comparison to the wild type eye (A). The wild-type ciliary body (B) was thicker and 
more complex than the mutant (E) and had begun the process of folding (arrows) at the 
future ciliary epithelium (pigmented and non-pigmented) to produce the ciliary 
processes. No such folding was observed in the mutant and the iris stroma also appeared 
thinner and less well developed than the wild-type. In both the wild-type (C) and mutant 
retina (F), internal limiting membranes were present, the ganglion cell nuclear layer was 
present and around four cells thick, together with axonal projections and inner plexiform 
layer, and future inner nuclear layer. Ectopic nuclei were again observed in the outer 
nuclear layer of the mutant retina and not in the wild type (arrows). In the newborn (P1) 
eyes from unpigmented animals, there was a marked difference in size between the wild-
type (G) and mutant (J). Additionally, there was no vitreous in the mutant, with the lens 
and retina directly apposed to each other. The retina appeared thinner in the mutant and 
the ciliary body was grossly abnormal.  However, lens, cornea, RPE and retinal layers 
are present and were comparable to the wild-type. Comparison of the developing wild-
type (H) and mutant (K) ciliary body at higher magnification revealed severe structural 
disorganisation in the mutant to the pigmented ciliary processes, while the unpigmented 
region was unidentifiable. In contrast, mutant lens was of normal appearance and lens 
capsules were identified in both mutant and wild-type. In the mutant retina (L), again the 
projections from ganglion cells appear to be disorganised and were not arranged in the 
apical to basal orientation typical of the wild-type retina (I). Scale bars = 100 µm. ILM, 
inner limiting membrane; LC, lens capsule; PC, pigmented ciliary processes; UP, 
unpigmented ciliary processes. * The detachment of RPE from retina is processing 




4.4.5. Late neonates displayed severe retinal defects 
 
  Retinas were examined at P21, by which time full retinal differentiation 
should have occurred. The wild type retina (figure 4.2.10A) displayed all of the features 
consistent with a mature, correctly laminated retina, however both heterozygote and 
homozygote displayed rosetting in the outer nuclear layer (figures 1.10B & C). These 
rosettes consisted of a central core of non-nuclear cell processes surrounded by multiple 
nuclei of photoreceptor cells. Additionally, in both mutants there was a complete lack of 
the inner and outer segments between the RPE and outer nuclear layer (arrows). In the 
homozygote, it was also noted that the outer plexiform layer was thinner and had various 
deviations towards the photoreceptor nuclei in regions between rosettes (arrowheads), 
suggesting that in fact the rosettes were forcing the overlying retinal layers anteriorally 
and that where there were no rosettes this didn’t occur. Indeed, the combination of 
rosettes and photoreceptor nuclei seemed to result in a thickened outer nuclear layer in 
both mutants. In contrast, the inner nuclear layers of mutant retinas seemed unaffected 
but there was a suggestion of thinner inner plexiform layers in both. Additionally, the 
ganglion cell layer was thinner in the homozygote (filled arrows) and was less well 
organised than in the wild type and heterozygote, and in both mutants this cell layer was 





Figure 4.2.10  Retinal layer organisation abnormalities are present in 
postnatal mutant eyes.  
Postnatal eyes of wild type (A), and both mutant genotypes (B & C) were analysed at 
P21 for retinal abnormalities. In both mutants, rosetting (*) was observed in the outer 
nuclear layer and was characterised by foci of tightly organised non-nuclear cell 
projections surrounded by multiple nuclei of cells from the outer layer. Lens was 
directly apposed to the internal retina, and in addition, mutants lacked an outer segment 
between the RPE and the outer nuclear layer (arrows). In the homozygote, there was also 
disruption in the inner plexiform layer at regions adjacent to the rosettes, with an 
apparent deviation towards the gaps between rosettes observed (arrowheads). In contrast 
to both wild-type and heterozygote, the mutant ganglion cell layer was thinner and 




4.5. Genetic mapping of the Mp locus 
 
4.5.1. Mapping crosses 
Crosses were set up to facilitate mapping of the Mp locus (figure 4.3.1A). The 
original background of this line was a mix of inbred strains C3H and 101. To rederive 
the line ISCI IVF was performed with oocytes from F1 female C57Bl6/j x CBA mice. 
The G0 progeny were outcrossed to the inbred strain C57Bl6/j. Phenotypically 
heterozygous F1 animals were then backcrossed to C57Bl6/j. To generate a second 
independent line, heterozygous F1 animals from the initial cross were crossed to the 
CD1 outbred strain. These mice have a mutation in the tyrosinase gene (Jackson and 
Bennett, 1990) that results in albinism. These animals lack pigmentation in the RPE and 
are thus advantageous for OPT analysis of gene expression. Within both backgrounds, 
mice were also intercrossed to produce litters containing homozygote Mp progeny. 
Spleens or tails were used for genomic DNA extraction. 
 
4.5.2. Karyotyping revealed normal chromosomes in Mp 
Karyotyping analysis was performed on chromosomes prepared from cardiac 
blood samples collected from two11-week, phenotypically heterozygous male Mp 
animals from the 3rd backcross to C57Bl6/j. A total of 7 metaphase preparations were 
analysed, with some incomplete for the full complement of chromosomes. Nevertheless, 
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chromosomes were arranged according to homologous pairs and size and a composite 
analysis was performed and indicated there to be no chromosomal abnormality greater 
than 10 Mb detectable (Figure 4.3.1B).  Sample preparation and analysis was done with 
the guidance of Dr. Judy Fantes (MRC Human Genetics Unit). Analytical software 
analysis of Mp chromosome images was done exclusively by Dr. Judy Fantes (formerly 






Figure 4.3.1  Mapping strategy and karyotype analysis of Mp mice 
revealed no detectable large chromosomal abnormality. 
(A) Mp sperm was injected into oocytes of a F1 (C57Bl6/j x CBA) female. The affected 
progeny, G0 heterozygotes, were outcrossed to unaffected C57Bl6/j. These F1 progeny 
were then successively outcrossed to C57Bl6/j for genetic mapping, to CD1 for 
phenotype analysis, or were intercrossed to produce litters containing homozygotes. (B) 
Karyotype preparations from para-cardiac blood samples of heterozygote males from the 
3rd backcross to C57Bl6/j were arranged in homologous pairs according to size. There 
was no obvious chromosomal abnormality detected ≥10 Mb. 
 
4.5.3. The Mp phenotype has full penetrance on two different strain backgrounds 
Phenotype data was recorded for all backcrosses and intercrosses, on both 
backgrounds, for penetrance analysis. The expected number of heterozygous progeny 
from matings between a heterozygote and an unaffected animal is 50% for a monogenic, 
autosomal trait (or a 1:1 ratio). Similarly, in matings between two heterozygous animals 
full penetrance is indicated by the presence of 25% wild type, 50% heterozygous, and 
25% homozygous progeny (or a 1:2:1 ratio, respectively). Numbers were not analysed 
for penetrance in the 2nd outcross to C57Bl6/j. However, no evidence of unequal 
distribution was found by chi-square goodness of fit tests (Appendix 6.3) in the 3rd, 
fourth or 5th outcross to C57Bl6/j and to the first outcross to CD1. In the 3rd outcross to 
C57Bl6/j (figure 4.3.2A) there were 57% heterozygotes and 43% wild-type animals 
recorded (n=131, χ2 = 2.76, P<0.1). In the 4th cross these were 45% and 55%, 
respectively (n=95, χ2 =0.85; p<0.36); and 61% and 39% in the 5th cross (n=18, χ2 
=0.89; p<0.35). While intercrosses between affected animals (figure 4.3.2B) of all 
generations recorded on this background were: 22% wild type; 20% homozygote and 
58% heterozygote (n=87, χ2 =2.68; p<0.26). In the F1 outcross to the CD1 background 
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(figure 4.20C), there were 51% wild type and 49% heterozygotes (n=39, χ2 =0.026; 
p<0.87), while intercrosses between these affected animals gave 23% wild types; 27% 
homozygotes and 50% heterozygotes (figure 4.3D) (n=23; χ2 =0.09; p<0.96). Thus the 
null hypothesis of the phenotype data having an unrelated distribution is rejected, and 
the alternative hypothesis, that the data are consistent with full penetrance, is accepted. 






Figure 4.3.2  Analysis of crosses revealed full penetrance of the Mp 
phenotype.  
Data from 3rd; 4th and 5th outcrosses to C57Bl6/j revealed values consistent with full 
penetrance of the heterozygous phenotype (A) with percentages of heterozygotes 
recorded as 57%; 45%; and 61%, respectively, with n values of 131; 95; and 18, 
respectively. Intercrosses between affected animals on the same background yielded 
58% heterozygotes; 20% homozygotes and 22% wild-types, where n=87 (B). On the F1 
generation of Mp outcrossed to the CD1 outbred background, there were 49% 
heterozygotes to 51% wild-types (C; n=39), while intercrosses between F1 affected 
animals gave 50% heterozygotes; 27% homozygotes and 23% wild-type progeny (D; 
n=22). 
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4.5.4. Genetic Mapping of Mp Using a Whole Genome 768 SNP Panel Array 
Initial whole genome analysis was performed on genomic DNA from 8 x F2 
generation heterozygous animals using the 768 SNP Genotyping Panel (Moran et al., 
2006) together with the F1 and G0 parental DNAs. There were 594 informative SNPs 
between C3H and C57Bl6/j; 430 between 101 and C57Bl6/j; 288 between 101:CBA; 
and 111 between C3H:CBA. Candidate regions were identified by loci showing 
heterozygosity for markers specific for C57Bl6/j and other background strains 
(C3H/HeJ, CBA/J and 101) indicating no meiotic recombination on the host strain 
(C3H) had occurred. The largest candidate interval on this basis was on chromosome 11, 
between markers rs3705751 and 11.114.529 (Figure 4.3.3.A), at 75.432 – 113.477 Mb, 
respectively with a genetic distance of ~38 Mb. This region contained a total of 10 
markers that could discriminate between C57Bl6/j and the C3H/HeJ, CBA/J and 101 
backgrounds strains. However, one segment of ~10 Mb between markers rs3697441-
rs13481185 (89.4 Mb-99.6 Mb, respectively) which was indistinguishable between 
C57Bl6/j and 101. Using an additional 3x phenotypically heterozygote animals of the F2 
generation, however, this critical interval was discounted on the basis that all were 
genetically homozygous for C57Bl6/j at 6x fully informative microsatellite PCR 
markers used, with an average genetic distance of 5.5 Mb (figure 4.3.3B). Chromosome 
11 was therefore discounted as a candidate for Mp with no other obvious candidate 





Figure 4.3.3  Analysis of a candidate region for Mp on chromosome 11.  
(A) SNP array identified a candidate region on chromosome 11 between markers 
rs3705751-11.114.529, where DNA was from animals Mp1-9 of the 2nd backcross to 
C57Bl6/j, and Mp11 and Mp12 were parental DNAs from 1st backcross and initial 
microinjections, respectively. Mp8 and Mp10 were wild-type animals miscalled as 
heterozygotes due to their phenotyping being carried out at P16, prior to full opening of 
the eyelids. (B) Further analysis using 3 x F2 heterozygote animals ruled out this region 
as a locus for Mp as all 6x markers tested were homozygous for C57Bl6/j. For each 
marker, red indicated homozygosity for C57Bl6/j; yellow was heterozygosity for 
C57Bl6/j and any other background discriminative from C57Bl6/j where the 
corresponding marker was blue for that strain. Red colouring for background strains 
indicated that a marker could not be discriminated from C57Bl6/j. Mp4-11; -12; and –13 
were additional 2nd backcross Mp heterozygotes added to the mapping assay. C57Bl6/j 
(B6); 101; C3H/HeJ; and CBA/J were control DNAs. 
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4.5.5. Whole genome mapping was performed using microsatellite markers  
 An alternative mapping strategy was adopted using PCR-amplifiable 
microsatellite markers that discriminate between C57Bl6/j and C3H strains. An initial 
panel was used for analysis of DNA from an F1 affected parent to identify those markers 
that were fully informative, i.e. displayed heterozygosity for C57Bl6/j and C3H in 
control DNA samples. In total, 73x autosomal markers were chosen, with an average 
density of ~33.8 Mb per marker. Genomic DNA extracted from phenotypically 
heterozygote (n=38) and wild-type (n=30) animals from the 3rd outcross was pooled by 
phenotype category, using equal amounts of total DNA per animal. The PCR markers 
were then analysed for the enrichment of C3H alleles segregating with the heterozygous 
pool. Peak sizes were recorded and ratios of C57Bl6/j to C3H were calculated for each 
marker, with these values then used to further calculate the ratios between wild types 
and heterozygotes (figure 4.4.3).  
 
4.5.6. Evidence of Mp linkage to chromosome 18 was identified 
Of the 73 markers used, 57 (79.1%) gave peaks of a recordable size 
corresponding to C57Bl6/j alleles only. For the remaining 16 markers, only 
chromosomes 5; 10; 11 and 18 were identified with >1 marker showing enrichment for 
C3H peaks versus C57Bl6/j in the heterozygous pool, with chromosome 5 having a 
single marker with a ≥ 2x fold enrichment for C3H: C57Bl6/j, while there were two on 
chromosome 18. However, one of these markers on chromosome 18, D18MIT149 at a 
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genomic position ~45 Mb, was >28 fold enriched for C3H (figure 4.3.4), strongly 











Figure 4.3.4  Mapping Mp using a whole genome microsatellite marker 
analysis.  
Ratios of peak sizes from C3H:C57Bl6/j for alleles of fully informative autosomal 
microsatellite markers amplified from pooled wild-type and heterozygote DNA samples 
were calculated. Enrichment for C3H was seen for 3x consecutive markers 
(D18MIT146; D18MIT 149; and D18MIT8) on chromosome 18, co-segregating with 
heterozygosity, and thus implicated chromosome18 as a candidate locus for Mp. There 






4.5.7. Analysis of chromosome 18 as a candidate for Mp 
The heterozygote DNA samples used for the pooled sample analysis (n=38) were 
then analysed separately for a series of microsatellite markers on chromosome 18 to 
confirm the linkage and to identify meiotic recombinants. 4 different haplotypes were 
identified within this group of animals (figure 4.3.5A). Critically, there were two 
animals with a haplotype displaying a meiotic recombination event between markers 
D18MIT74 and D18MIT184, positioned at 53 and 67 Mb, respectively (figure 4.3.5A).  
This indicated a candidate interval for Mp between these two markers, however there 
was also the possibility that the locus lies distal to 67 Mb, as markers were not used in 
these regions, although this would require a double recombination to have occurred. 
However, this was unlikely as on review of the SNP marker panel data (figure 4.3.5B), 
two heterozygotes displayed homozygosity for C57Bl6/j for all SNP markers distal to 
66.9 Mb. In contrast the other animals were all consistent with the Mp locus being 
proximal to this marker, except for a single animal who appeared as homozygous for 
C57Bl6/j across all of chromosome 18. This may have been a result of the non-
informativeness of certain SNP markers used proximal to 57.7 Mb between strains 101 
and C57Bl6/j in the genetic background, or possibly due to the poor density of coverage, 
that particular animal may have been incorrectly phenotyped, or may have been a double 
meiotic recombinant. Therefore, the critical interval for Mp was defined as between 53-






Figure 4.3.5 Haplotype analysis of strain specific markers on chromosome 
18 refined the Mp interval to between 53- 67 Mb.  
DNA samples of 38x heterozygotes from 3rd outcross to C57Bl6/j were used in 
individual PCR reactions for microsatellite markers discriminatory for strain-specific 
alleles (A). Analysis of the 4x haplotypes generated indicated there to be no meiotic 
recombinants between markers D18MIT74 and D18MIT184, at 53Mb and 67Mb 
respectively. This data was arranged according to genomic position (right) and for the 
number of animals displaying each haplotype (top). Filled boxes indicated homozygosity 
for C57Bl6/j at that locus, whereas empty boxes were assigned for alleles heterozygous 
for C57Bl6/j and C3H. Arrow indicates region without recombinants. (B) SNP marker 
analysis on chromosome 18 of animals from 2nd outcross to C57Bl6/j, and their parental 
G0 and F1 heterozygotes, indicated that at least 2 animals were homozygous for 
C57Bl6/j at loci distal from 66.9 Mb (arrow), indicated by red fill. Background strains 
with blue fill indicated that markers were discriminatory from the C57Bl6/j background, 
whereas red indicated markers to be non-informative between that strain and C57Bl6/j. 
There was a single animal that displayed apparent homozygosity for C57Bl6/j at all 
markers on chromosome 18 (asterix), however this may have resulted from markers at 
loci proximal to marker rs3705107 being non-informative for the different strain 
backgrounds (white asterix). (C) Agarose gel electrophoresis of PCR products from 
D18Mit184 identifying recombinant animals with single amplicon for C57Bl6/j allele, 




4.5.8. Identifying Fibrillin-2 as a candidate for Mp 
  The Fibrillin-2 (Fbn2) gene is located on chromosome 18, positioned at 
~58 Mb. Homozygous loss-of-function mutations in Fbn2 give rise to hindlimb 
oligodactyly in the mouse but do not exhibit an eye phenotype (Arteaga-Solis et al., 
2001; Chaudhry et al., 2001). Thus, Fbn2 is a reasonable candidate for Mp. PCR-based 
sequencing analysis of the Fbn2 mRNA was decided as an appropriate strategy for 
identifying mutations in the gene and to check for transcript integrity, due to the large 
size of the full gene (20.1 kb). RT-PCR reactions were designed to amplify 10 
overlapping portions covering the entire coding sequence from 65 exons of Fbn2 from 
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cDNA samples prepared from RNA extracted from excised hearts of phenotypically 
wild-type, heterozygote and mutant adult animals. Amplicons were generated for all 
fragments in all representative genotypes, except for fragment 10, specific for exons 61-
65, which was not amplified in the homozygote sample (figure 4.3.6A).  The bands from 
the heterozygote and homozygote samples appeared as more intense than those of the 
wild-type for fragments 1-9, yet the homozygote band was missing completely for this 
terminal amplicon and the heterozygote was less intense than the wild-type, implying a 
reduction in dosage of the template in the heterozygote sample and a loss of template in 
the mutant. This result was replicated in RNA isolated from eye tissue from the same 
animals. This implied that the failure in amplification of Fbn2 cDNA fragment 10 was 
not a result of a mutation affecting the annealing of these primers to the DNA template, 
but rather that the mutation specifically affects the 3’-end of the Fbn2 transcript in the 







Figure 4.3.6.  RT-PCR analysis failed to amplify several 3’-exons of 
Fibrillin-2 in Mp.  
(A) RT-PCR using overlapping amplicons for the entire coding sequence of Fbn2 
indicated that amplicon 10 (boxed area) at the 3’-most region could not be amplified 
using cDNA generated from homozygote (M) animals (white asterix) and that there was 
reduced band intensity in the heterozygote (H) compared to wild type (W). The 
remaining amplicons were successfully amplified in all samples. (B) Figure (not to 
scale) indicating the positions of the RT-PCR amplicons relative to the 3’-end of the 
wild-type transcript illustrated the approximate position of the Mp genetic lesion. Note 
that primers 10-forward and 9-reverse overlapped each other and therefore reduce the 




4.5.9. The Mp candidate interval was refined to within intron 62 of Fbn2  
The next step was to identify whether the 3’-most exons 61-65 of Fbn2 were 
present in mutant animals. As the forward primer for Fbn2 cDNA amplicon 10 
overlapped with the reverse primer for fragment 9 (figure 4.3.6B) the candidate region 
for Mp was refined from between exons 62-65, to between exons 63-65, at the positions 
of the relevant forward and reverse primers. A PCR reaction using primers that annealed 
to Intronic DNA flanking each of the last four exons showed that these exons were 
present in genomic DNA of mutant animals (figure 4.3.7A). Subsequent sequence 
analysis revealed no mutations in these regions. The causative mutation for Mp was 
likely therefore to be within intronic DNA between these exons. PCR reactions were 
designed to amplify the intronic sequences between these four exons, with the same 
primers used to amplify the exons but in different combinations. It was possible to 
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amplify the introns between exons 61-62; 63-64; and 64-65 (referred to as introns 61; 
63; and 64, respectively from here on) for all three genotypes (figure 4.3.7B); however 
amplifying the largest intronic region (4.8 kb) between exons 62-63 was initially not 
possible for any sample. This region was therefore divided into 7x overlapping 
fragments (figure 4.3.7C) that covered the entire intron. Fragments E and F did not 
produce amplicons from the mutant DNA (figure 4.3.7D), thus localising the possible 
mutation to this region. Using the reverse and forward primer positions of fragments D 
and G, respectively, the candidate Mp locus interval is refined to 451 bp  (figure 4.3.7C), 







Figure 4.3.7  The Mp genetic lesion was refined to within 450 bp of intron 
62 in the Fbn2 gene.   
(A) Exons 62-65 of Fbn2 were all amplified successfully from mutant genomic DNA 
samples with no apparent deviation in size of amplicons, indicating their presence within 
the genome of mutant animals. These products were subsequently sequenced and found 
not to contain any mutations. (B) Intronic regions between the last four exons were 
PCR-amplified as normal-sized fragments compared to the wild type, for all except 
intron 62, which initially was unable to amplify in all samples (asterix). (C) This intron 
was split into overlapping amplicons for PCR amplification of genomic DNA and 
analysis revealed that there were two adjacent regions that did not amplify from the 
mutant sample- amplicons E & F (white asterix). (D) Figure (not to scale) indicating the 
positions of genomic amplicons relative intron 62. This illustrated the approximate 
location of the Mp genetic lesion and implied that the critical region affected in Mp was 
positioned between primers for D-reverse and G-forward, an interval of 451 bp. 
 
 
4.5.10. 3’-RACE identifies two genetic lesions in Fbn2 and the adjacent Isoc1 gene 
Total RNA isolated from hearts of mutant and wild-type animals was subjected 
to 3’-RACE PCR (as described in the methods section). The resulting PCR products 
were run out on an agarose gel and inspected for the presence of any differential bands. 
The predicted size of the Wt Fbn2-fragment using the Fbn2-specific and adaptor primers 
in reactions was ~ 1.1 Kb. Consistent with this there was a strong band present in the Wt 
that was absent in the mutant (figure 4.3.8A). Conversely, a strong band of 
approximately 750 bp was seen in the mutant but not in the Wt. These bands were 
subsequently cloned and sequenced. A BLAT Search of the sequences confirmed the 
Wt-specific band as Fbn2, with 100% sequence identity to the Fbn2 locus between 
58,169,774-58,180,136 bp on chromosome 18 (figure 4.3.8B), corresponding to the 3’-
most end of the transcript. For the 750 bp mutant band, two separate hits on 
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chromosome 18 were identified, each with 100% sequence identity to the query 
sequence. The genomic coordinates of these were 58,837,418-58,837,929 bp and 
58,178,391-58,180,136 bp, and included the coding regions of two separate genes: Isoc1 
(Isochorismatase domain-containing protein-1) and Fbn2, respectively.  
 
Isoc1 is a 5-exon gene positioned at 58.8 Mb on chromosome 18, within 1 Mb 
from Fbn2 and the two genes are separated by the solute channel gene Slc27a6, 
positioned at 58.7 Mb (figure 4.3.8C). The sequence obtained from the mutant indicates 
that the transcript is specific for Fbn2 up to, and including, the final nucleotide of exon 
62 (Ensembl ID ENSMUSE00000143682). The sequence then reads directly into the 
fifth and final exon of Isoc1 (Ensembl ID ENSMUSE00000659305) without the 
additional of any non-endogenous nucleotides. The mutant transcript is therefore likely a 
fusion of these two genes, where exons 63-65 of Fbn2 have been replaced by the last 









Figure 4.3.8  3’-RACE identified a fusion of Fbn2 to the adjacent Isoc1 
gene.  
Analysis of differential PCR bands between wild-type and mutant transcripts generated 
by 3’-RACE identified a band (single asterix) at ~1.1 kb not present in the mutant 
(arrowhead) and a 750 bp band present in the mutant (double asterix) that was not 
present in the wild-type (arrowhead) (A).  These amplicons were then excised, cloned 
and sequenced. The wild type band was confirmed as being fully Fbn2 by its genomic 
position identified using BLAT against the mouse genome (B; top panel), while 
similarly the mutant was identified as being Fbn2 between nucleotides 1-232, then 
reading into the Isoc1 gene from nucleotides 233-719 (B; bottom panel). All hits for the 
query sequences displayed 100% identity to the reference sequence identified. The 
genomic positions of these two genes on chromosome 18 are within 1 Mb of each other 
and separated by the solute-channel gene Slc27a6, as depicted using the Ensembl 




4.5.11. Sequence analysis reveals a balanced genomic inversion within non-coding 
regions of the Isoc1 and Fbn2 genes 
 
 Using combinations of primers specific for intron 62 of the Fbn2 gene, 
and primers specific for the last intron of Isoc1, amplicons were successfully generated 
by standard PCR using genomic DNA from a homozygote animal. Amplicons from a 
reaction with an Isoc1 forward and a Fbn2 reverse primer were sequenced and identified 
the location of the fusion to the single-nucleotide level (Figure 4.3.9A).  In the Fbn2 
gene, within intron 62, the sequence reads up to nucleotide 58,175,674 and in Isoc1, the 
sequence reads up to base 58,835,147 bp (Isoc1, intron-4) on mouse chromosome 18, 








Figure 4.3.9  Chromosomal breakpoints were identified within 3’-introns of 
both Fbn2 and Isoc1.  
(A) Sequence data from PCR reactions with Isoc1 forward and Fbn2 reverse primers of 
heterozygote and homozygote genomic DNA identified the balanced breakpoint at the 
nucleotide level (left panel; arrow) from chromatogram data indicating the position of 
Fbn2 and Isoc1 specific sequence (right panel; arrow). (B) Figure indicating the 
positions of the balanced inversion affecting the Fbn2 and Isoc1 genes at 58,175,674 and 
58,835,147 bp, respectively. Note that transcription of Fbn2 is considered to be from the 
minus strand, and Isoc1 is from the plus strand. 
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4.5.12. The Mp genomic inversion results in reciprocal fusions of the Fbn2 and 
Isoc1 mRNAs  
 
To confirm the Fbn2-Isoc1 fusion identified by 3’-RACE, and to ascertain 
whether this was reciprocated by an Isoc1-Fbn2 fusion, RT-PCR was designed using 
primers specific to each gene. As mentioned above, it was only possible to amplify Fbn2 
fragment 10 from the wild type and heterozygous cDNA samples. Additionally, using 
primers specific for the 3’-most region of Isoc1 cDNA, it was also only possible to 
generate amplicons from the wild type and heterozygous cDNA samples (Figure 
4.3.10A, top two panels). In contrast, the combination of Fbn2-forward and Isoc1-
reverse primers generated amplicons from cDNA of mutant and heterozygote, as did 
using forward and reverse primers specific for Isoc1 and Fbn2, respectively (Figure 
4.3.10A, bottom two panels). This confirmed the fusion of Fbn2-Isoc1 and also revealed 
that a complementary fusion had occurred between the two genes, confirming the 
inverted genomic rearrangement (Figure 4.3.9B).  Sequence data generated from these 
amplicons revealed that the sequence read was continuous from the final nucleotide of 
exon 62 of Fbn2 into the first nucleotide of Isoc1 exon 5, with no extra nucleotides 







Figure 4.3.10.   The transcripts of Fbn2 and Isoc1 in Mp were reciprocally 
fused.  
(A) Top panels: RT-PCR using primers specific for the 3’-ends of each Fbn2 and Isoc1 
mRNAs failed to amplify products from homozygous cDNA. Central panels: using 
different combinations of these same primers confirmed the reciprocal fusion event 
between Fbn2 and Isoc1 cDNAs.  Bottom panel: control RT-PCR of 18s ribosomal 
DNA. (B) Sequence data from Isoc1 forward and Fbn2 reverse primer RT-PCR 
indicated that the fusion read directly from exon 4 of Isoc1 to exon 63 of Fbn2 (arrows), 
with no extra nucleotides incorporated. 
 
4.5.13. Predicted consequence for translation of Fbn2Mp  
Fbn2 is a 2907 amino acid protein of 313.6 kDa (unprocessed-precursor), 
containing 47x EGF-like domains, of which 42 are calcium binding (cbEGF), and 9x TB 
(TGFβ-binding) domains (Figure 4.3.11A). The coding-sequence for the fused Fbn2-
Isoc1 transcript of was used to generate a predicted protein for Fbn2Mp using the translate 
tool on the ExPASy website (http://expasy.org/tools/#translate). The adjoined Isoc1 
sequence was immediately knocked out of frame and resulted in the addition of 7x 
amino acids, with no known motif or functional domain, followed by a termination 
codon (Figure 4.3.11B). A polyclonal anti-Fbn2 antibody (PAb0868), specific to the N-
terminal region of the Fbn2 protein (Figure 4.3.11C), was kindly provided by Professor 
Lynn Sakai (Shriners Hospital for Children, Oregon Health and Sciences University, 






Figure 4.3.11. Protein structure of Fbn2 and Fbn2Mp. Cartoon indicating functional 
domains present in the wild type Fbn2 protein (A). The Mp protein is missing the final 
cbEGF domain and the unique C-terminus, which have been replaced by 7x amino acids 
and (red text) a premature stop codon (B). The polyclonal antibody (PAb0868) is 
reactive to a peptide generated from the N-terminal of Fbn2 and therefore is predicted to 
be reactive to Fbn2Mp (C).  
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4.6. Developmental expression analysis of Fbn2 and Isoc1 in Mp 
4.6.1. Developmental expression of Fbn2 is consistent with phenotype in Mp 
 Although I performed the image capture and analysis, whole mount In 
Situs were done by Dr. David McBride (University of Cambridge, formerly MRC 
Human Genetics Unit), Expression of Fbn2 was analysed at embryonic stages E10.5, 
E11.5 and E12.5 in wild type embryos (figure 4.4.1). Ocular expression was identified at 
all three stages, beginning in the dorsal-most region at E10.5 and then spreading laterally 
to surround the entire developing eye by E12.5 (figure 4.4.1A & B). This early 
expression domain was considered to be within the peri-ocular mesenchyme adjacent to 
the neural retina and RPE, however as development proceeded, Fbn2 expression was 
also noted in the distal-most region of the neural retina as a ‘ring’ of expression. This 
area corresponds to the developing ciliary body (CB). Little or no expression was noted 
in the central neural retina or lens, however there was signal observed in the region of 
the closing choroid fissure in the ventral eye at E11.5 and E12.5 (figure 4.4.1B).  
 
Fbn2 expression was also observed in limbs from the same embryos (figure 
4.4.1A & C), although signal was not identified at E10.5. At E11.5, Expression was 
noted mostly in central areas of the proximal fore and hindlimb buds, but not in the 
distal regions, i.e. the developing hand plates (figure 4.4.1C). By E12.5, the expression 
pattern had extended to include proximal and distal regions of both fore- and hindlimbs. 
However, it was noted that expression pattern differed between the distal fore and 
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hindlimbs. In the forelimbs expression appeared to be located within the developing 
digit condensations, with digits 2-4 expressing strongest. In the hindlimbs however, 
there was expression between, but not within, the developing digit condensations and 






Figure 4.4.1 WISH expression of Fbn2 in wild type animals was consistent 
with the Mp phenotype.  
Whole mount in situs (WISH) were performed on wild-type embryos at stages E10.5; 
E11.5; and E12.5 (A). At E10.5, the Fbn2 probe was positive for expression in tissue 
surrounding the dorsal eye (red arrows), and somites (white arrows), but appeared 
negative in both the fore and hind limb-buds at this stage. By E11.5, the ocular 
expression domain had spread laterally to surround the entire eye region, but maintained 
the strongest signal dorsally. There was also Fbn2 expression in the proximal regions of 
the developing limb-buds (forelimbs - black arrows; hindlimbs -arrowheads), but not in 
the distal limb areas, i.e. the developing hand-plates, at this stage. At E12.5 the ocular 
expression appeared refined to the peripheral retina. At the same stage, the limb 
expression was more pronounced in both fore- and hind-limbs and it was possible to 
correspond Fbn2 signal to the developing digit, wrist and proximal structures. Close-up 
views of eyes at stages E10.5; E11.5 and E12.5 (B) identified clear domains of Fbn2 
expression. Signal was seen in only the dorsal region of the E10.5 eye (red arrows, a 
dashed line outlines the ocular field), in peripheral retinal area likely to be periocular 
mesenchyme and not neural retina. However, in the E11.5 eye this domain had expanded 
laterally to surround the entire eye with strong signal. There is little or no expression 
seen in the central neural retina (white arrow), however a highly specific ‘ringed’ 
domain of expression was visible at the distal tip of the retina (white arrowhead) and 
also in the closing choroid fissure (red arrowhead) in the ventral retina. Fbn2 expression 
at E12.5 was similar in distribution to E11.5 in the periocular mesenchyme (red arrows), 
and a reduced, but intense, signal was seen in the ventral retina in the region of the 
fissure (red arrowhead). The expression domain at the distal tip of the retina was 
maintained (white arrowhead). In the developing limbs (C), strong expression signal was 
visible in both forelimb (FL) and hindlimb (HL) at E11.5 within the central proximal 
regions, but not in the peripheral regions of the handplates. At E12.5 the strong signal 
was maintained in the proximal limb in both FL and HL, but in the FL there was 
extensive expression in the posterior region of this domain (arrowhead). In the FL there 
was signal in regions consistent with the condensations of digits 2; 3; and 4 (red arrows), 
but in contrast the corresponding regions in the HL did not show signal. Rather, there 
was signal in the inter-digital regions between the condensations (red arrows).  
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4.6.2. Expression of Fbn2 was observed throughout the developing wild type eye 
 Section in situ of paraffin embedded eyes with the same Fbn2 probe 
identified the specific domains of expression within the developing mouse eye (figure 
4.4.2). At E12.5, expression was noted in the peri-ocular mesenchyme surrounding the 
eye (figure 4.4.2A & B) and in the lateral edges of the developing CB and adjacent RPE 
at the anterior region of the retina (figure 4.4.2C). Some signal was observed in 
mesenchymal cells of the developing cornea, but no signal was identified in the central 
retina. At E16.5, Fbn2 expression was identified in the peri-ocular mesenchyme but not 
in the central retina (figure 4.4.2D). Expression in the CB was more intense than at 
E12.5 and covered the majority of the anterior tip of the retina (figure 4.4.2E & F). 
There was also expression in cells of the developing iris stroma (figure 4.4.2F). These 








Figure 4.4.2  Fbn2 is expression was observed in various cell types during 
wild type eye development.  
Section in situ hybridisation on paraffin embedded wild-type eyes at E12.5 (A-C) and 
E16.5 (D-F) using probe for Fbn2 3’-UTR. At E12.5 cells positive for Fbn2 transcripts 
were identified in large domains of expression within the periocular mesenchyme 
proximal to the retina (A & B), and in a small subset of cells of the developing ciliary 
body at the anterior tips of the retina (enlarged in C). This domain extended into some 
cells of the anterior region of the RPE. Low signal was also identified in some 
mesenchymal cells of the developing corneal stroma.  However, cells of the retina, the 
vitreous body and the lens were not seen to express Fbn2. (Scale bar = 50 µm). At E16.5 
positive cells were observed in the mesenchyme proximal to the retina (D), within cells 
of the ciliary body, the developing iris stroma, and in the surface ectoderm covering the 
cornea (E & F). As at E12.5, cells of the lens and retina were not seen as positive for 
Fbn2 signal at this stage. C, cornea; CB, ciliary body; Ir, iris; L, lens; M, mesenchyme; 
OS, optic stalk; R, retina; SE, surface epithelium. Scale bar = 50 µm 
 
 
4.6.3. Isoc1 expression was unidentified in developing wild type embryos 
 Whole mount and section in situ hybridisation analysis of Isoc1 
expression was performed in embryos at developmental stages E10.5, E11.5 and E12.5 
(figure 4.4.3). No evidence of expression was observed in any part of the embryos 
analysed in either whole mounts or sections. In whole mounts, particular attention was 
paid to those regions affected in the Mp phenotype, yet no expression was identified in 
eyes or limbs at either of the embryonic stages (figure 4.4.3). Additionally, analysis of 







Figure 4.4.3  Developmental expression of Isoc1 was undetectable by RNA 
in situ hybridisation.  
 Signal from the Isoc1 probe (A) was undetectable at each stage of development 
analysed, with no expression apparent in any regions of the developing embryos 
including the developing limb (filled arrows and arrowheads) and eye structures 
(arrows) described as positive for Fbn2 expression. Dashed lines indicate ocular (red) 
and limb (black) structures. Section in situs of paraffin embedded sections illustrated 
that at higher definition analysis there was no Isoc1 expression identified within 
developing ocular structures at E12.5 (B). 
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4.6.4. Developmental Fbn2Mp expression in homozygotes is consistent with wild 
type Fbn2 expression in the eyes and limbs 
 As the in situ probe used above was complimentary to the 3’-untranslated 
region of the Isoc1 gene, and the Mp genetic inversion resulted in this region fused to the 
Fbn2 gene, and vice versa, the Isoc1 probe was used to report Fbn2 expression and the 
Fbn2 probe was used to report Isoc1 expression in mutant samples (figure 4.4.4A). In 
section in situs, Fbn2Mp expression in mutant eyes duplicated the wild type ocular Fbn2 
expression pattern (figure 4.4.4B & C), with Fbn2Mp transcripts identified in peri-ocular 
mesenchyme and distal retina (figure 4.4.4C). Additionally, expression analysis in 
mutant limbs (figure 4.4.4D) revealed similar results: mutant Fbn2Mp transcripts seen 
using the Isoc1 probe in homozygote limbs reproduced the wild type Fbn2 expression 
observed with the Fbn2 probe. Expression of Isoc1Mp in the mutant was not identified 
with the Fbn2 probe and there was no wild type expression observed with the 
Isoc1probe. Whole mount In Situs were done by Dr. Peter Branney (MRC Human 
Genetics Unit), Non-quantitative RT-PCR was used with RNA from whole embryos and 






Figure 4.4.4. The Isoc1 In Situ probe reported unchanged domains of Fbn2 
Mp expression in mutant eyes and limbs.  
The In Situ Probes used so far were designed for specificity to the 3’-UTRs of wild type 
Isoc1 and Fbn2. However, due to the nature of the inversion at the Mp locus, these 
probes were suitable to report expression of the mutant transcripts, i.e. the Isoc1 probe is 
predicted to report Fbn2Mp expression and, vice versa, the Fbn2 probe should report 
Isoc1Mp expression (A). Section In Situs (B & C) at E13.5 using the Isoc1 probe 
identified that expression of Fbn2Mp in the homozygote (C) was identical to Fbn2 
expression in the wild type (B). Domains of overlapping Fbn2Mp and wild-type Fbn2 
expression were observed in cells of the peri-ocular mesenchyme (M), developing 
ciliary body (CB) and cells within the vitreous body (VB). There appeared to be possible 
loss of Fbn2Mp expression in the developing cornea (C) of Mp eyes, although surface 
ectoderm expression adjacent to the lateral retina was intact. In both cases, the lens (L) 
and central neural retina (R) did not display expression. These probes were also used for 
WISH analysis (D) on a litter of genotyped E13.5 embryos from an intercross between 
Mp-heterozygotes. Wild-type limbs displayed expression using the Fbn2-probe but 
homozygotes did not. In contrast, wild type limbs analysed with Isoc1-probe did not 
show expression, whereas homozygotes were positive. Expression of the gene lying 
between Isoc1 and Fbn2 on chromosome 18 was analysed qualitatively by RT-PCR on 





4.6.5. Ocular distribution of mutant Fbn2Mp protein was abnormal in developing 
Mp eyes 
 Using an anti-Fbn2 primary antibody, the localisation of wild type and 
mutant protein was investigated in developing eyes at E13.5 and E16.5 (figures 3.5A-D 
& E-F, respectively). Wild type protein was identified in the developing corneal 
mesenchyme, in the mesenchyme of the developing sclera, in the exterior surface 
membrane of the lens, in the inner limiting membrane between the retina and vitreous 
body, and distributed throughout the vitreous body, while there was no signal seen 
within either the anterior or central retina, or in RPE (figure 4.4.5 A &C). The strongest 
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signal was seen in regions where the lens and retina are adjacent, between the anterior 
internal retina and at the equator of the lens. At these foci, and amongst the cells of the 
corneal mesenchyme, wild type Fbn2 protein was clearly extracellular and appeared to 
be organised into matrix-like arrangements (figure 4.4.5C). In contrast, no Fbn2 was 
identified between lens and retina or in the vitreous body in mutant eyes (figure 4.4.5B). 
However, positive signal was observed in the CB, anterior retina, RPE, peri-ocular 
mesenchyme and in some regions of the central retina (figure 4.4.5B & D), with the 
strongest signal seen in anterior retina.  
 
Localisation of the mutant protein appeared to be intracellular, as no Fbn2 was 
present in the extracellular regions identified in the wild type, and protein signals always 
appeared punctate and were associated with adjacent nuclei (figure 4.4.5D). The contrast 
between wild type and mutant protein distribution was most evident in the corneal 
mesenchyme, where Fbn2 was continuous and linear in wild type (figure 4.4.5C) but 
punctate and compact in the mutant (figure 4.4.5D). The same overall distribution 
patterns were also evident at E16.5, with wild type (figure 4.4.5E) signal present in the 
extracellular regions between lens and retina, inner limiting retinal membrane, and 
within the mesenchyme of developing cornea, sclera, and iris. While mutant Fbn2 was 
located intracellularly in CB, anterior retina, developing iris, cornea and scleral 








Figure 4.4.5 Abnormal localisation of Fbn2 protein in Mp/Mp embryonic 
eyes.  
Using the anti-Fbn2 PAb 0868 on E13.5 embryonic sections (A-D), wild-type Fbn2 
signal was identified in the developing cornea, in mesenchyme of the developing sclera, 
in the exterior surface of the lens, and in the inner limiting membrane between the retina 
and vitreous body, as well as in the vitreous body itself in wild-type eyes (A & C). In 
contrast, no extracellular signal from mutant protein was observed in the vitreous or 
external membranes of the lens or retina in mutant eyes (B & D). Some signal was 
observed dispersed with cells of the mesenchyme in both developing cornea and sclera, 
yet the strongest signal was seen within the anterior retina and CB. Enlarged views of 
both wild-type (C) and mutant (D) illustrated the difference in the distribution of Fbn2 
protein, with the wild-type signal clearly localised to the extracellular space between the 
adjacent lens and retina (arrowheads), as well as forming matrix-like arrangements 
amongst cells of the developing cornea (white arrowheads). In contrast, mutant Fbn2 
was not observed in extracellular regions and was localised adjacent to nuclei in 
punctate and non-continuous arrangements. There was no signal seen within either the 
anterior retina or peripheral retina, or in the RPE of the wild type. In the mutant 
however, Fbn2Mp signal was clearly observed within the retina, with the strongest signal 
seen in the anterior region, but also with cells distributed throughout the central retina. 
Additionally, many small regions of signal were observed throughout the RPE and 
developing cornea (arrows). At E16.5 (E & F), the distribution of wild-type protein (E) 
was similar to at E13.5. There was strong extracellular localisation in the region where 
the lens and anterior retina are directly apposed (highlighted & enlarged window), in and 
adjacent to the mesenchyme of the developing sclera (arrows) and cornea (white arrow), 
and in the forming iris (arrowheads). Signal was not present in the vitreous but was 
distributed throughout the inner limiting membrane of the retina (white arrowheads). 
Again, there was no Fbn2 observed within the retina of the wild type. An enlarged view 
of the distal retina indicated the extracellular localisation of Fbn2 protein in the wild 
type (E, inset). In the mutant (F), signal was observed in the anterior region of the retina 
(arrows). This was consistent with the Fbn2Mp localisation at E13.5 and was in contrast 
to the wild-type distribution. There was also signal present in developing iris, cornea, 
RPE and mesenchyme. An enlarged view of the anterior retina domain of expression 
indicated that the Fbn2Mp localisation might be intracellular, due to the intimate 
association of discrete signal foci with nuclei present in this region, and additionally the 
complete absence of extracellular signal.  C, cornea; L, lens; VB, vitreous body; ILM, 
inner limiting membrane; R, retina; M, mesenchyme; AR, anterior retina; PR, peripheral 
retina; RPE, retinal pigmented epithelium; Ir, iris. (* in (A) indicates artefacts of 
processing). 
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4.6.6. Fbn2Mp protein formed intracellular inclusion bodies 
 Analysis of neonate skin cells using transmission Electron microscopy 
(TEM) revealed the presence of large organised inclusions within the mutant cells that 
were not present in wild type cells (figure 4.4.6). There were numerous foci of 
intracellular material throughout the cell body (figure 4.4.6B), which, when analysed at 
higher magnification, revealed that these inclusions were surrounded by membrane from 
the endoplasmic reticulum (ER). Further analysis by TEM with the anti-Fbn2 antibody 
identified the mutant intracellular inclusion bodies as positive for the presence of Fbn2 
(figure 4.4.7A). The same analysis in the wild type revealed the presence of Fbn2-
positive microfibrils of normal appearance. Prepared samples were shipped and all EM 
analysis was done by Doug Keene and Sara Tufa (Shriners Hospital for Children, Oregon 
Health Sciences University, Portland, Oregon). 
 
 
Immunohistochemistry on MEFs (figure 4.4.7B) with the anti-Fbn2 antibody 
illustrated the intracellular nature of the inclusion bodies in the mutants and confirmed 
their close proximity to cell nuclei. In contrast, the Fbn2 signal in wild type MEFs was 
organised into extracellular matrix and no intracellular Fbn2 was observed. Higher 
magnification of a single Fbn2-positive MEF cell reveals the inclusion is organised into 
fibril-like structures within the cell and that these are closely bundled together adjacent to 









Figure 4.4.6. Transmission EM revealed inclusion bodies in the ER of 
mutant cells.  
Transmission EM of a wild type cell processed from neonate skin (A) displayed regular 
cellular morphology and organelles and extracellular collagen fibres. In contrast, cells 
prepared from neonate Mp/Mp skin (B) revealed the presence of many large foci of 
intracellular material (arrows) throughout the cell body. Enlarged image (inset) indicated 
that the inclusions were surrounded by ER membranes, and suggested that their 
subcellular localisation was within the ER (arrowheads). Scale bars = 5 µm. Nucleus, N; 








Figure 4.4.7. Immunolocalisation and immunofluoresence revealed that 
intracellular inclusions were Fbn2-positive in Mp/Mp skin cells and 
embryonic fibroblasts.  
Using anti-Fbn2 PAb 0868 directed gold labelling, Fbn2 staining was only observed in 
extracellular microfibrils of the wild-type skin specimen. However, the intracellular 
inclusions of Mp/Mp skin were identified as positive for the presence of Fbn2Mp protein 
(A). Scale bars approx. 500 nm. Immunohistochemistry illustrated a normal Fbn2-
positive extracellular matrix in 4 day-old wild-type MEF cultures and no intracellular 
signal (B). In contrast, equivalent Mp/Mp cultures were apparently absent for Fbn2Mp in 
the extracellular matrix but were positive for large aggregates of intracellular protein 
(scale bar = 50 µm).  Enlarged view of single embryonic Mp/Mp fibroblast cell (C) 
illustrated the presence of large accumulations of protein adjacent to the nucleus 




4.7. Towards a molecular mechanism for the Mp ocular phenotype 
 
4.7.1. The UPR response is elicited in mutant MEF cultures.  
 Primary MEF cultures were established from E13.5 littermates. Two cell 
lines for each genotype were grown under normal conditions in 20% serum for 1 week 
and analysed for the presence of Fbn2 protein inclusions (figure 4.5.1A). Tunicamycin 
(Tn), a known inhibitor of glycoprotein synthesis and inducer of ER stress, was added to 
cultures for 30 min. Cells were cultured normally and then harvested after X hours. The 
unfolded protein response (UPR) was assayed for by RT-PCR of the  Xbp1 transcript.  
Xbp1 is alternatively spliced under ER stress conditions to produce a transcript reduced 
by 26 bp and is thus a good marker for UPR. It was possible to assay for the ratio of 
unspliced (pU) to spliced (pS)  Xbp1 using ABI310 genetic analyser to measure for peak 
heights of the differently sized amplicons (figure 4.5.1B). The average ratios of unspliced 
to spliced  Xbp1 peak heights were plotted for triplicate reactions of 2x cell lines for each 
genotype (figure 4.5.1C). In cells cultured with the vehicle alone (DMSO), both 
heterozygote and homozygote ratios were significantly lower than in wild type cells, 
indicating enhanced levels of  Xbp1 splicing. The addition of 0.5 µg/ml Tn was sufficient 
to alter the wild type MEFs ratio to within comparable levels of the mutant vehicle alone 
samples and also reduced the homozygote ratios. The heterozygote ratio actually 
increased at this dose. An increased dose of 5.0 µg/ml Tn dramatically reduced the ratio 
in all samples tested, indicating that cells were exhibiting considerable UPR response. 
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The  Xbp1 splicing response to increased Tn dose in all of these cell groups indicates the 
validity of this assay and confirms the observation that in the vehicle-alone treatment 
group, the heterozygote and homozygote have elevated levels of spliced  Xbp1 and 
therefore are likely to already be under ER stress. This suggests that the accumulation of 






Figure 4.5.1 Fbn2 protein aggregates were associated with the UPR-
response in mutant MEFs.  
Cultured MEFs derived from E13.5 embryos were cultured for X days and analysed for 
the presence of Fbn2 protein (A). Heterozygote and homozygote MEFs were positive for 
Fbn2 intracellular inclusions, in contrast to wild type MEFs, which displayed only 
extracellular Fbn2 (Scale bar = 50 µm). (B) Peak sizes of unspliced (pU) and spliced 
(pS)  Xbp1 amplicons were measured using an ABI310 Genetic Analyser. The pU:pS 
ratio was used as an indicator of  Xbp1 splicing levels in tested cell populations. MEFs 
expressing Fbn2 were assayed for the UPR response by the application of Tunicamycin 
(C). In cell populations treated with vehicle alone, both heterozygote and homozygote 
ratios were significantly lower than in wild type cells, indicating enhanced levels of  
Xbp1 splicing. The addition of 0.5 µg/ml Tn reduced these ratios in wild type and 
homozygote populations, while the heterozygote ratio actually increased at this dose. 
However, all were lower than the wild type vehicle-alone group.  Addition of 5.0 µg/ml 
Tn reduced ratios in all groups to comparable levels with high levels of spliced  Xbp1. 
Two cell lines were tested per genotype; PCR reactions were performed in triplicate. 
Error bars indicate 95% confidence intervals. 
 
 
4.7.2.  The UPR response is elicited in mutant eyes at E16.5.  
The heat shock protein Hspa5 (Grp78 or Bip) is a member of the heat shock/stress 
response protein family and is a well-established marker for ER stress and the UPR 
response. We applied a BiP RNA in situ probe to ocular sections from mutant and wild 
type E16.5 embryos. BiP expression was observed in the iris, CB and anterior-lateral 
retina regions of mutant eyes (figure 4.5.2A & C). In contrast, these areas were either 
negative for BiP expression in wild types, or there was low-level expression that was 
more restricted to the ciliary body and iris (figure 4.5.2B; D & E). The regions of BiP 
expression in both mutant and wild type at E16.5 were consistent with Fbn2 expression, 
and the domain of mutant BiP overlaps with the location of Fbn2Mp aggregates. Thus, 
mutant eyes exhibit enhanced expression of the UPR marker BiP in regions spatially and 
temporally consistent with Fbn2Mp aggregates.  
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The  Xbp1 splicing RT-PCR assay was applied to RNA collected from dissected 
eyes of E16.5 embryos (figure 4.5.2F). The ratio of unspliced to spliced  Xbp1 in the 
mutant eyes was significantly lower than in wild types, indicating enhanced splicing of  
Xbp1 to the UPR isoform in mutant eyes. Agarose gels of  Xbp1 confirmed the specificity 






Figure 4.5.2 The UPR-response was coincident with Fbn2 expression in 
mutant embryonic eyes.  
Expression of the UPR-response marker Bip was observed in regions of the mutant 
mouse eye overlapping with Fbn2Mp expression. Bip transcripts (arrows) were identified 
in the developing CB, the Iris stroma and in the lateral anterior retina of mutant eyes at 
E16.5 (A & C- enlarged). Cells in these foci were previously identified as positive for 
Fbn2Mp expression and Fbn2Mp aggregate build up. Some restricted foci of low positive 
signal were observed in developing wild type eyes (B & D – enlarged; & E). Weak 
expression was restricted solely to some cells of the CB and iris stroma, and was neither 
as strong, or diffuse, as in mutant samples, and did not extend into the lateral anterior 
retina (Scale bar = 100 µm).   Xbp1 spicing assay identified reduced ratios of pU:pS in 
RNA extracted from excised eyes of genotyped E16.5 littermates (F) and thus indicated 
increased levels of  Xbp1 spicing in mutant eyes. Agarose gel electrophoresis confirmed 




4.7.3. Apoptotic cells were identified in mutant retinas at E13.5 and E16.5 
 Analysis of apoptotic cells in mutant and wild type eyes was performed at 
E13.5 (figure 4.5.3) and E16.5 (figure 4.5.4) using a primary antibody to activated 
caspase-3, an established marker for apoptotic cells. At E13.5 positive cells were 
identified throughout the central retina and in RPE of mutant eyes (figure 4.5.4A). In 
contrast, no positive cells were identified in wild type eyes at this stage (figure 4.5.4B & 
D). There were slightly more cells in the anterior region of the neural retina than in the 
central retina (figure 4.5.4C) and these positive cells displayed different morphologies, 
suggesting there was no one single cell type, but rather that there were various cell types 
undergoing apoptosis. Positive cells were dispersed throughout both inner and outer 
retinal layers. Co-immunostaining was attempted using antibodies to activated caspase-3 
and Fbn2 in the mutant eyes (figure 4.5.4E), which showed that not all Fbn2 positive 
cells were apoptotic and that distribution of activated caspase-3 did not necessarily 
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associate with Fbn2 aggregates. The distribution of activated caspase-3 positive cells in 
E16.5 mutant eyes (figure 4.5.4 A & C) was consistent with E13.5. Cells were observed 
throughout the retina, and different cell types were seen to be positive, based on their 
morphology. However, there were no apoptotic cells observed in the inner neuroblastic 
layer. In contrast, there was only a single positive cell observed in the entire wild type 
retina at the same stage, and this was positioned in the inner neuroblastic layer. Together, 
these data suggest that mutant retinas are increased for apoptotic cells in comparison to 
wild types, and that various undifferentiated cell types are affected. Although the ocular 
locations of apoptotic cells are consistent with the distribution of Fbn2Mp inclusions, there 













Figure 4.5.3 Apoptotic retinal cells were identified in mutant eyes at E13.5.  
Immunohistochemistry with an Activated Caspase-3 antibody identified positive cells 
(arrowheads) in the neuroblastic retina, and in RPE (arrows) of mutant eyes at E13.5 (A 
& C –enlarged). In contrast, no signal was observed in wild type littermate cells (B & D 
–enlarged). Positive cells in mutant retinas displayed different morphologies (black and 
yellow arrowheads), indicating them to be various cell types. Co-immunostaining with 
both Fbn2 (green) and Activated Caspase-3 (red) antibodies did not reveal extensive co-
localisation of these proteins (E) and identified only one cell positive for both proteins 








Figure 4.5.4 Apoptotic retinal cells were identified in mutant eyes at E16.5.  
Consistent with the E13.5 data, immunohistochemistry with an Activated Caspase-3 
antibody identified positive cells (arrowheads) throughout the neuroblastic retina of 
mutant eyes at E16.5 (A & C –enlarged). In contrast, only a single positive cell was 
identified in the wild type (B & D –enlarged), with this cell positioned in the inner layer 




4.7.4. Retinal layer specification, as determined by Sox2 and Pax6 immunostaining, 
is normal in Mp 
 The inner neuroblastic layer of the neural retina was Pax6 positive and 
Sox2 negative in E13.5 developing eyes of both mutant and wild type (figure 4.5.5A & 
B). In contrast, the outer nuclear layer is Sox2 positive and Pax6 negative. These domains 
define retinal patterning throughout development and at E16.5 they remain intact (figure 
4.5.5E & F). However, there were cells observed in the Pax6-positive inner layer that 
were expressing only Sox2, while there were also some Pax6-only expressing cells in the 
predominantly Sox2-positive outer layer. There was no difference observed between wild 
type and homozygote in these domains seen at either stage.  
 
4.7.5. Anterior Sox2 and Pax6 positive domains define the developing ciliary body 
and are disrupted in Mp. 
 The developing CB at the anterior of the neural retina was Pax6-positive 
and Sox2-negative in both mutant and wild type eyes at E13.5 (figure 4.5.5C & D) and 
E16.5 (figure 4.5.5G & H).  However, in wild types of both stages, there is a clear 
boundary between the anterior-most region of the outer nuclear layer of the retina and the 
distal portion of the developing CB, which was defined by a small and discrete band of 
Sox2 and Pax6 positive cells (figure 4.5.5C & G). In the mutants however, the Pax6-
positive regions appeared truncated, while the Sox2/Pax6 positive cells were diffuse and 
spread into the outer nuclear layer of the neural retina (figure 4.5.5D & H). There was no 
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clear boundary of expression observed between the developing outer nuclear layer and 










Figure 4.5.5 Co-immunostaining with Sox2 and Pax6 revealed defects in 
the ciliary-retinal boundary.  
The developing retina at E13.5 (A-D) displayed clear domains of expression for Sox2 
and Pax6. In the wild type (A) and mutant eye (B), the majority of nuclei in the outer 
neuroblastic layer of the central retina were Sox2 (red) positive, whereas nuclei in the 
inner neuroblastic region were pax6 positive (green). In both wild type and homozygote, 
these domains were clearly defined and non-overlapping. In the anterior retina, there 
were additional domains of Pax6 only expression at the distal-most tips. These were 
directly adjacent to a group of cells that were co-expressing Sox2 and Pax6 (arrows) in 
the wild type (C), which defined a clear boundary between central retina and the 
developing CB. In contrast, the mutant displayed subtle differences in this region. The 
co-expressing cells were more diffuse into the central retina and did not clearly define 
the retina-CB boundary (D). At E16.5 (E-H), the inner neuroblastic layers of both wild 
type (E) and homozygote (F) remained Pax6 positive and the outer neuroblastic layers 
were Sox2 positive.  At this stage, there were also many nuclei within the outer layer 
that were positive for Pax6 only, and some that were expressing only Sox2. There were 
also some Sox2-only positive nuclei observed in the inner layer. This was consistent in 
both homozygote and wild type samples.  Higher magnification of the anterior region of 
retinas revealed a large domain of Pax6-only nuclei in the developing CB in the wild 
type retina (G), while this domain is truncated in the mutant (H), with the domain of 
Pax6-Sox2 co-expressing nuclei shifted anteriorally within this region. Scale bars =50 
µm. 
 
4.7.6.  Immunostaining of Lef1 in Mp eyes revealed increased levels in ciliary body 
and ectopic retinal expression 
 Lef1 expression was analysed by immunostaining in developing wild type 
and mutant eyes at E13.5 and E15.5 (figure 4.5.6) and at E18.5 (figure 4.5.7). In wild 
type eyes at E13.5 (figure 4.5.6A-C), nuclear Lef1 was observed solely in the cells at the 
distal-most tip of CB and RPE and did not spread into the peripheral neural retina. In 
contrast, positive nuclei were observed in the CB domain and RPE of the mutant (figure 
4.5.6D-F), with the CB domain extended into peripheral neural retina and displayed a 
more intense signal than in the wild type, indicating higher levels of Lef1 protein. In the 
wild type at E15.5, Lef1 signal in the anterior retina clearly defined the developing CB 
(figure 4.5.6D). This region contained only subsets of nuclei that were positive for Lef1 
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signal, and some that were positive for Lef1 in their cytoplasm (figure 4.5.6H & I). In the 
mutant, the CB was also positive for nuclear Lef1 signal, however in contrast to the wild 
type, the signal was increased in intensity and there were fewer non-expressing cells 
(figure 4.5.6J-K). RPE and iris stroma were also positive In addition, there were also 
nuclei, positively stained for Lef1 in the neural retina (figure 4.5.6L). These cells had 
circular nuclei and were situated in vacuoles, and were not intimately associated with the 












Figure 4.5.6 Increased Lef1 immunostaining in the developing ciliary body 
and retinas of mutant eyes.   
Lef1 positive cells were identified in the anterior region of developing retinas at E13.5 
(A-F). In the wild type (A-C), Lef1 signal was nuclear and positive cells were refined to 
the anterior-most group of cells of CB and RPE (arrows). In contrast, positive cell nuclei 
were identified in the anterior retina of both the RPE and CB but also the CB domain 
appeared to extend into the peripheral regions of the central retina in the mutant (D-E).  
Additionally, these cells appeared to be more intensely stained than in wild type, 
indicating higher levels of Lef1 expression.  B & C and E and F are higher 
magnification images of A and D, respectively. At E15.5, the domains of Lef1 staining 
(arrows) clearly defined the developing CB of both wild type (G) and mutant (J). Higher 
magnification of the wild type domains (H & I) revealed that only subsets of the nuclei 
in this region were positively stained (arrows) and that there was also some cytoplasmic 
staining (arrowheads). In the mutant, although the region of Lef1 signal overlapped with 
the wild type, the signal was increased in the mutant (K & L). Also, there were fewer 
non-expressing cells in the mutant CB (arrowheads), while there were also cell nuclei 
identified within the central retina that were Lef1 positive (arrows). These circular nuclei 
were not intimately associated with the adjacent retinal cells and appeared to be 
positioned within vacuoles. 
 
 
4.7.7. Immunostaining of Mp eyes at E18.5 revealed expansion of ectopic retinal 
Lef1 
 In wild type eyes, the only Lef1 positive domains were in cornea, iris 
stroma and CB (figure 4.5.7A). The cells of the CB displayed strongly nuclear staining 
(figure 4.5.7B) and clearly defined the ciliary from the neural retina. No staining was 
observed in the wild type neural retina at this stage. In the homozygote, iris and cornea 
were positive for Lef1 signal, in addition to the truncated CB (figure 4.5.7C & D). In 
contrast to the wild type, the mutant displayed numerous cells positive for Lef1within the 
inner nuclear layer of the neural retina (figure 4.5.7E). Although the mutant CB was 
small and thinner than the wild type, several nuclei were observed as positive for Lef1 










Figure 4.5.7 Ectopic Lef1 immunostaining in the retinas of E18.5 mutant 
eyes.  
In wild type eyes at E18.5 (A & B), Lef1 signal was seen in the CB (arrows), cornea 
(filled arrows) and some cells of the iris stroma (B; arrowheads). The strongest signal 
intensity was seen in the nuclei of CB. In the mutant eye at E18.5 (C-F), consistent with 
wild type expression, Lef1 positive cells were seen in the CB (arrows), cornea (filled 
arrows) and iris stroma (arrowheads). However, strong signal was also observed within 
cells throughout the mutant retina (white arrows: D & E). Lef1 signal (arrows) was seen 





4.7.8. Ectopic expression of Chx10 in the outer nuclear layer of mutant retina 
The homeodomain gene Chx10 induces cells of the inner nuclear layer and thus 
was used as a marker for development of this region of the retina. The expression of 
Chx10 was analysed by RNA in situ hybridisation on E15.5 eye sections. In the wild type 
(figure 4.5.8) expression was clearly restricted to the inner nuclear layer of the 
developing retina. In contrast, numerous Chx10 expressing cells were observed in the 
outer nuclear layer in addition to those seen in the inner layer. Thus, the inner nuclear 







Figure 4.5.8 Ectopic expression of Chx10 in the retinas of E15.5 mutant 
eyes.  
RNA In Situ hybridisation using a probe specific to Chx10 mRNA identified specific 
signal in cells of the inner neuroblastic layer of the developing wild type retina at E15.5 
(A & B). There was no staining in the outer neuroblastic layer. In the mutant, although 
exact plane of section differed to the wild type sample, in addition to positive cells 
within the inner neuroblastic layer, Chx10 expressing cells were also observed in the 




5.1. OAS project discussion 
5.1.1. The OAS locus is a 3.4 Mb interval on central chromosome 14 
A critical interval for OAS was identified by autozygosity mapping using 10k 
SNP arrays using meiotic recombination events in 4 affected individuals from 3 unrelated 
consanguineous families. The OAS interval mapped to between 69,425,921-73,059,612 
Mb on chromosome 14 and this locus was confirmed by linkage analysis with a 
significant LOD score of 5.3 at theta = 0. By combining our data with that from other 
families typed by our Dutch collaborators we were able to refine the OAS interval 
slightly to 3.4 Mb between 69,652,605-73,059,612 Mb. The region contains 19 known 
protein-coding genes. The region contains 19 known protein-coding genes.  Using 
bioinformatic resources, each gene was assessed for its candidacy as the likely OAS 
gene. Expression during embryonic development was analysed using the Visigene 
application available at UCSC (http://genome.ucsc.edu/index.html), together with the 
Gene Expression Database available at the Mouse Genome Informatics/JAX website 
(http://www.informatics.jax.org/expression.shtml), and information from the EMAGE 
Database of the Edinburgh Mouse Atlas Project (http://genex.hgu.mrc.ac.uk/). Known 
mutations in the mouse (spontaneous and generated knock-outs; 
http://www.informatics.jax.org/) were also analysed to look for comparable phenotypes. I 
also investigated published data of the currently known functions of these genes during 
development and disease, and whether there had been interactions identified with known 
genes important during ocular or limb development, or for any interactions with signaling 
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pathways that occur during these events. As none of these presented as obvious 
candidates, on the basis of these investigations, we decided to sequence all coding exons.   
For practical reasons these were prioritised for sequence analysis by their degree of 
sequence conservation through evolution. 
 
5.1.2. No pathogenic mutations were identified in the OAS locus 
So far, I have sequenced 61% of all the coding exons in the OAS interval in 8 
unrelated affected individuals. 19 silent SNPs, 7 known missense polymorphisms and 
5 missense changes not previously reported were identified. All of the known 
missense changes were considered to be non-pathogenic polymorphisms on the basis 
that either the allele frequencies were >1% in populations studied (rs2286838, 
ZFYVE1; rs2280792 & rs4903104, both in PAPLN) or they were in non-conserved 
amino acids within the encoded protein (ADAM21, rs8010994 & rs3829452). The 
only other SNP identified was rs3829456 (K247Q) also in ADAM21 and was in a 
conserved residue in the protein. However, it is highly unlikely that a SNP identified 
in the general population would be causative for OAS, based on the rarity of the 
disease; therefore all known SNPs were preliminarily discounted from further 
investigation.  
 
Additionally, 4 of the 5 novel missense changes were identified in ADAM21 (a 
disintegrin and metalloprotease domain family 21 gene), a 2.4 kb single exon gene 
encoding a single-pass membrane anchored protein implicated in cell-cell and cell-
matrix adhesions that has no phenotype in a Adam21 null mouse (MGI allele ID: 
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3663320). ADAM21 has not been associated with any human disease and its 
expression profile during vertebrate development remains unknown. All of the amino 
acid changes were predicted to be non-pathogenic. In three, the biochemical nature of 
the amino acid change was retained (V158L; I161V; V216M), with both alleles 
encoding non-polar sidechains. In one change (F159C), an aromatic non-polar side-
chain was replaced by an uncharged polar side-chain. However, this missense change 
was also considered as non-pathogenic, as at the equivalent position in the 
homologous mouse protein, there is also an uncharged polar side-chain amino acid 
(N; asparagine). Overall, the ADAM21 gene has only 68% sequence similarity to the 
mouse homologue, suggesting it is not under strongly conserved functional selection.  
 
The only other missense change identified so far was in the 36-exon gene, 
Pecanex-like-1 (PCNX), a homologue of the Drosophila pecanex gene. PCNX 
function has been linked to spermatogenesis in mammals (Geisinger et al., 2005). The 
nucleotide identified change resulted in a T471S amino acid replacement. Both have 
uncharged polar side-chains and at the equivalent amino acid position in the mouse 
homologue is a glutamine residue, another uncharged amino acid with a polar side 
chain. Thus, these changes were not considered as pathogenic and were excluded as 
responsible for OAS. 
 
5.1.3. VSX2 and Cis-acting transcriptional regulation 
In addition to minimal promoters, many genes additionally require multiple cis-
acting genomic elements for correct spatiotemporal expression. These may be 
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enhancers or repressors and can be positioned within introns, or upstream and/or 
downstream of the gene over which they exert control, and may be positioned up to a 
distance of 1 Mb in either direction (Kleinjan and van Heyningen, 2005).   
 
The homeodomain gene VSX2 (formerly referred to as CHX10) is situated on 
chromosome 14 at 73,775,928- 73,799,194 Mb, and is therefore positioned 713 kb 
genomically distal to the critical interval identified for OAS. VSX2 has been identified 
as defective in cases of recessive non-syndromic microphthalmia with cataracts and 
iris abnormalities (Percin et al., 2000). VSX2 is embryologically expressed in mouse 
optic vesicle and the proliferative layers of the neural retina, while mice with a Vsx2 
null mutation present with microphthalmia (Burmeister et al., 1996). Our Dutch 
collaborators have sequenced the entire intragenic region of this gene in their OAS 
patient cohort and have not identified any mutations (Dr. Han Brunner, personal 
communication).  
 
Although VSX2 mutations in mouse or man have not been associated with any 
limb deformities, and its expression during limb development has not been reported, it 
may be possible that cis-regulatory elements that are important in the control of 
spatiotemporal expression of VSX2, or other genes in the candidate region, during 
development may have been perturbed in OAS. Therefore, future attention towards 
identifying conserved non-coding elements, particularly influencing transcriptional 
regulation of VSX2, and analysing them in the OAS patient cohorts is required. 
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The future of the OAS project will involve the use of microsatellite (CAn) markers 
to further refine the candidate interval, analysis of a fourth “Edinburgh family” for 
autozygosity mapping and linkage. Additionally, amalgamation of sequencing data from 
the two collaborative groups will identify exons that still require sequencing.  Analysis of 
the expression patterns of all the genes in the interval will be conducted to identify if any 
have specific, or overlapping expression with ocular and limb development at key 
embryonic stages. It may prove that sequencing of the entire candidate region may be 
necessary to identify the genetic lesion in OAS. For this, cell lines will need to be 
established to generate sufficient DNA quantities to enable next-generation sequence 
capture technologies 
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5.2. Mp project discussion 
5.2.1. An expanded phenotypic description of Mp 
The original description of the major external features of Mp associated with 
heterozygous and homozygous mice were confirmed in our reconstituted lines on two 
independent strain backgrounds. However, I did find some important differences in other 
aspects of the original phenotype report of the Mp line (Phipps, 1964).  In particular we 
did not observe the reported neonatal mortality in homozygotes.  In our facility these 
animals were viable and survived normally post weaning.  This is likely to be due to 
differences in stain background and/or animal husbandry procedures.  It was also clear 
that when the eyes were dissected the homozygotes were microphthalmic and not 
anophthalmic.  
 
I was also able to expand the descriptive ocular pathology associated in adult Mp 
animals.  This pathology was pan ocular and begins relatively early in development with 
an ocular growth phenotype identifiable by E15.5, with a graded reduction in eye size 
between Mp/+ and Mp/Mp, compared to wild type.   The post natal phenotype was 
characterised by; lens cataracts, abnormal lamination and rosette structures in the neural 
retina, an absence of vitreous body and abnormally formed ciliary body.  In Mp/Mp 
adults the ocular features were similar but were of substantially increased severity. 
Marked corneal thickening was only seen in homozygotes.   The retinal rosettes were 
mainly composed of disorganised rod photoreceptors, and were associated with a reduced 
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number of cells within the inner nuclear layer. Abnormal development of the ciliary body 
was identified from E15.5 onwards in both homozygote and heterozygote.  
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5.2.2. Fbn2 as a candidate gene for Mp 
Mp was mapped to a region on chromosome 18, between 53-67 Mb. This interval 
contains 119 gene sequences according to the Ensembl database, however of these 
Fibrillin2 (Fbn2) stood out as a very strong candidate gene. 
 
There are currently four alleles of mouse Fbn2 (Figure 5.2.1), which display 
hindlimb oligodactyly identical to Mp. In all, this phenotype occurs as a result of 
synostosis of phalanges between autopodia rays 2 to 4, (osseous syndactyly). Consistent 
with Mp, oligodactyly was never noted in digits 1 or 5 in these animals. The shaker-with-
syndactylism (Sy) phenotype is caused by an irradiation-induced 0.7 cM deletion of the 
Fbn2 locus (Chaudhry et al., 2001; Johnson et al., 1998) (Figure 5.1) and includes the 
two solute channel genes Slc26a6 and Slc12a2. The auditory/vestibular defects have been 
attributed to the loss of Slc12a2 and are genetically separate from loss of Fbn2 (Chaudhry 
et al., 2001). The fused-phalanges allele (Syfp) resulted from a spontaneous single 
nucleotide deletion in exon 39, which resulted in frameshift of the transcript and 
introduced a premature termination codon after 44 amino acid residues (Chaudhry et al., 
2001). No Fbn2 protein was detected in immunoblots with protein samples prepared from 
Sy/Sy and Syfp/Syfp mice. In contrast, the Syfp-2j mouse also has fused phalanges but Fbn2 
protein can be detected by immunoblots. However, the spontaneous mutation results in a 
21-nucleotide deletion including the last 7 nucleotides at the 3’-end of exon 38. This 
results in exon-skipping and is predicted to affect the structure and function of the mutant 
protein (Chaudhry et al., 2001). The Fbn2ko mouse line was created by gene-targeted 
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replacement of exon-1 of the Fbn2 gene with a neomycin cassette (Artega-Solis et al., 
2001), resulting in loss of detectable Fbn2 protein.  
 




Figure 5.1.1 Mouse Fbn2 allelic series. There are currently four published mouse 
mutations in the Fbn2 gene that result in oligodactyly. Shaker-with-syndactylism (Sy) is a 
0.7cM irradiation induced genomic deletion; fused phalanges (Syfp) is a spontaneous 
frame-shift allele with the introduction of a termination codon after 44 amino acids; a 
second spontaneous allele with fused phalanges (Syfp-2j) results from an exon-skipping 
mutation affecting exons 38-39; and the gene-targeted Fbn2-null mouse (Fbn2ko). 
(Arteaga-Solis et al., 2001; Chaudhry et al., 2001; Johnson et al., 1998) 
 
5.2.3. Fibrillin family proteins  
Mouse Fbn2 is a 65 exon, 315 kDa cysteine-rich extracellular matrix (ECM) 
glycoprotein belonging to the fibrillin family of proteins (Hubmacher et al., 2006). In 
humans, bovines and avians, there are three fibrillins, FBN1, FBN2, and FBN3. However, 
in the mouse, there is no Fbn3 homologue, possibly due to a genomic rearrangement 
event during evolutionary divergence (Corson et al., 2004). The protein structure of the 
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fibrillins is closely related at the domain level (Hubmacher et al., 2006). Their prominent 
motif is the epidermal growth factor (EGF)-like domain, of which there are between 46-
47, depending on the protein (human and mouse FBN2 have 47), and most of these EGF-
domains are calcium-binding (cbEGF) common to many ECM domains. Human FBN2 
has 43 cbEGF domains, while mouse has 42.  The third characteristic motif of the FBNs 
is the transforming growth factor (TGF)-binding domain (TB domain). These domains 
are only present in the FBNs and in the latent transforming growth factor binding group 
of proteins (LTBPs), which have 7x and 3x motifs, respectively. The combined binding 
of FBNs and LTBPs to extracellular TGFβ ligands has recently been identified as a 
potent mechanism for the control of growth factor signaling in development and disease 
(Charbonneau et al., 2004; Habashi et al., 2006; Hubmacher et al., 2006; Kaartinen and 
Warburton, 2003). The human and mouse Fbn2 proteins share 96.3% sequence identity at 
the amino acid level (with 100% coverage). 
 
5.2.4. Human fibrillinopathies 
In humans, autosomal dominant mutations in FBN1 result in the skeletal, 
cardiovascular and ocular features of Marfan syndrome (MIM #154700), whereas FBN2 
mutations appear to only affect the skeletal regions, and patients present with long digits 
(arachnodactyly), distal joint contractures and crumpled ears, in the syndrome Congenital 
Contractural Arachnodactyly (also referred to as Beals syndrome; MIM+0121050). A 
mutation in FBN1 (a deletion of exon 41) has been identified in autosomal-dominant 
Weill Marchesani syndrome (MIM #277600) (Faivre et al., 2003b), a congenital disease 
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of connective tissue, brachydactyly, joint stiffness, thickened skin and ocular 
malformations, including ectopia lentis and microspherophakia (Faivre et al., 2003a). The 
FBN3 is located close to the autosomal recessive Weill Marchesani locus on human 
chromosome 19p13. However, although FBN3 mutations may yet be identified associated 
with this disease, only mutations in the extracellular metalloprotease ADAMTS10 have so 
far been identified (Dragoneau et al., 2004). The two separately inherited forms of the 
disease have been extensively reviewed and display clinical homogeneity, despite genetic 
heterogeneity (Faivre et al., 2003a). 
 
 The fibrillinopathies have convincing phenotypic overlap with the features 
described for the Mp mouse and in combination to the features described for the allelic 
series of Fbn2 described for the mouse, Fbn2 was an excellent candidate for Mp. Thus, 
further mapping studies were focused on this gene.  
 
5.2.5. Mp is due to a 660kb inversion 
Mp is associated with an inversion of 660 kb.  The inversion break points are 
situated within the 3’- exons of two genes: Fbn2 and Isochorismatase domain containing-
1 (Isoc1). Isoc1 is 5-exon gene encoding a novel 32 kDa protein with a possible 
peroxisomal cellular localisation but whose role remains undefined in mammalian 
organisms. The Isochorismatase domain, also known as 2, 3-dyhydroxybenzoate 
synthase, is predicted to belong to a family of hydrolase enzymes involved in catalysing 
the conversion of isochorismate to 2,3-dyhydroxybenzoate and pyruvate in bacteria 
(Rusnak et al., 1990) [http://supfam.cs.bris.ac.uk/SUPERFAMILY/cgi-
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bin/scop.cgi?sunid=52499]. No mutations or developmental expression patterns of this 
gene have so far been described in mammals and there have been no knock-out studies 
completed in the mouse from which to infer a role in eye development. 
 
5.2.6. Differing fates of the Mp-affected mRNAs 
The Mp inversion results in two reciprocal fusion transcripts, identifiable by RT-
PCR. The last (3’-) exon of Isoc1 was replaced by the final three exons of 3’-Fbn2 gene, 
and vice versa. This resulted in premature termination codons for both transcripts. 
However, the locations of the induced nonsense codons predicts two contrasting 
transcript fates: The Isoc1 transcript was predicted to be degraded by nonsense mediated 
decay (NMD), a cellular surveillance mechanism that selectively degrades mRNA 
species harbouring a premature stop codon occurring 5’ to the last intron (Chang et al., 
2007; Nagy and Maquat, 1998). Conversely, the induced termination codon in Fbn2 was 
within the 5’-most exon (i.e. the fused last Isoc1 exon) with no 3’-introns and therefore 
was predicted to translate to a truncated but stable mRNA, resulting in a Fbn2 protein 
missing C-terminal amino acids. This included the loss of the last cbEGF domain, and the 
unique C-terminus sequence, including an N-glycosylation site and a proprotein 
processing site. The sequence encoded by the Isoc1 fusion was out of frame and resulted 
in seven additional amino acids prior to a termination codon. The foreign amino acids did 
not display similarity to any known protein motifs.  
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5.2.7. Loss of Fbn2 causes hind limb oligodactyly in the mouse 
WISH analysis of spatial gene expression revealed the presence of Fbn2 
transcripts in limbs at E10.5, E11.5 and E12.5. These are key developmental stages 
during limb development, when patterning of the autopod, growth and chondrogenesis 
occur, and therefore is temporally consistent with Fbn2 loss-of-function in the developing 
limb causing an oligodactyly phenotype.  In addition, this phenotype is consistent with 
the Fbn2 allelic series in the mouse. This phenotype has been attributed to abnormal 
TGFβ signaling between digit primordial as a result of loss of functional Fbn2 in the 
extracellular matrix in the developing autopod (Arteaga-Solis et al., 2001). Indeed, the 
prodomain of Bmp7 has been shown to interact directly with the N-terminal region of 
Fbn1 (Gregory et al., 2005), and is suggested to similarly bind with Fbn2. Compound 
heterozygote mice for Bmp7-/+ and Fbn2-/+ exhibit phenotypic limb-pattering defects 
consistent with the combined null mutations of each gene. Therefore, the complete 
absence of Fbn2 in the mid-axial region of the developing limb autopod may abolish 
targeting or deposition of Bmp7 to the ECM (Hubmacher et al., 2006), and therefore 
affect the precise growth factor cues required for the correct decisions between PCD and 
chondrogenesis within the interdigital rays. Therefore, the functional and developmental 




5.2.8. Evidence for Fbn2Mp aetiology in the Mp ocular phenotype  
No eye phenotype has yet been reported in Fbn2 null mice (Arteaga-Solis et al., 
2001; Chaudhry et al., 2001) or associated with FBN2 mutations in humans. 
Unsurprisingly therefore, the ocular developmental expression pattern of Fbn2 has not 
been extensively examined in either. However, the specific temporal and spatial 
expression pattern of Fbn2 I have identified in the mouse suggests a functional 
requirement for Fbn2 during ocular development. Specifically, transcripts of both species 
(wild type and mutant) were identified in the ciliary body and mesenchyme of the 
developing eye at E13.5-E16.5 by section in situs, in addition to the ocular Fbn2 
expression observed by whole-mount in situs at E10.5-E12.5.  
 
At the protein level, wild type Fbn2 was located in the extracellular matrix of the 
corneal and pre-scleral mesenchyme, in the inner limiting membrane of the retina, in 
early vitreous body and high levels were observed in the vitreous space where lens and 
retina are opposed and in contact at the anterior of the eye. In Mp mutant animals, Fbn2Mp 
expression was consistent with the wild type expression pattern in the eye. In contrast 
however, no mutant protein was identified in the extracellular spaces, vitreous, 
membranes or between cells in the eye. Instead, signal was identified inside cells in 
regions overlapping with wild type and mutant Fbn2 expression; in the developing ciliary 
body and RPE in anterior retina and in the pre-scleral mesenchyme. Additionally, several 
positively stained cells were identified distributed throughout the central retina, which 
had different morphologies to adjacent cells and therefore were considered to be different 
cell types. This suggested that in Mp mice, consistent with Fbn2-null mice, there is no 
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Fbn2 incorporated into the ECM within ocular tissues, however in contrast to Fbn2-null 
mice, there is intracellular Fbn2 retained within Fbn2-expresing cells. 
 
No antibody was available to identify the location of Isoc1 protein, however in 
both wild types and mutants, Isoc1 and Isoc1Mp expression was undetectable by RNA In 
Situ studies in the eye. Expression of the Slc27a6 gene, which encodes member of the 
fatty acid transport protein family involved in the transfer of long-chain fatty acids across 
membranes lies genomically between Fbn2 and Isoc1 within the inverted interval. 
Theoretically, Slc27a6 gene expression could have been affected by the Mp mutation, 
however analysis by RT-PCR revealed expression in the eye appeared unaltered in Mp. 
Additionally, in the shaker with syndactyly spontaneous mutation Fbn2sy, caused by a 
7cM genomic deletion, this gene is completely removed and no ocular phenotype has 
been described.  
 
Although loss of Isoc1 function cannot be completely disregarded as the 
pathogenic cause of the ocular mutation seen in Mp, the distribution of Fbn2 transcripts 
and protein in developing wild type and mutant eyes indicated strongly that mutant Fbn2 
was likely be the main aetiology towards the ocular pathology of Mp. Therefore, 
investigations into the Mp ocular pathology were focused on Fbn2. 
 
5.2.9. Mutant Fbn2 was retained in the ER of expressing cells and caused ER stress 
We investigated the subcellular localisation of Fbn2Mp protein in expressing cells. 
The ER is the first component of the secretory pathway for transmembrane or secreted 
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proteins and is their intracellular location for protein folding and post-translational 
modifications (e.g. N-glycosylation and sulphide-bond formation), before translocation to 
the golgi and secretion or membrane integration. Therefore, numerous secretory and 
membrane proteins are reliant on normal passage through the ER and golgi for function.  
 
For Fbn2 protein to be transported to extracellular matrix, it must be processed via 
the secretory pathway and thus travel through the ER. As the N-terminal of Fbn2 was 
unaffected in Mp, the nascent peptide was presumed to engage and direct conventional 
secretory pathway protein synthesis into the ER (Nothwehr and Gordon, 1990). However, 
the loss of the C-terminal region of Fbn2Mp, including removal of a furin cleavage site, 
predicted an arrest of its transport through the ER/trans-golgi network (Lonnqvist et al., 
1998). The intracellular localisation of mutant protein aggregates and the lack of 
extracellular Fbn2 in mutants were consistent with this hypothesis, in that mutant Fbn2Mp 
was retained and accumulated in the ER. Using skin cells from mutant animals for 
transmission EM analyses, large intracellular inclusions were identified that 
immunostained positively for Fbn2 and appeared to be associated with the ER membrane.  
In fibroblasts, immunocytochemistry identified large Fbn2 protein aggregates directly 
adjacent to the nucleus, again consistent with ER localisation. It was therefore accepted 
that intracellular Fbn2Mp aggregates were localised to within the ER of expressing cells. 
 
5.2.10. The ER stress response 
Cell autonomous quality control mechanisms exist to ensure that only correctly 
folded and modified proteins exit the ER (Malhotra and Kaufman, 2007; Schroder, 2008). 
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Slowly folding or permanently unfolded proteins are either retained within the ER lumen 
in complexes with chaperones or are targeted for degradation via the ER-associated 
proteasomal degradation mechanism (ERAD), or removed and degraded by autophagy. 
However, the accumulation of misfolded proteins, immune to ERAD and autophagy may 
perturb ER homeostasis and cause ER stress, and this stress triggers the evolutionarily 
conserved unfolded protein response (UPR).  
 
To maintain homeostasis of the ER, several ER-transmembrane proteins monitor 
the folding status of proteins within the ER lumen and can initiate adaptive responses to 
ER stress. PERK (eukaryotic translation initiation factor2-alpha kinase) is a 
transmembrane kinase; IRE1 (endonuclease inositol-requiring enzyme-1) is a 
transmembrane protein kinase endoribonuclease; and ATF6 (activating transcription 
factor 6) is a transmembrane bZIP transcription factor. Each has domains extending into 
the ER lumen. The heat-shock protein family member HSP70 protein and ER stress 
sensor BiP (GRP78 or Kar2p) is thought to relate the status of the ER lumen to the 
luminal domains of these proteins. Normally bound to these sensors in non-stress 
situations, it is released and binds to hydrophobic patches exposed on protein folding 
intermediates. Upon increased accumulation of unfolded proteins, BiP protein is released 
from the ER-lumen domains of PERK, IRE1 and possibly ATF6, and induces their UPR 
specific responses. 
 
Activated PERK and IRE1 are trans-autophosphorylated and cooperate to 
coordinate protective responses to ER stress (Schroder, 2008). These include the 
 244 
inhibition of global mRNA translation by the phosphorylation of eIF2α by PERK. 
Additionally, PERK also induces the selective transcription of the majority of UPR-
dependent chaperone genes, required to increase protein-folding activity within the 
stressed ER.  
 
IRE1 initiates the non-conventional splicing of the X-box binding protein-1 
transcription factor ( Xbp1) by ATF6 (Yoshida et al., 2001) to introduce a potent 
transcriptional activation domain that binds and activates transcription from the UPR-
element, a minimal motif found upstream of many UPR-target genes necessary and 
sufficient for UPR gene activation (Malhotra and Kaufman, 2007). This leads to an 
increase in the expression of BiP and other chaperone proteins for enhanced ER protein-
folding activity.  The IRE1 ribonuclease activity removes a 26-nucleotide region from the  
Xbp1 transcript to create a larger form of  Xbp1 protein. This differential in  Xbp1 
transcript size has been effectively and routinely used as a marker for ER stress at the 
RNA level by RT-PCR (Lin et al., 2007; Ulianich et al., 2008) and has be supported by 
the analysis of BiP expression by RNA in situ hybridisation (Tsang et al., 2007). 
 
Although the primary function of the UPR is to be protective, chronic ER stress 
can lead to apoptosis in cells as a tissue-protective mechanism, and its activation is 
triggered by persistent PERK activity after initial IRE1 responses have abated (Lin et al., 
2007). Indeed, one mRNA that escapes translational inhibition during UPR and whose 
translation is actually activated in response to PERK-dependent P-eIF2α, is the bZIP 
transcription factor ATF4. This protein has a major role in the activation of the pro-
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apoptotic bZIP transcription factor CHOP (DDIT3, or GADD153) after prolonged or 
severe ER stress (Malhotra and Kaufman, 2007; Schroder, 2008). 
 
5.2.11. Fbn2Mp accumulation caused ER stress in Mp eyes 
Increased BiP expression was identified in the developing ciliary body in E16.5 
mutant but not normal eyes, overlapping with the expression of Fbn2 and the spatial 
distribution of mutant protein aggregates. Furthermore, we designed a novel RT-PCR 
based assay to identify the ratio of spliced to unspliced  Xbp1 transcripts and revealed 
that Fbn2 expressing MEFs from heterozygotes and homozygotes had increased levels of 
spliced  Xbp1 compared to wild types, consistent with the UPR response. The specificity 
of the assay was confirmed using chemical induction of ER stress with tunicamycin, and 
this assay was then performed with RNA isolated from dissected eyes and showed that 
homozygotes had an increased level of spliced  Xbp1, compared to wild types. Together; 
these results indicated that Fbn2Mp aggregates triggered the ER stress response in mutant 
eyes, specifically in the developing CB. 
 
5.2.12. ER stress in Mp eyes did not necessarily associate with apoptosis 
Prolonged ER stress can trigger activation of cell death pathways (Schroder, 
2008). We investigated the abundance of Activated-Caspase-3 (A-Casp3) protein as a 
specific marker for cell death in mutant eyes. Caspase-3 is a cysteine aspartic acid 
protease and is one of the effector caspases, which are cleaved from their inactive pro-
enzyme forms into an active multimeric enzymes, either by self-proteolysis or by other 
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active (initiator-) capases, in cells undergoing apoptosis (Thornberry and Lazebnik, 
1998). We observed numerous positively stained cells within the retinas of mutant eyes, 
but not in wild types. Although these apoptotic cells were observed throughout the 
retinas, there was no specific enrichment for co-localisation with the highly positive 
Fbn2Mp cells identified in the developing ciliary body that had been shown to be positive 
for elevated BiP expression. Furthermore, although suggestive data was found, co-
immunofluorescence could not fully confirm co-localisation of Fbn2Mp aggregates with 
A-Casp3 in all cases. This indicated that although apoptosis was possibly linked to the 
accumulation of intracellular Fbn2Mp, and therefore ER stress, the presence of aggregates 
did not necessarily result in programmed cell death. Additionally, the apoptotic cells 
dispersed throughout the retina, as determined by positive A-Casp3 staining, may be the 
same cells identified with abnormal morphology observed within the outer layer of the 
neural retina at E16.5 and E18.5 by H&E staining. The rosetting seen in the cells of adult 
retinas may be a direct consequence of regionalised apoptosis in cells with Fbn2Mp 
aggregates, by disrupting intercellular signaling and causing disorientation of the 




5.2.13. Fbn2Mp aggregates in the peripheral Mp retina may affect production of a 
retinal lamination and ciliary body determining factor 
Cells in the developing anterior retinal have recently been identified in both 
mouse and chick as producers of a factor required for correct retinal lamination and vital 
for ciliary development: Wnt2b (formerly Wnt13)(Cho and Cepko, 2006; Kubo et al., 
2003; Nakagawa et al., 2003). Wnts are secreted morphogenetic ligands vital for many 
aspects of development (Logan and Nusse, 2004). They are lipid-modified glycoproteins 
that undergo post-translational modifications that are vital to their secretion and function; 
glycosylation and the addition of the lipid moieties palmitate and palmitoleic acid by 
palmitoylation within the ER (Hausmann et al., 2007). Loss of Wnt2b results in complete 
failure of ciliary development, while its ectopic expression in the central neural retina 
induces ciliary marker expression and retinal folding reminiscent of mature ciliary 
processes (Cho and Cepko, 2006). In addition, Wnt2b signal emanating from CB cells 
has been identified as an important factor determining correct lamination of retinal cells 
by maintenance of the early neuroepithelial layer, while Wnt2b added to disorganised 
neural retina cells in culture can restore correct lamination (Nakagawa et al., 2003). 
Blocking of Wnt downstream signaling by a dominant-negative Lef1 resulted in 
premature neuronal differentiation in the developing ciliary body and inhibited 
proliferation (Kubo et al., 2003). Thus Wnt2b may diffuse from the peripheral retina into 
the central retina and confer early patterning of the neural retina and provide competence 
for later lamination-specific events.  
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The requirement of Wnt2b for both ciliary body formation and correct retinal 
lamination was therefore intriguing in the context of the Mp ocular pathology, where 
there is a failure both. In mouse and chick, In Situ studies have identified Wnt2b 
transcripts in the developing ciliary body and distal RPE (Cho and Cepko, 2006; Liu et 
al., 2003). This overlaps both temporally and spatially with the location of Fbn2 
expression and protein aggregate build up in Mp. Thus, loss of ciliary-specific Wnt2b 
signal predicts a loss of correct CB development, and vice versa, and abnormal retinal 
lamination as a consequence. Therefore misregulation of canonical Wnt signaling, 
specifically through the Wnt2b ligand, represents a plausible candidate mechanism for 
the ocular pathogenesis in Mp, distinct from a loss of function of Fbn2. 
 
5.2.14. Aberrant Lef1 expression indicates Wnt responses were abnormal in the 
developing Mp ciliary body 
The transcription factor Lef1 (Lymphoid enhancer factor, a HMG group protein) 
is a positive activator of canonical Wnt signaling that initiates the expression of Wnt 
target genes in cooperation with nuclear β-catenin, T-cell transcription factor (Tcf) family 
proteins and various other cooperative transcription factors. As we were unable to 
directly assess the Wnt2b expression pattern and distribution in Mp eyes, either by In Situ 
hybridisation or immunostaining, a Lef1 antibody was used as a marker for canonical 
Wnt signaling. In Wild types, a positive domain of Lef1 localisation was clearly 
identified in the ciliary body and distal tip RPE at E13.5, becoming a clearly defined 
boundary of non-expressing cells at the peripheral limit of the ciliary at E15.5. This is 
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consistent with the known Wnt2b expression domain. The domains of Lef1 expression in 
Mp were consistent with wild type, but the signal was increased at E13.5 and E15.5, and 
the boundary at the peripheral margin of the ciliary was poorly defined at E15.5 and 
spread slightly into the peripheral retina.  
 
The differential Lef1 staining in the ciliary between wild type and mutants 
indicated that mis-regulation of Wnt signaling was likely, either by an increase in 
localised Wnt signaling or inappropriate activation of the canonical Wnt pathway. 
Equally however, there could be disruption to feedback mechanisms controlling Lef1 
expression, possibly independent of the presence of Wnt ligand, resulting in increased 
and ectopic expression. Without In Situ or immunostaining data for Wnt2b and co-
expression data for Fbn2Mp in these cells, it is difficult to evaluate misregulation of Wnt2b 
as a mechanism for Mp ciliary pathology. Work is on going to identify the relationship 
between Lef1 up-regulation and Wnt2b status.  
 
5.2.15. A Pax6/Lef1-Sox2 boundary defines the developing ciliary body and was 
abnormal in Mp 
SOX2 is an SRY-related HMG-box (SOX) transcription factor involved in stem-
cell maintenance in the developing central nervous system. Heterozygous loss of function 
mutations in SOX2 results in severe ocular malformations (Fantes et al., 2003). However, 
nuclear Lef1 has been identified as a positive activator of Sox2 expression through direct 
binding to the Sox2 (N-1) promoter in chick (Takemoto et al., 2006). Nuclear Sox2 
protein was identified in the neuroblastic region of the neural retina at E13.5 and E16.5, 
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but was excluded from the Lef1-positive developing ciliary body. In contrast, the paired-
box transcription factor, Pax6, was excluded form these regions and was specifically 
localised to the inner layer of differentiating cell nuclei within the retina and extended 
into the ciliary body to the anterior tip.  
 
PAX6 mutations have also been implicated in ocular malformations, such as 
aniridia and Peter’s anomaly, and result in the small eye phenotype in the mouse. Sox2 
protein overlapped with Pax6 in the ciliary-retinal boundary at E13.5 and E16.5 but 
showed mutually exclusive distribution in the developing central retina; with nuclear 
Sox2 protein localised to the neuroblastic outer regions, and Pax6 within the nuclei of 
cells in the inner layer of differentiating neurons. These domains of expression were 
defined by clear boundaries in wild type eyes. In the mutant ciliary, these margins were 
blurred and the coexpressing domains seemed to extend into the central retina at E13.5, 
suggesting a possible reduction in Sox2 expression and/or increased activation of Pax6. 
In contrast, at E16.5 the clearly visible Pax6-only domain in the wild type ciliary was 
reduced in the mutant and the coexpressing cells of the CB-retinal boundary were shifted 
anteriorally. Together these data suggest Sox2 is excluded from the developing ciliary 
body, but that Pax6 is be required for its development. The presence of Sox2/Pax6 
positive cells in the CB-retinal boundary may specifically identify the ciliary marginal 
zone, a previously described population of multipotent stem cells at the retina-ciliary 
margin (Kubo and Nakagawa, 2008). In the mutants, the Pax6-only zone is truncated and 
probably reflects the loss of developing ciliary cells. Additionally, the Pax6/Sox2 domain 
had extended toward the central retina, reflecting a possible increase in Pax6, or a 
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decrease in Sox2 expression. Otherwise, the retinal patterning of Sox2 and Pax6 was 
unaffected in Mp. From this data, coexpression of Pax6 and Lef1 in the absence of Sox2 
expression defines the developing ciliary body in normal eyes.  
 
Although co-expression studies were not carried out, the distribution of Sox2 and 
Lef1 suggests cells that were Lef1-positive were Sox2-negative in wild type and mutant 
retinas. As the upregulation of Lef1 is considered as a marker for the active state of the 
canonical Wnt pathway, our data is in direct contrast to the current model where Lef1 
acts as an activator for Sox2 expression (Takemoto et al., 2006). Lef proteins can assume 
diverse regulatory functions on gene targets by their association with different nuclear 
proteins. Lef1 transcription factors mediate transcriptional response to Wnt signals by 
interacting with stabilised beta-catenin. In the absence of Wnt ligand-receptor binding, 
and thus an unstable beta-catenin, Lef proteins can associate with Tle homologues of the 
Drosophila Groucho co-repressor family of proteins to repress target gene activation 
(Levanon et al., 1998).  
 
Whether Lef1 can also act as a transcriptional repressor in the presence of 
activated Wnt signaling is obscure, and additionally the specific Tle interactors for Lef1 
in the developing ciliary body are currently unknown. It is clear from our data here 
involving Sox2 in the developing ciliary that more research on the Wnt/Lef/Sox2 
pathway is required within this context. 
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5.2.16. Rosetting was a non-specific response to general retinal stress 
Mp retinas are dysplastic with lamination defects and rosetting. The Mp rosettes 
were comprised of disorganised photoreceptor cells, shown by morphology and 
immunohistochemical staining for Rhodopsin.  The rosettes were not identified during 
embryogenic retinal development and were only seen in eyes studied at P21 and onwards, 
after retinal differentiation has occurred. Similar developmental defects are seen with 
mutations in various genes involved in diverse processes during retinal development: 
Notch1 conditional knock-outs leading to the precocious differentiation of neural 
progenitors (Jadhav et al., 2006), toxigenic ablation by expression of the Diptheria toxin-
A gene from the RPE affecting signaling interactions between RPE and retina (Raymond 
and Jackson, 1995), Selective removal of the miRNA activating enzyme Dicer from 
developing retinal cells and therefore affecting microRNA function (Damiani et al., 
2008), loss of combined retinoic acid receptors reducing retinal progenitor proliferation 
(Grondona et al., 1996), loss of photoreceptor determining specific nuclear receptor 
(NR2E3) (Akhmedov et al., 2000); and, in vitro, the loss of ciliary-derived Wnt2b as 
previously explained (Nakagawa et al., 2003).  This type of retinal dysplasia is thus 
generally considered to be a non-specific response to diverse stimuli that aberrantly affect 
retinal differentiation during development, and the general morphology is similar 
regardless of the molecular mechanism. 
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5.2.17. Fbn2Mp aggregates may promote dedifferentiation of retinal cells through ER 
stress response mechanisms 
Chx10, Calbindin, PKCα and DAPI immunostaining revealed an overall 
reduction in the cell numbers of the inner nuclear layer in adults, but no gross structural 
malformations. Why cells of this particular region of the retina are reduced is unclear, as 
both Fbn2Mp-positive and A-Casp3-positive cells were not enriched within any specific 
retinal layer. Although the reduction in cells of the adult inner nuclear layer reflects the 
overall increased apoptosis observed in Mp, it may be more indicative of reduced 
proliferation of neuroblastic progenitor cells, or of precocious, or deviant, differentiation 
programmes. Ectopic Chx10 expressing and Lef1-positive cells were identified by 
histological analysis in the outer (neuroblastic) layer of the embryonic retina. Although it 
was not specifically identified in these cells, it seems reasonable to infer that these are 
Fbn2Mp-positive cells and therefore eliciting the UPR. 
 
The initial response of the UPR in response to ER stress is protective. Therefore 
not all cells that elicit the UPR will undergo apoptosis. Surviving ER stress by the UPR, 
however, can affect the transcription and translation of genes required for particular cell 
differentiation programmes, resulting in altered differentiation and even dedifferentiation. 
For example, in the differentiating chondrocytes of transgenic mice expressing a mutant 
form of Col10a1, the mutant protein was retained in the ER and UPR markers were 
preferentially identified. Consequently, although these expressing cells survived, their 
differentiation programme was severely interrupted and they re-entered the cell-cycle, 
resulting in disruption to the highly coordinated events of endochondral ossification and 
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consequently a chondroplasia phenotype (Tsang et al., 2007).  Similarly, chemically 
induced ER stress in PC Cl3 thyroid cells resulted in inhibition of differentiation in the 
absence of apoptosis, together with an epithelial to mesenchymal transition (Ulianich et 
al., 2008).  
 
Lef1 and Vsx2 expression are markers for undifferentiated cells under the 
influence of Wnt2b signaling in the ciliary body and are mediators of gene transcription 
in undifferentiated, proliferating cells (Burmeister et al., 1996; Kubo et al., 2005). It is 
therefore possible in these cells that the intrinsic gene expression profile required for an 
inner nuclear layer cell fate has been perturbed, and has been replaced by the expression 
of genes required for proliferation. As a consequence, it is likely that they would also 
affect adjacent cells, probably through the creation of foci of aberrant cell extrinsic 
signaling. The absence of specific differentiation could then paradoxically lead to an 
overall decrease in cell numbers of the inner nuclear layer, due to the inability to respond 
to spatially-specific cues for correct cell-type specification. It may also lead to the 
localised increase in rod photoreceptor cells, which are organised into rosettes. Indeed, in 
Notch1 conditional mutants, the retinal phenotype of rosetting in the outer nuclear layer 
and a decrease in retinal cell types and size was attributed to the early differentiation of 
photoreceptors and an associated reduction in progenitors (Jadhav et al., 2006). 
Quantitative analysis of inner nuclear layer and photoreceptor cell numbers was not done 
in this study, however careful examination of the ratios between these cell-types may 
reveal clues into the formation of rosettes.  
 
 255 
5.2.18. Vitreous pathology as an indirect consequence of Fbn2Mp aggregates 
Cells of the ciliary body, as with chondrocytes and P13 Cl3 thyroid cells 
(collagens and thyroglobulin, respectively), synthesise and excrete large quantities of 
proteins through their ER, many of which require various post-translational 
modifications. Ciliary cells have been identified as the main expressing cells of those 
collagens that are vital for vitreous body development and function (Col2a1, Col9a1 and 
Col11a1) (Bishop et al., 2002). During protein synthesis events, pro-collagens pass 
through the ER where they are extensively processed and post-translationally modified 
by glycosylation, hydroxylation and disulfide-bond formation (Lodish, 1999). They are 
then secreted extracellularly into the vitreous where they fulfil vital structural and 
possibly signaling-regulation functions.  
 
Arrest in global transcription and translation within ER stressed cells of the ciliary 
due to Fbn2Mp aggregates and the eventual loss of a functional CB would presumably 
prevent such major constituents of the VB from being synthesised and thus would be 
predicted have severe implications to the development of the VB. We were unable to 
identify Collagen2A1 or Collagen11A1 expression overlapping with wild type ciliary 
Fbn2 expressing cells or ciliary cells positive for Fbn2Mp inclusions by In Situ 
hybridisation, or by using an anti- Collagen2A1 monoclonal antibody in developing eyes 
in this study. Nevertheless, the ciliary body has been implicated as the major source of 
collagen production in mouse and chick (Bishop et al., 2002; Ihanamaki et al., 2004), and 
overlaps both temporally and spatially with the localisation of Fbn2Mp aggregates and ER 
stress in Mp.  Additionally, the disruption of healthy VB has been implicated in various 
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ocular phenotypes including dominant disorders associated with collagen mutations, such 
as Sticklers syndrome, Marshall syndrome, and Kniest dysplasia (Ihanamaki et al., 2004), 
and in the regulation of eye size in mice (Halfter et al., 2006). It is possible therefore that 
the absence of VB in Mp mice was due to a combination of (i) a reduced number of 
ciliary body cells capable of producing vitreous components and (ii) the arrest of normal 
post-translational modification and transport through the ER/trans-golgi protein secretory 
pathway of collagens due to ER stress in those developing CB cells remaining in the Mp 
eye. It is worth pointing out that these are not mutually exclusive and are also 
transposable to Wnt2b signaling and synthesis.  
 
 
5.2.19. A Synodiporic effect of the ER stress response may underlie ‘worse than 
null’ pathologies 
Although currently unproven in this model, the potential loss of collagens or 
Wnt2b synthesis due to the UPR caused by the Mp mutation raises an intriguing and 
novel paradigm for disease pathology. Any developmentally critical membrane or 
secretory protein that requires passage through, and post-translational modification 
within, the ER for its correct synthesis and function (perhaps a morphogen or membrane-
integrated ligand-receptor), has a dependency on undisturbed ER function. Somatic loss-
of-function mutations in such genes may have specific pathologies associated with their 
global loss. However, tissue and time specific co-expression of a second secretory or 
membrane protein that is abnormal (either chronically misfolded or over-expressed) and 
that subsequently triggers the ER stress response has the potential to prevent the normal 
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function of the first protein, thus resulting in tissue-specific phenotypic consequences 
indirect from the pathology associated with loss of the mutant protein. We have termed 
this a “synodiporic effect”, from the Greek, synodiporia meaning fellow travellers or 
those walking the street together. Such effects may have significant implications for 




5.3. Perspectives and further work 
5.3.1. Retrospective lessons from the two projects 
The finding that a truncated from of Fbn2 resulting from a balanced 
rearrangement has implications for the OAS project. The Mp mutation was not picked up 
by direct sequencing of coding exons, and would be unlikely to have been identified by 
SNP array analysis. However, we have used both of these strategies to investigate the 
genetic aetiology of OAS. It is possible that a small genetic rearrangement may be 
present in the candidate interval but is unidentifiable by direct exon sequencing. 
 
Of interest in the OAS candidate region are two ADAM genes. These share 
homology with the ADAMTS genes, which also contain thrombospondin motifs. 
Thrombospondins are secreted proteins that associate with the extracellular matrix and 
ADAMTS10 has been identified as a matrix-localised protein (Dagoneau et al., 2004). 
Recessive mutations in ADAMTS10 cause Weil-Marchesani syndrome (Dagoneau et al., 
2004) closely associated with fibrillinopathies, but with ocular features such as ectopia of 
the lens, microspherophakia, myopia and glaucoma. The complete sequencing of the two 
ADAM genes may yet yield pathogenic mutations, but additionally there may be other 
genes within the interval that have as yet unknown associations with the extracellular 
matrix and may also have important roles in the development of eyes and limbs. The 
extracellular matrix as an important, higher level component of signalling cascades, 
through the sequestration and controlled release of growth factors, is becoming 
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increasingly appreciated within the field of developmental biology and must be 
considered as a potential involvement in the pathogenicity of OAS. 
 
5.3.2. OAS project further work 
In order to maximise the chances of identifying the causative mutation of OAS, I 
plan to initially narrow the critical region already mapped and looked for shared 
haplotypes in the OAS families within the current Edinburgh cohort. This will be done 
using highly informative microsatellite PCR markers. Additionally, we have recently 
recruited a fourth OAS family to the current Edinburgh cohort. This family contains a 
female proband with classical OAS features. There are two unaffected sisters and the 
parents are reported as non-consanguineous, however they originate from the same 
village in Northern Portugal. DNA from this family will be assessed using SNP arrays 
and autozygosity mapping to potentially reduce the critical interval for OAS. 
 
Concurrently, efforts will be made to finish sequencing of all of the exons in the 
Edinburgh cohort and to perform a fully combined analysis of the sequence datasets from 
both collaborative groups, as it is possible that the mutation has not been identified 
because the exon(s) containing causative mutation(s) have simply not been sequenced 
yet, or that there is a genomic deletion that encompasses several exons but that has been 
unnoticed due to these exons failing PCR reactions and shared between the two groups.  
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We will also look for non-genic deletions, duplications and insertions using both 
custom and whole genome array comparative genome hybridisation (aCGH). 
Additionally, it may be appropriate to tailor next-generation sequence capture 
technologies to obtain patient sequence data targeted for the entire critical interval. 
 
5.3.3. Mp mouse project further work  
For the Mp mouse, confirmation of Fbn2Mp as the sole aetiological agent in the 
ocular phenotype is currently being assessed using global RNAi knockdown of 
endogenous Fbn2 expression. This antisense transcript has been designed in a vector to 
be ubiquitously expressed and therefore should prevent global translation of Fbn2 
transcripts. RNAi-Fbn2 knockdowns in Mp/+ and Mp/Mp animals should therefore 
rescue the ocular phenotype, as there will be no mutant protein aggregates to accumulate 
in the ER of expressing cells. Loss of Fbn2 should therefore recapitulate the hind-limb 
oligodactyly in both mutants and in wild types, consistent will loss of Fbn2 protein seen 
in the Fbn2-allelic series.  Thus, if proven experimentally, this will confirm mutant Fbn2 
as the sole aetiological agent responsible for the ocular phenotype in Mp. 
 
Co-immunohistochemistry analyses are ongoing to identify whether intracellular 
Fbn2Mp containing cells are also positive for Wnt2b, Lef1, or Sox2, and markers of 
apoptosis, and additionally to confirm that all Lef1-positive cells were negative for Sox2 
in both wild type and mutant eyes. It will be interesting to identify the consequence of ER 
stress on Wnt2b expression in the early CB and therefore immunostaining and in situs are 
currently being repeated, and will be complimented by quantitative RT-PCR analysis on 
 261 
dissected eyes. It will also be interesting to identify what the binding partners of Lef1 are 
in the context of Sox2 repression and what are the chromatin regions involved in such 
Sox2 repression. This work would benefit from the establishment of primary cultures of 
embryonic ciliary cells for applications such as immunoprecipitation and chromatin 
immunoprecipitation, and this resource would also be useful to generate information of 
the transcriptional consequence of ER stress invoked by Fbn2Mp aggregates. 
 
A conditional Wnt2b KO mouse, specifically within the developing ciliary body, 
may provide valuable data on the relationship between Wnt signaling and ciliary 
development, and also demonstrate the effect of loss of Wnt2b on retinal lamination. It 
may also be useful to cross the Mp mouse with the BAT-gal mouse; a model to report 
cells responding to canonical Wnt signaling through a ß-catenin activated LacZ reporter 
transgene (Maretto et al., 2003). Furthermore, inducing chronic ER stress specifically in 
the ciliary body by the forced expression of mutant secretory proteins, or by gross 
overexpression of normal ER-processed proteins could recapitulate the primary ciliary 







6.1. Sequence conservation of OAS Critical Interval exons 






NUMB ENSE00001023973 72852851 33 1.000 
RBM25  ENSE00000807985 72650747 48 1.000 
RBM25  ENSE00001097359 72636128 84 1.000 
RBM25  ENSE00001228548 72635841 54 1.000 
DPF3 ENSE00001487855 72430518 32 1.000 
RGS6 ENSE00001487858 72076502 54 1.000 
SIPA1L1 ENSE00000911799 71241191 63 1.000 
PCNX ENSE00001344332 70547962 58 1.000 
MED6 ENSE00001013677 70122226 28 1.000 
SYNJ2BP ENSE00000658851 69924940 137 1.000 
PCNX ENSE00001136831 70532211 185 1.000 
RBM25  ENSE00001228606 72656174 93 1.000 
RGS6 ENSE00001320224 72009333 82 1.000 
RBM25  ENSE00001228669 72608103 106 1.000 
RBM25  ENSE00001424956 72612780 50 1.000 
PCNX ENSE00001136843 70505491 90 1.000 
MED6 ENSE00000911704 70129766 83 1.000 
PCNX ENSE00001136850 70498696 106 1.000 
SIPA1L1 ENSE00001097265 71194803 104 1.000 
NUMB ENSE00000911849 72859591 75 1.000 
RGS6 ENSE00001306101 71888556 100 1.000 
RBM25  ENSE00001228492 72648613 99 1.000 
PCNX ENSE00000658877 70504668 46 1.000 
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MED6 ENSE00001094579 70137086 22 1.000 
RGS6 ENSE00001327135 72002219 65 1.000 
ZFYVE1 ENSE00001239379 72514598 98 1.000 
RBM25  ENSE00001228568 72619955 58 1.000 
RBM25  ENSE00001228514 72644287 74 1.000 
PCNX ENSE00001376246 70646265 141 0.999 
RBM25  ENSE00001291453 72633376 186 0.999 
MAP3K9 ENSE00001137119 70272431 69 0.999 
PCNX ENSE00001136916 70593979 216 0.999 
SIPA1L1 ENSE00000911800 71241692 119 0.999 
PSEN1 ENSE00000808001 72734492 99 0.999 
RGS6 ENSE00001310174 72098878 41 0.999 
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SIPA1L1 ENSE00001097258 71274711 85 0.999 
PCNX ENSE00000658912 70563242 111 0.999 
SIPA1L1 ENSE00001487894 71274714 82 0.999 
PCNX ENSE00001136837 70525037 133 0.999 
PSEN1 ENSE00001153963 72753587 119 0.999 
MED6 ENSE00000911710 70133081 92 0.999 
RGS6 ENSE00001316047 72011086 75 0.999 
PCNX ENSE00001324795 70546104 91 0.999 
RGS6 ENSE00001318934 71994732 107 0.999 
PSEN1 ENSE00000808004 72742847 87 0.999 
RGS6 ENSE00001301612 72006468 77 0.999 
RBM25  ENSE00001097369 72639653 287 0.999 
PCNX ENSE00000911750 70610015 254 0.999 
DPF3 ENSE00001487849 72260094 96 0.999 
MED6 ENSE00000911712 70134088 160 0.999 
RBM25  ENSE00001426056 72613830 168 0.999 
PSEN1 ENSE00001383186 72755595 156 0.999 
MED6 ENSE00000940919 70129350 109 0.999 
PCNX ENSE00000658918 70570401 106 0.999 
RBM25  ENSE00001310903 72624462 161 0.999 
ZFYVE1 ENSE00001097340 72512012 171 0.999 
RGS6 ENSE00001322773 71990989 51 0.998 
RBM25  ENSE00000807981 72645803 151 0.998 
PCNX ENSE00000911764 70625662 151 0.998 
ZFYVE1 ENSE00001097332 72514388 118 0.998 
NUMB ENSE00001130483 72892087 126 0.998 
NUMB ENSE00001428128 72892087 126 0.998 
RGS6 ENSE00001313498 72014729 62 0.998 
PCNX ENSE00000658913 70565170 92 0.998 
NUMB ENSE00001343504 72815742 144 0.998 
SIPA1L1 ENSE00000911788 71197780 158 0.998 
NUMB ENSE00000911845 72833672 75 0.998 
PCNX ENSE00000911762 70624800 101 0.998 
NUMB ENSE00001343493 72823571 205 0.998 
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RGS6 ENSE00001370140 72072694 43 0.998 
PCNX ENSE00001013713 70559670 33 0.998 
NUMB ENSE00000911841 72829195 141 0.998 
SIPA1L1 ENSE00000911792 71208818 275 0.998 
ZFYVE1 ENSE00001341037 72507343 233 0.997 
MAP3K9 ENSE00000658869 70286403 149 0.997 
PCNX ENSE00000807893 70591974 59 0.997 
SYNJ2BP ENSE00000658850 69912146 96 0.997 
WDR21A ENSE00001097316 72483603 50 0.997 
ZFYVE1 ENSE00001097334 72518250 107 0.997 
RGS6 ENSE00001297037 72076502 67 0.997 
RGS6 ENSE00001296991 72072647 90 0.997 
RGS6 ENSE00001365869 72098878 51 0.997 
PSEN1 ENSE00001023918 72723314 68 0.997 
RGS6 ENSE00001487857 72076711 21 0.997 
SIPA1L1 ENSE00001097255 71260117 240 0.996 
PCNX ENSE00000911774 70639865 275 0.996 
PCNX ENSE00001097234 70555479 154 0.996 
RGS6 ENSE00001315171 72072647 45 0.996 
NUMB ENSE00001343510 72818820 147 0.996 
PCNX ENSE00000911740 70587122 109 0.996 
PCNX ENSE00001218898 70483385 209 0.996 
PCNX ENSE00000807888 70572535 93 0.996 
RGS6 ENSE00001379107 71501262 84 0.996 
ZFYVE1 ENSE00001097329 72515322 109 0.995 
TTC9 ENSE00001332325 70207546 80 0.995 
RGS6 ENSE00001294400 72031613 111 0.995 
RBM25  ENSE00001228524 72642657 90 0.995 
SIPA1L1 ENSE00000911784 71186805 175 0.994 
RGS6 ENSE00001300134 72046615 126 0.994 
RGS6 ENSE00001307727 71996093 52 0.994 
PCNX ENSE00000911736 70584277 178 0.993 
ZFYVE1 ENSE00001097346 72529604 215 0.993 
PSEN1 ENSE00001343119 72684481 87 0.992 
PSEN1 ENSE00000807988 72684481 75 0.991 
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PCNX ENSE00000658919 70583434 142 0.990 
PSEN1 ENSE00001130583 72710027 142 0.990 
ZFYVE1 ENSE00001097338 72511240 181 0.990 
ZFYVE1 ENSE00001097333 72534272 505 0.989 
RBM25  ENSE00001228635 72647989 275 0.988 
PSEN1 ENSE00000807997 72729105 221 0.987 
SIPA1L1 ENSE00000911782 71160518 189 0.986 
DPF3 ENSE00001487851 72268268 128 0.984 
SIPA1L1 ENSE00001097260 71270136 147 0.983 
RBM25  ENSE00001331913 72647292 325 0.983 
MAP3K9 ENSE00001229326 70278821 241 0.983 
SIPA1L1 ENSE00000911796 71235451 147 0.982 
C14orf112 ENSE00000658846 69865644 63 0.981 
RBM25  ENSE00001023894 72642320 223 0.981 
PAPLN ENSE00000659138 72782097 61 0.980 
HEATR4 ENSE00001331701 73035528 70 0.980 
PCNX ENSE00000807890 70588353 130 0.980 
SIPA1L1 ENSE00001385874 71275488 144 0.980 
MED6 ENSE00000940920 70127736 116 0.975 
PCNX ENSE00000658943 70645922 141 0.972 
PCNX ENSE00000911728 70581603 151 0.969 
MAP3K9 ENSE00001137138 70276512 123 0.967 
SIPA1L1 ENSE00000911790 71207589 574 0.967 
RGS6 ENSE00001323708 72013203 99 0.967 
MAP3K9 ENSE00001137145 70337137 414 0.966 
C14orf112 ENSE00000996466 69862803 117 0.963 
PCNX ENSE00000911755 70612659 231 0.959 
MAP3K9 ENSE00000658868 70285299 176 0.956 
WDR21A ENSE00000807942 72476681 158 0.955 
WDR21A ENSE00001154214 72490625 99 0.955 
DPF3 ENSE00001487854 72308194 161 0.952 
C14orf112 ENSE00000658847 69879128 72 0.949 
MAP3K9 ENSE00001229351 70297472 181 0.947 
SIPA1L1 ENSE00000911798 71238851 125 0.944 
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SIPA1L1 ENSE00001097256 71271747 115 0.943 
PCNX ENSE00000658917 70569899 110 0.938 
SIPA1L1 ENSE00000911794 71221832 270 0.934 
WDR21A ENSE00001097312 72492847 115 0.934 
PAPLN ENSE00000659144 72787368 124 0.928 
PCNX ENSE00000807899 70645074 443 0.925 
PAPLN ENSE00000493787 72788125 173 0.925 
PCNX ENSE00000911770 70638460 231 0.924 
PCNX ENSE00001294182 70549455 218 0.924 
TTC9 ENSE00000940946 70204034 183 0.915 
HEATR4 ENSE00001331697 73034612 190 0.912 
RGS6 ENSE00001299646 72054812 187 0.909 
HEATR4 ENSE00001331713 73042924 105 0.908 
SIPA1L1 ENSE00001097259 71261140 166 0.907 
WDR21A ENSE00001097307 72488259 80 0.907 
SIPA1L1 ENSE00001369903 71124343 1498 0.905 
SIPA1L1 ENSE00001097254 71266525 247 0.899 
SIPA1L1 ENSE00000911801 71245692 443 0.897 
NUMB ENSE00001412617 72820542 294 0.895 
SIPA1L1 ENSE00000911780 71155227 131 0.891 
WDR21A ENSE00001097314 72490847 98 0.888 
SYNJ2BP ENSE00000807864 69909461 141 0.886 
WDR21A ENSE00001390019 72476788 51 0.884 
MAP3K9 ENSE00001401213 70266850 485 0.882 
PAPLN ENSE00000659146 72787947 81 0.874 
HEATR4 ENSE00001331694 73033058 79 0.872 
PCNX ENSE00000658910 70562587 172 0.864 
MAP3K9 ENSE00001137128 70274715 154 0.863 
WDR21A ENSE00001097303 72491984 174 0.856 
ZFYVE1 ENSE00001097326 72560487 483 0.844 
HEATR4 ENSE00001331709 73039352 119 0.843 
WDR21A ENSE00001097298 72482345 144 0.842 
SYNJ2BP ENSE00000807865 69953370 64 0.841 
PAPLN ENSE00000659147 72788479 124 0.838 
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MAP3K9 ENSE00001013682 70270856 113 0.832 
PAPLN ENSE00000659136 72781105 116 0.830 
ZFYVE1 ENSE00001097327 72510541 114 0.823 
WDR21A ENSE00001097293 72479455 103 0.817 
NUMB ENSE00001426692 72813039 716 0.817 
NUMB ENSE00001431562 72813039 716 0.817 
MED6 ENSE00001094575 70121283 131 0.815 
NUMB ENSE00001332295 72820684 152 0.811 
WDR21A ENSE00001130632 72495073 194 0.800 
WDR21A ENSE00000807943 72478206 80 0.800 
PCNX ENSE00001136840 70513412 1707 0.788 
PAPLN ENSE00000659142 72786445 131 0.784 
PAPLN ENSE00000808009 72802962 128 0.776 
PCNX ENSE00001218491 70444321 153 0.743 
PSEN1 ENSE00000807990 72707258 251 0.730 
MAP3K9 ENSE00000807873 70269009 804 0.723 
PAPLN ENSE00000659148 72789110 127 0.697 
PAPLN ENSE00000494198 72805018 164 0.688 
PAPLN ENSE00000659140 72782534 103 0.661 
HEATR4 ENSE00001331705 73037007 181 0.644 
PAPLN ENSE00000659152 72791338 142 0.642 
PAPLN ENSE00000808010 72803184 109 0.627 
HEATR4 ENSE00001331730 73055480 141 0.601 
PAPLN ENSE00001413827 72808956 170 0.594 
DPF3 ENSE00001487853 72289725 108 0.581 
HEATR4 ENSE00001331717 73044591 161 0.558 
PAPLN ENSE00000493778 72790215 208 0.553 
PCNX ENSE00000807898 70641705 206 0.544 
PSEN1 ENSE00001153970 72748230 174 0.540 
C14orf112 ENSE00000996467 69895989 69 0.537 
PAPLN ENSE00000659159 72801831 138 0.534 
PAPLN ENSE00000659154 72795861 146 0.524 
PAPLN ENSE00000659155 72797617 139 0.491 
PSEN1 ENSE00001130552 72748230 90 0.467 
HEATR4 ENSE00001331720 73045769 162 0.445 
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PAPLN ENSE00000659157 72800672 125 0.441 
PAPLN ENSE00001391023 72808956 67 0.410 
MAP3K9 ENSE00000807879 70345236 406 0.407 
PAPLN ENSE00001371832 72800672 150 0.381 
PAPLN ENSE00001385454 72797170 121 0.375 
TTC9 ENSE00001167125 70178258 745 0.354 
HEATR4 ENSE00001331733 73057309 188 0.354 
HEATR4 ENSE00001331723 73048463 144 0.330 
PAPLN ENSE00000519940 72798811 478 0.309 
PAPLN ENSE00000659134 72776240 54 0.305 
PAPLN ENSE00000659156 72800106 138 0.296 
PAPLN ENSE00001372628 72795730 277 0.281 
HEATR4 ENSE00001331724 73050488 204 0.257 
PAPLN ENSE00000659153 72795440 81 0.237 
ADAM21 ENSE00000940930 69993970 2169 0.217 
RGS6 ENSE00001422262 72098921 291 0.216 
HEATR4 ENSE00001331690 73031685 160 0.213 
PAPLN ENSE00000659151 72790974 183 0.189 
HEATR4 ENSE00001331685 73029523 59 0.156 
HEATR4 ENSE00001331736 73015064 237 0.126 
ADAM20 ENSE00000911696 70059047 2331 0.124 
WDR21A ENSE00001377695 72474440 98 0.095 
WDR21A ENSE00000807940 72474440 92 0.093 
WDR21A ENSE00001374971 72476263 101 0.075 
DPF3 ENSE00001487847 72148929 147 0.051 
PAPLN ENSE00000659149 72789622 66 0.030 
PAPLN ENSE00001487683 72798966 323 0.029 
PAPLN ENSE00000519943 72801017 171 0.023 
PAPLN ENSE00001387318 72801049 139 0.015 
MAP3K9 ENSE00000807874 70270227 42 0.005 




6.2. Oligonucleotide primer sequences and predicted product size 
 
Exon ID Fwd oligo sequence Rev oligo sequence Product 
size 
(bp) 
ENSE00000996466 AGACATAGTCTCGCTCTGTTCG ATTTGTGAGGCCGAGGTG 243 
ENSE00000658846 TGGCTATAGTATTTCAGCCATCTC CTTTTAAGGCAGATAAAACCAGTAAC 228 
ENSE00000658847 GAATTCTGGTCTTCTGTTTTGC ACAATTCTCCTAAACCAGAACATAC 186 
ENSE00000996467 CCGAGCACCAAATAACCAAG ACATGGGGACTCCATAGCC 199 
ENSE00000807864 CATGGTGAAACCCCATGTC TCTTTTCCTCCCTCTTGCTG 288 
ENSE00000658850 TTTGGCCATTTGAAAATAAATTG ACAGTGCAAAAGCCTGGTG 219 
ENSE00000658851 CTTTCTTCTTCACCCCCATC GGCTTAGGGAGCAAAGGAC 230 
ENSE00000807865 AGGCTGCTGAAACCGAAAC GACCCTTTCCGCACATACC 194 
ENSE00000940930 TGCCTCACACCTTGTCCTC TGTGCTCAGTTTCAGGGATG 2317 
ENSE00000911696 CAGCTTCATAATGGCAGTGG TGAGGGACAACAGCTTGAAAC 2473 
ENSE00001094575 TGCATGTAGATGCTTTTAAAACTG GATTCCACTTCTGGAACTCTATCC 284 
ENSE00001013677 TTGCCAAGTTGACCTGTTTTC CCACAGCTCATTTCACATGC 186 
ENSE00000940920 GACACCAAACTAAGTAGGCAATG ATGCCATAAAGAAGTGTCAAATC 217 
ENSE00000940919 TGAGTATTTACTTTGGAAAGTTTGGTC GAAAACAGCTTCATTCTCAGAGG 239 
ENSE00000911704 TTAGCAGTTTGTGTCCATAGCTG GCAACTTACACAAGGCAGAGG 236 
ENSE00000911712 TGTTTGTTGGATTGGATTCTTTC GCACTTCATGATCCACAGTTTG 308 
ENSE00001094579 CCCTCTTCCGCTCTACGTC AACATCCCAAACTGGTCCAC 199 
ENSE00001167125 TTAATCCTCCCCTCCTTCG CACAGCAGGAGAATCTGCAC 914 
ENSE00000940946 AGAGCTGGCCACTGTTGTG CACCAGAGCAGGGAGGAAG 278 
ENSE00001332325 CTGCAGACACAGCCTTTGC AGGGGATGCCTGGAAGTC 224 
ENSE00001401213 CATTTGCTGCCTGGATGTG AGCGATTCTCCTGCCTCAG 587 
ENSE00000807873 TTCCTGCCACCTCATTTCC TGAGGAGGCACAAAGAAAGG 906 
ENSE00000807874 AGGGCAAGAGGAGAAAAAGTG GCTGGGTGTGTCTGTGAGG 216 
ENSE00001013682 CATGGAGCTGAGGGTCAAG CAGGGAGCAGGGAGACAG 227 
ENSE00001137119 CTTGGGTGTTTTGGTGTGG AAGGAAATGGAAGGGAGATTG 209 
ENSE00001137128 AGCCCTGTCTGTCCATTTTC TCCTATGTTTAAATGGTACATCCATC 268 
ENSE00001137138 CTGTCCCTCAAGGATGCTG AGGTGCCCCTGTGTGTTC 268 
ENSE00001229326 GCACTGAGCACCCCAGTC CGAGTTCTTTGCCCTGCTC 338 
ENSE00000658868 TTGCTTCTGTCCATTCATGC CCAGAGGTCCCTGTGAGTG 314 
ENSE00000658869 GGGAGAATGTGGGATGCTC CAAGAGGCAAAGTGTCTCCAG 291 
ENSE00001229351 TGTTCTGTGGTTTCCCTGTG TGTGTGTGCCACCAAGATG 303 
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ENSE00001137145 GCCGTGTTTACCCACTCAG TCGTGGGATACAACTGCAAC 562 
ENSE00000807879 - - - 
ENSE00001218491 - - - 
ENSE00001218898 - - - 
ENSE00001136850 CAAAGGAAAAGCATTGGAGTC TCAGGAGGAGGGAAAAAGG 215 
ENSE00000658877 TTTTGTTTGATAATCTTGCTAGTGTG AACCAAAATGAAAGGGAAAGG 186 
ENSE00001136843 TGCCACCCTACAGCCTTAC AAACTTCTGCCAAATTGTATGC 240 
ENSE00001136840 - - 1500bp 
ENSE00001136837 TGGGAAGTCAAGGGAAAGC TGGCGGAACAGATTAGAAGG 283 
ENSE00001136831 TTTTCTCTTTTCTTCCCTGTAATG CAATTGTTACCCATCATCTGC 302 
ENSE00001324795 AAGGAAAAATTCTGAGTATTCTAATGG TGGCAAACATATGAAAGTACACAC 195 
ENSE00001344332 TGAATCTCATCTGAATGTTAAAGG TTCATCAATTTTTATGGCTTTTATAG 234 
ENSE00001294182 - - - 
ENSE00001097234 AACTTCATATTTATGTCTTCCCTTCC CAAAATCCTCTGCCTTTTAACAC 309 
ENSE00001013713 TTTCAGGCATTTTGAAAGTTG TGATGCATTCCAAACAAAAC 210 
ENSE00000658910 - - - 
ENSE00000658912 CTCTCAGTGGACACAAGAATGG TGGAAAAGCATTTTAATGGTCAG 264 
ENSE00000658913 AATATTTTAAATGCTTTTCAGTGACC CGATACCAGGGGAAGAAATC 276 
ENSE00000658917 TTTTTCCAAAATACGTACATAAAAGG AAAGGCATTGGGAAAAAGAG 290 
ENSE00000658918 TGCCCGTTTGAATTACTGG TTCCTCATATAACATGATCAACTGTC 241 
ENSE00000807888 TGCCAATTGGGAATAAAGG GCCTGGGTGACAGAGTGAG 237 
ENSE00000911728 ACAATGAGTCTCAAAATCACTCC TCAATATAGCAAAGGGAAAAACTC 266 
ENSE00000658919 TTCTTTCTCATCACATTGACAAAC AACAGCCCCCAGTAGTCAG 257 
ENSE00000911736 - - - 
ENSE00000911740 AGAACTTCTCCTAATACATTTTACAGG AAGGTCATGCCTATAAACCAAC 286 
ENSE00000807890 TTTTGCGAGGGTTTGTTTG TTCCCAGTAGGAAAGATAAAAATTG 249 
ENSE00000807893 CATTTCCTATAGTTTCTTCCTCAGTC TTCATAGAGGATTCCCAACAAG 243 
ENSE00001136916 AACAATCTTGTTTGTCAAGAGGAC AGGTGCCACAGGAGTATGC 331 
ENSE00000911750 TTCCCACTTTCTGGTTTTCC TCATTCCCAAGAAGAAACTCTG 362 
ENSE00000911755 TTGGAATTTATTTCATTGAGTAATCTG TGCATCTTTGGAAAAACCTG 369 
ENSE00000911762 CGCTATATTATTTCGATTTATGATTTG GCTATACAGCTTCCCATGCTC 230 
ENSE00000911764 AGGTGATTCTGATGCACACG CAGCAGCGTGAGAATGGAC 330 
ENSE00000911770 - - - 
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ENSE00000911774 TTATTCTTGGCCCCTTAACC GGTCAGGAATACACCAGCAC 366 
ENSE00000807898 CCCATTTTGAAGTGATCTTGG AGCCTCTATGGCTAAGAAGCTAAC 313 
ENSE00000807899 GGGGAAAAAGTCTTAGAAACTGC TTCACAACAGTCCTTCATTCAAC 615 
ENSE00000658943 CTGTGAAAAGCATTTTGTTTGAG ACCATGCATCCAAGTGAGG 297 
ENSE00001376246 GTATATTCCAGGTCTCCAGTGC CAATGCCTTGGAATTGAGAG 245 
ENSE00001369903 TGGAAGCCATTCTCCAAAAG TTCAGAAAGTACTGCAAAAGAAAATG 1640 
ENSE00000911780 CTGAGTGACAACCTTAAATACTGAGC TGCTTTCTTCCCCATTTCAG 275 
ENSE00000911782 TGTTCAGGCATCTCACATCC CGGAAGCCTAGCAATAAACC 300 
ENSE00000911784 TGGGACAAAGTGGATCTGC TGCACAACAGCACAACAGG 289 
ENSE00001097265 - - - 
ENSE00000911788 GGGGGAAGCAAATGATTG AACCAGCCAACATCCACAG 255 
ENSE00000911790 TTGTGAGACTGAGAAATACTGACG TGAAAACTTTATGAAAGAGAAACTGC 679 
ENSE00000911792 CCAGTTCCATGTCCACCAC GTACACAAACCCTGCACTCG 397 
ENSE00000911794 ATGTGGTTCCACCAGCAAG TTACATTTGGGGCAGAGAGAG 386 
ENSE00000911796 CCTTGGGATTTTCCCTTTG TGAAAGAAATGATGCCAACAG 256 
ENSE00000911798 TCCCCTCATGGGTAAGGTC ACCTAAGTCACCTTGTAAAAGCAAC 234 
ENSE00000911799 TGGAACCCCATCTTGAACG CAGGCATGGATGCAATCAC 209 
ENSE00000911800 CACCATGTGCTTGTTTCTGC GGCCATGCAGAGGAAAGAG 270 
ENSE00000911801 TCTGTTATTCTCTTGTTCAGGAAGC GGAACTGGGCTTAGGTCTGG 559 
ENSE00001097255 TGTTCAACCCAGCCATCAC CCGGCCTCTTTTGTTGTAAG 430 
ENSE00001097259 AGCCAGCCTTGTTGAGTTG CCCATCATGTCTGGCTTG 271 
ENSE00001097254 ACCTTGGTCTCAGGGATCTG CATCATCAACAGGGCCATC 355 
ENSE00001097260 TTCCACAGGCACAAGAAGC GAGTGGATGGAGACTGCTCAC 260 
ENSE00001097256 AGATAGGGCCAGGGATGTG TGGCAGATGTGACACAAGG 222 
ENSE00001097258 AACAAACCCAGCCATGGAG GGGCTCTCATGGTTCAAGG 206 
ENSE00001487894 AACAAACCCAGCCATGGAG GGGCTCTCATGGTTCAAGG 206 
ENSE00001385874 TGGGGCCAACACCTCTTAG GCTGCAGGACACTCACTGG 249 
ENSE00001379107 TCCTTCGTGACTTAATGGTTTATTC AACAGTCCACACGGACAGC 190 
ENSE00001306101 - - - 
ENSE00001322773 AACATGTTTCTTCTGCCACAG GCAGGGGAATCTAGTTTGG 202 
ENSE00001318934 CTGGGGGTGATGACAGTTG TCAGATGATGTTGTGAAGAAAAGG 259 
ENSE00001307727 CTGGGTGTGGGAGGGAAG CTGCACCCCCAGAAGTGAC 181 
ENSE00001327135 TGGACAGATGGATGGATGG CGGAGCTGCAGATATGATTTTAC 206 
ENSE00001301612 AAGCATAGGTGTCGATGTGC TTCACACCATTTCCAAATTCC 210 
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ENSE00001320224 ACGCTGGAGCAAGTGTCAG CACCTGGTGGCTAAAGACG 247 
ENSE00001316047 TGTGACATGGGCTAAATTGG TGGAAGGGCTATTCACATCAG 195 
ENSE00001323708 AAGCCACCCTCCAATTCTG AAACTGGCCACGTCTCCTC 203 
ENSE00001313498 TGCAGGATTTGGGTTTGTG CTTGGCATTGAACACATTCG 236 
ENSE00001294400 GGGTTTTCTAAGGAAATCAGTGG CTCATGATCTCATGGATTTTTGTC 225 
ENSE00001300134 TGACACGAGCTTTTCTCTGG GAGATGGAGAGACCGATTATGC 256 
ENSE00001299646 CATGGGACATCAGCTCTGG GAAGGGGACAAATGAACACC 324 
ENSE00001296991 ACTGGTTGACAGCCCTTCC CAAGCAGCAGGCAAGAGTC 195 
ENSE00001315171 ACTGGTTGACAGCCCTTCC GCAGCAGGCAAGAGTCAAC 192 
ENSE00001370140 ACTGGTTGACAGCCCTTCC CAAGCAGCAGGCAAGAGTC 195 
ENSE00001487858 TGCTGCTGTTTGGGAACC AAAACCAAAACCAAAAGAAAAGC 187 
ENSE00001297037 TGCTGCTGTTTGGGAACC CCACCCCAAAGGAAACAAC 243 
ENSE00001487857 - - - 
ENSE00001402687 GTCGGCCCAAGATTTGAAC TCAACAGAGGTGGAACAAAGG 198 
ENSE00001310174 TCACCTGTCTGGCTCTCTGTC GGAAACTCTGTCCGCAGATG 210 
ENSE00001365869 CTCTGTCCCTCTGTGTGTGC TCCTCGTAAGGAAACTCTGTCC 199 
ENSE00001422262 GTGCCTCTCTGTCGCTGTC TGACAGGAACCCCACGAC 405 
ENSE00001487847 GGATCGAGCAGCCTTCTTC GCACACCCCAACATGAAAG 299 
ENSE00001487849 TTCCCTTTGCATTTCGTTTC CCCAGCCTCCCTCATCTC 194 
ENSE00001487851 CCCTGCCTGCTTCTAGTGG TTCTGGAAGCGCTATGGTG 238 
ENSE00001487853 GAATGACGGGGTTAGTCAGG CTCCCACCTTTCCCATCAC 238 
ENSE00001487854 CCCTCTGGGTGTGTTTCAG TGGTTTCCCAGACAAGCTG 303 
ENSE00001487855 - - - 
ENSE00001377695 CCATGCCCACACACAGAG AATGCCAGAAGCACACTGG 200 
ENSE00000807940 CCATGCCCACACACAGAG AATGCCAGAAGCACACTGG 200 
ENSE00001374971 CGTCAGAATGGCTGGAACTC TCTCAGCCTTCCCTGTGTG 216 
ENSE00000807942 GTGGTCAGTTCACAGTGGTTG AGTGGATGGACAGGTGCTG 272 
ENSE00001390019 AAACGCTACTTCCGCTTGC AGTGGATGGACAGGTGCTG 188 
ENSE00000807943 ACATTCTCCATCATCCCCTAAC CCATGAAAATAAGAAACAGGAAAAG 213 
ENSE00001097293 CCCCGAATCTTCTTCATGG GGTTTGATGACTGGCAACG 248 
ENSE00001097298 CCTCTTAGGCAGTCCACCAG CTACCCCCAGGGTCAAGTG 257 
ENSE00001097316 TGTGTCCCCACATGTTATTCC GCCCACAGATACCCAGGTC 200 
ENSE00001097307 CTGAAGGGTAAATGTCCATGC AGCTCTCGGGAGACAGAGG 204 
ENSE00001154214 TTTCCGAACCCAGTGGTC GGCCTGTTAAGGCCTCTTC 216 
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ENSE00001097314 GTTGTCCCTCTCCCCAGAC TCTGGCCAAATTTCTACATGG 220 
ENSE00001097303 CCAGCCTCAGAGGGATGTC TTCAGCAGAACCCTTTCACC 306 
ENSE00001097312 CTTCCTGGCTTTGCACTTG CCTCTGCTGCTGAAGTTGC 273 
ENSE00001130632 ATCTTGGGAAGCCATGTCC TTACTCCCGTAAGTCAAATCCAC 327 
ENSE00001341037 TTCTCCTCAAGAGCCTGGAC GGAAGGCACTGATGGAATG 364 
ENSE00001097327 TTTTCCATTTGGGAGAGGAC CTCAACCCGCATCCACTAC 217 
ENSE00001097338 TCAGCTGAGCAGACATGTACC GGAGGTTCTCCCCTCCAC 288 
ENSE00001097340 TCACCAAACATCCCTCTTCC GCAAAGCGGCATTAAGTAGG 309 
ENSE00001097332 TTCTGGTGCGTTTGTCTCC CATGAAAAACTGAACGACACAAG 239 
ENSE00001239379 GCTGGTAAAACCCCGTGTC GGGAGACAAACGCACCAG 222 
ENSE00001097329 TGGCTCCTTTAGCCGTCTC TGCCAAAGAGAGAGTGGTCAG 216 
ENSE00001097334 GCCTGTGTTGCTTGTACGG AGGGGATCTGCATCCACAC 294 
ENSE00001097346 TGCTAGGGTTACAGGTGTGG GCTGGCGAACTGAGTGTTC 386 
ENSE00001097333 TTCCTTGTCCTTGGGAAGC ACCAAATAGCTGCCTCCTTG 659 
ENSE00001097326 - - - 
ENSE00001228669 TCAAATAAAATGATTTGTCATGTCC CACAAAGACAAAAGTACAAGTTTAACG 211 
ENSE00001424956 TTAATTGTGTGGCATGTTGTTG TGTTCAGCTTAAAAGCACTAGCAC 181 
ENSE00001426056 TGTGGTAGGAAATTTAATTGCTG AAAAAGCAATCACTGAAAGTCTTC 314 
ENSE00001228568 - - - 
ENSE00001310903 TGGACTCTAGTGATTCTACTTTTCC ACACTGAAATAGCACAGTCTGG 300 
ENSE00001291453 GAGTGATTTTGATTTTCTTGCTTG AAAAAGAAAACTGACATGTAATCAAAG 335 
ENSE00001228548 ATAGGGCATTGCTTTGCAG CAACAATCAGCAGTAAACACAGG 183 
ENSE00001097359 AACTGTTTATATTGAAGTAGGGTGTTC TTTGTCTCTTTGCTTTGGATTC 214 
ENSE00001097369 GCCGGGAAAAATCTGAATAC TGAATGCAAATGGTACTCTGG 433 
ENSE00001023894 TGTTGTCCTCCTTTACTTTGGTC TTGATTAACCTATTAAGGGATACCAAG 356 
ENSE00001228524 GCCTTTATTCTTAAATCTTGGTATCC GCTTGTGCATTTCAATTATTAAGTTAC 287 
ENSE00001228514 GTCTGGGTCAGAAAAATCTGTTTAC TGCAGATGGAAAAACACAGC 232 
ENSE00000807981 TTGAAAAGAGGTGCTGTTGG CTGGGATTACAGGCGTGAG 290 
ENSE00001331913 AAAACAAAAATCAAGTTGAATGG GTATTTGCAGGGGTGAAGG 442 
ENSE00001228635 GCATTGCTTTTGAGGGATG TGGCATATTCCAACTGTTCC 411 
ENSE00001228492 TCTCAGGAAAAATCATGAAGC GGAACTTGACTCTGTAAAATTTCTG 277 
ENSE00000807985 AAGTTCCTGTATGAATTTGAGGATTC AACGTGGTGAGACCCCATC 241 
ENSE00001228606 TGGCAGATGTTGATGATTGC GTCCTTAAAAGGGTGGCAAAG 207 
ENSE00001343119 TCAAGAGGCTTTGTTTTCTGTG CTAGCCCCCTCAGCATTTC 223 
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ENSE00000807988 TTTCCCTTTTCAGAACCTCAAG CTGGCAAAGGCAGTTTCAG 187 
ENSE00000807990 CCGTTACCTTGATTCTGCTG GGCCTTCAAGGTGATGATG 390 
ENSE00001130583 GGAGGTGGTAATGTGGTTGG ACCCAACCATAAGAAGAACAGG 265 
ENSE00001023918 TTTAAGGGTTGTGGGACCTG AATGATAGCTACACAGCACAAAGG 183 
ENSE00000807997 TTGGGAGCCATCACATTATTC GTGGGGCATTCCTGTGAC 348 
ENSE00000808001 TCCTCCCTACCACCCATTTAC TGTGCTTCAGTTCCGATAAATTC 235 
ENSE00000808004 ACTGGCGATTTGTGTGGAG AACAGTGACCCTGAAAAATCAAG 228 
ENSE00001153970 TGTTTCCATGTAATTTTCTTAAAGG AGCTACCTAAAGGAATCCATGAC 298 
ENSE00001130552 TGTTTCCATGTAATTTTCTTAAAGG TGCTGGAAAGTTCCTGGAC 219 
ENSE00001153963 GGGGTTGAGTAGGGCAGTG GAACTGCCTTAAAGGGACTGTG 285 
ENSE00001383186 TTGAGTTTTGCCTGAAAATGC TTTGTCCTCCCCAGATTTTG 289 
ENSE00000659134 GGGCCATAGGGAGAGACG GACTCCCCTGCAGGTTCC 201 
ENSE00000659136 GGCTCAGGCTGTGAGTGG CCCCTGCTCCTGCTTTAAC 212 
ENSE00000659138 TGCAGAGAGCCCCAGAAC ATCCCAATGGGGAAATCG 204 
ENSE00000659140 - - - 
ENSE00000659142 GGTAAGCCTTGGGTCTTGG GGGTGATGGACAGGGAAAC 279 
ENSE00000659144 CTGATGTGGCCATGATGC GAAGGGACAGGCAAGGAAG 231 
ENSE00000659146 GAGAGGGATAGCCCAGCAC AGTCAGCCAGAGGGAGCAG 203 
ENSE00000493787 AGGTCCTAGGCAGGTCTGG GAGCTTGGCAGCCTCTTG 320 
ENSE00000659147 GAGTGGCTCTGGGCTTGAG GGAGAGGGCTGTGACTTGC 309 
ENSE00000659148 CGCTTGGTGAATGTTGACTG CCCTTCCCACCCAAGTTC 238 
ENSE00000659149 CAGCAGAGGGTTTGGCTTG GTGACAGGGTGGCACCAG 211 
ENSE00000493778 CTCAGGGCTGGGTTTCTG GCTACCCAGGTCCAGCAC 315 
ENSE00000659151 CGCTAGCTGTCCGAACTGG TGCCAGAGACCAGGGTCAG 303 
ENSE00000659152 ACCTTCCCCTGCCTCTCTC TGCTTGCTGGGTTTGTAGC 295 
ENSE00000659153 TCCTCTCTTCCTCCCTCTCC ACCCCCATGTACCATCCAC 202 
ENSE00001372628 GAAGGTGGGTCCAACGTG CCACCTTCCCTCTTTGACG 408 
ENSE00000659154 CAGGGGAGAACGAGGTGAC CCACCTTCCCTCTTTGACG 273 
ENSE00001385454 CATGGGGAGCCTCAGAGC CAAAGCGGCAAAGATCCTG 294 
ENSE00000659155 CAACAATGGCCAGATCCAC TGGTGGGAGCAGAGTCTACC 244 
ENSE00000519940 GGAGGCTGAGAGGATGGAG CTGGCATGCTCCTTGTCTG 611 
ENSE00001487683 GCCAATGTAACCGCTTCTG TGTCTGGGCGTCCTAACC 439 
ENSE00000659156 TTAGGGTGGTTCTGGTCCTG GGGGCTGTCACACCTGTC 245 
ENSE00000659157 GACTCACTGTTGCCCTTGG ATCCTGGCCTTCCCACTC 244 
 276 
Exon ID Fwd oligo sequence Rev oligo sequence Product 
size 
(bp) 
ENSE00001371832 AAGACTCACTGTTGCCCTTG GGAATTGACTCAGAGAGACACC 310 
ENSE00000519943 CGTAAGTCCCTGCTGGTCTC CGTTCCCCTCCTTATCCAC 308 
ENSE00001387318 CCCTTTTCCTCACAGCTCAC CGTTCCCCTCCTTATCCAC 266 
ENSE00000659159 AGGTGCCCATGGGAGTAGG GGGCTGGAGGCAGAATAGG 251 
ENSE00000808009 GAGAGGGGAGGCTCCTTG TACCCATGCCACCTGACC 226 
ENSE00000808010 TGGGTAGGGCAGGATCTTC TGTGAAGGTCTGGGGACAG 206 
ENSE00000494198 TCCCTCTGTCTCCCAGACC AGAGCCAGCCCTTGAGAAC 303 
ENSE00001413827 AGGAAATGAAATGGCAGGTG CCAGCCAGAGAGAGGAAGC 340 
ENSE00001391023 AGGAAATGAAATGGCAGGTG ACAGCTGGCACAGCAGAAG 211 
ENSE00001426692 AAAAGCCAAAATCTTTATTTTTATGC TGGAGAGTAAGACCAAAAGAACG 868 
ENSE00001431562 AAAAGCCAAAATCTTTATTTTTATGC TGGAGAGTAAGACCAAAAGAACG 868 
ENSE00001343504 TGACTGACACAGCTCCAAGG TCACTTATCTGATCCCAGAATCC 270 
ENSE00001343510 AAGTGCCAGCTTGCATCATAC GGAAGCTCAGGATGCCAAC 320 
ENSE00001412617 AAGGACCTAGAGGGCTTTCG CATGGGAAGTGATGAGAATGC 451 
ENSE00001332295 TCTGATGCCACGACCTCTC CATGGGAAGTGATGAGAATGC 276 
ENSE00001343493 TCTCAAAAACAAAACAAAACAAAAG TTGGGAAAAACTGCATTCC 341 
ENSE00000911841 TGCATCATGAAATGAACATCC CCAGAAAGAGCCCAGCTAAC 286 
ENSE00000911845 TTTGGAAGGCAGAGTCAGTG AGCCTGGGTGACAAGAGTG 245 
ENSE00001023973 - - - 
ENSE00000911849 TCAACCTGTATTCAATTTTCACC AAACACAGTTTTTACTGGGTCAC 266 
ENSE00001130483 TTTTGGACATCAGATTTTTGG TTGTCAGTTCTTTTCCACATACAG 286 
ENSE00001428128 TTTTGGACATCAGATTTTTGG TTGTCAGTTCTTTTCCACATACAG 286 
ENSE00001331736 CAGGCCTAACCACACGAAG GGGCGTGGAAAAATATGC 401 
ENSE00001331685 TGAAATGATCACGGATCAAGG GATTCTCCGCTGCCACTG 213 
ENSE00001331690 GCTGCCTAGTACAGGTGTTTTG CATCCAGATCCTGGAAGAGG 282 
ENSE00001331694 GGGATTCTTACCTGATTCCAAG AGGAGGACAGGGTCTGAGG 247 
ENSE00001331697 CAAAAGGGAAGGTATTGTTTGC GCAGGGACATATTCAATGAGC 368 
ENSE00001331701 GCACCCAGCTGTTTCTGG CCTGCACTTCACCCCATTAG 238 
ENSE00001331705 GGGTTGGGGGTTAGGTACTG GCCCTCTTCAGGTCAATCAG 293 
ENSE00001331709 AAAACAGCACAACGCCAAG GCCTGCCTCCTAAACACTTC 255 
ENSE00001331713 ATGCAGGATGCCATTTCAG TCAGCCTCTCTTAGGCTTTCTG 243 
ENSE00001331717 AGGGGGAAAACACATCACC GACCTAATTGCTCCCCAAAAC 261 
ENSE00001331720 CATGGCTGTAGGAAGGAAGC GAGGAAAGGACTGGGAAAGC 316 
ENSE00001331723 AACCCTAACCAGGTGGTTCTC CCTGGGTCCCTACCAGTTC 270 
ENSE00001331724 TGTGTGGCAGGGCCTAAG GCCTAGTCCCAGATGAGAACC 327 
ENSE00001331730 AGGAACCCAGGGAGAAAGG GGGTAATGATGGGAAGTAGCC 275 
ENSE00001331733 GAGGAAAGGGAACGAGCTG ACCTTCCTGGCCCATGTC 333 
Dashes indicate oligonucleotides that were designed individually using Primer3 due to a 
failure to generate primers with the original program. 
 277 
 
6.3. Chi-Square goodness of fit test for Mp penetrance analysis 
Data of affected and non-affected animals from the crosses were analysed using 
chi-square goodness of fit tests to investigate the penetrance of the Mp phenotype. The 
null hypothesis in this case is that the distribution of the data is not related and that 
penetrance is thus not full. The alternative hypothesis is that the data fits the accepted 
distribution for full penetrance of the phenotype, i.e. in heterozygote Vs wild-type 
crosses, the probability of an individual progeny being heterozygote is p = 0.5.  
 
Parameters for test: 
χ2= [(observed-expected)2/expected]+ [(observed-expected) 2/expected] 
Degrees of freedom (v) =total parameters-1 
Confidence limit is p>0.05
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6.3.1. 3rd Outcross to C56Bl6/j 
n=131 Wild Type Heterozygote 
Observed 56 75 
Expected 65.5 65.5 
 
v=1, χ2=2.756; p=0.097 
Thus we can reject the null hypothesis that the penetrance is not full, or more 
accurately, we cannot reject the alternative hypothesis. I.e. the probability that a value of 
2.756 or larger would come from the χ21distribution is <10%, or put another way if this 
was repeated numerous times then these values would occur <10% of the time. Although 
this value is small, it is greater than the standard 5% (p<0.05) used as a cut-off to 
determine whether values should be accepted from within the χ21distribution)  
6.3.2. 4th Outcross to C56Bl6/j 
n=95 Wild Type Heterozygote 
Observed 52 43 
Expected 47.5 47.5 
 
v=1; χ2=0.853; p=0.356 
Verdict: we reject the null hypothesis for this outcross. 
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6.3.3. 5th Outcross to C56Bl6/j 
n=18 Wild Type Heterozygote 
Observed 7 11 
Expected 9 9 
 
v=1; χ2=0.889; p=0.346 
Verdict: we reject the null hypothesis for this outcross. 
 
6.3.4. 1st Outcross to CD1 
n=39 Wild Type Heterozygote 
Observed 20 19 
Expected 19.5 19.5 
 
v=1; χ2=0.026; p=0.873 
Verdict: we reject the null hypothesis for this outcross. 
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6.3.5. Intercrosses on C56Bl6/j strain background 
n=87 Wild Type Heterozygote Homozygote 
Observed 19 51 19 
Expected 21.75 43.5 21.75 
 
v= 2; χ2= 2.678; p= 0.262 
Verdict: we reject the null hypothesis for this outcross. 
 
6.3.6. Intercrosses on CD1 strain background 
n=22 Wild Type Heterozygote Homozygote 
Observed 5 11 6 
Expected 5.5 11 5.5 
 
v= 2; χ2= 0.091; p= 0.956 
Verdict: we reject the null hypothesis for this outcross. 
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6.4. Oligonucleotide primers used for PCR reactions in the Mp project 
6.4.1. Microsatellite mapping  
Name 5'-3' sequence Size Fluorescent Tag  
D11Mit35_Forw AGTAACATGGAACATCGACGG 21  
D11Mit35_Rev TGCTCAGCTCTGGAGTGCTA 20  
D11Mit286_Forw AAGGCATATTAAATCTAAGGCTGTG 25  
D11Mit286_Rev CTAATCTCCTTGGCAGCAGG 20  
D11Mit132_Fwd GGTCAGAGGACAATCTTACATGC 23  
D11Mit132_Rev GTTCCAAGACAATGAGAGACCC 22  
D11Mit360_Fwd CTCTCTCACTGGAACCGTCC 20  
D11Mit360_Rev AGAGAAAGGCTCTGTGAGAAACA 23  
D11Mit333_Forw CATGTGGTTATTTTCTAGCCCC 22  
D11Mit333_Rev AGGCATCAATAACTATTTTTCAGTG 25  
D11Mit181_Fwd TCATCTGTCCCTGCCTCC 18  
D11Mit181_Rev TACTGTATTTGATACATATACGTGCCC 27  
D11Mit61_Forw ACCCTTTCTCAGCTTACAAGTCC 23  
D11Mit61_Rev GTATCAGAATCTGGTGCTTCTGG 23  
D11Mit119Fwd AAGCTTTTTCTATTTCAACCCTAA 24  
D11Mit119Rev GTCTTTTACAGCCCTTTTTGTAGC 24  
D11Mit39Fwd TTTCATGACCCCTAATTTCCC 21  
D11Mit39Rev GTGGGTGTGCCTGTCAATC 19  
D11MIT320_Fwd CCCATATAGTGAAGCAAGAAACG 23  
D11MIT320_Rev TTATAGTGTATGCATCCAGGTGTG 24  
D11Mit288_Fwd AGCATGAATTTAAAAGGCCTG 21  
D11Mit288_Rev GGCTGCTAGTTTTCCTGATG 20  
D18MIT94_Fwd TCACCTAGGACCCCCCTC 18  
D18MIT94_Rev AAGTAGTGAGAGGCCACCACA 21  
D18MIT64_Fwd 6TCAGATTCACTGCTAAGTCTTTTC 24 5'-6-FAM   
D18MIT64_Rev AGCAAGAAAAGCAGGTGAGG 20   
D18MIT116_Fwd 8CCTTAAAGGAGTGTGTATATTTTTGTG 27 5'-HEX   
D18MIT116_Rev TTGATGTTATCCTCTGGGCC 20   
D18MIT226_Fwd 8CAGGCAGGGTGCATATATTATAA 23 5'-HEX   
D18MIT226_Rev TATCTGTTTATGTGTGTACATTGTGTG 27   
D18MIT74_Fwd AGCCAGAGCTACAAAGTTTCAA 22   
D18MIT74_Rev GCTCTTGTAGAGCCATCATTCC 22   
D18MIT184_Fwd 9CACACATGTGTAGGTAGGTAGGTAGG 26 5'-TET   
D18MIT184_Rev CGCACAAGGACTACTGAAACA 21  
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6.4.2. Oligonucleotides for Fbn2 transcript analysis 
Name 5'-3' sequence Size 
FBN2cDNA1_Fwd TCTCCAGCCCTACTTCGTGT 20 
FBN2cDNA1_Rev GCTGGACACATCTCACAAGG 20 
FBN2cDNA2_Fwd GCCCGTGTTTCACTCAAGTC 20 
FBN2cDNA2_Rev CCATTACTGCAGGGATTGGA 20 
FBN2cDNA3_Fwd GATCCTTCCGCTGTGACTGT 20 
FBN2cDNA3_Fwd AGGAAGCAGTGCTCCATACG 20 
FBN2cDNA3_Rev AGGAAGCAGTGCTCCATACG 20 
FBN2cDNA4_Fwd AATGAATGCGAGGTGTTTCC 20 
FBN2cDNA4_Rev CGTAGCTTCCTTCGGAGTTG 20 
FBN2cDNA5_Fwd TGATCGGAACTTACCAGTGCT 21 
FBN2cDNA5_Rev GTTTCCTCCTGTCCTGTCCA 20 
FBN2cDNA6_Fwd AGTGTGAGATGGGCTTCACC 20 
FBN2cDNA6_Rev TGTCAAAGGTGAATCCAGGAA 21 
FBN2cDNA7_Fwd ACAAAGAGGATGTGCTGCTG 20 
FBN2cDNA7_Rev GAGCCCTCCAAATTCTGACA 20 
FBN2cDNA8_Fwd GCAACGAGGGTTACGAACTG 20 
FBN2cDNA8_Rev CCAGGCTTAGTCCTGCATTC 20 
FBN2cDNA9_Fwd CTGGACGAGTGTGCTGAGG 19 
FBN2cDNA9_Rev TCTTCACAGTTCAGCCCAGA 20 
FBN2cDNA10_Fwd GTCTCAGCCTTCCCTCTGTG 20 
FBN2cDNA10_Rev GTCGTCCTCATTGTGCTCCT 20 
 
 
6.4.3. Oligonucleotide primers for Fbn2 3’-exon and intron analysis 
Name 5'-3' sequence Size 
Fbn2_Ex62_Fwd TTTGTTCCCATTAAAGGTTGTG 22 
Fbn2_Ex62_Rev GCTTATCCAGACACTGAGGTTG 22 
Fbn2_Ex63_Fwd TTCATCCCCTCTGCCCC 17 
Fbn2_Ex63_Rev GCTGCCTGACCCTGACC 17 
Fbn2_Ex64_Fwd TGCGTCCATGTTTCCTAAAG 20 
Fbn2_Ex64_Fwd CAGGGCCAAGGAACACG 17 
Fbn2_Ex64_Rev CAGGGCCAAGGAACACG 17 
Fbn2_Ex65_Fwd TATCAGTCAATCGCAGGTGG 20 
Fbn2_Ex65_Rev CTTCTGAAGGCCGGCTG 17 
6.4.4. Oligonucleotide primers for Fbn2 intron 62 analysis 
Name 5'-3' sequence Size 
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Fbn2Int_1Fwd AACACGGCTGCCAGAATATC 20 
Fbn2Int_1Rev CCAGGCACGGTAATGTATGTC 21 
Fbn2Int_2Fwd AGGGCTAGGGTTAGCTCAGG 20 
Fbn2Int_2Rev GGGTTTCTTATGGGGAGCAC 20 
Fbn2Int_3Fwd TCGGAATAAATGCTGCTGAC 20 
Fbn2Int_3Rev TGATTGGCTGTTTAACTCAACG 22 
Fbn2Int_4Fwd GACTGCAGGCTTCATGGTTAG 21 
Fbn2Int_4Rev TCCATTTGTCATGGGATGTG 20 
Fbn2Int_5Fwd CTGTGTGCAGCTTGAAGAGG 20 
Fbn2Int_5Rev TCTGCTGTTCTGACGGACAC 20 
Fbn2Int_6Fwd ATCCCTCAGGGTTTCTGCTC 20 
Fbn2Int_6Rev TGCCTTGTTTGGCTATGTTG 20 
Fbn2Int_7Fwd AACGGGCAGCAGATATGAAC 20 
Fbn2Int_7Rev ACCGAAGCGCAGGTATTAG 19 
Fbn2Int_8Fwd TTCGCATATTAAGCAAATGACC 22 
Fbn2Int_8Rev CTTAGCACTTCCCCCAGCTC 20 
Fbn2Int_9Fwd GGGTCCTTTCCTGAATTTCTC 21 
Fbn2Int_9Rev CCACTCTGAAGTACCCTGGTG 21 
 
6.4.5. Fbn2 3’-RACE oligonucleotide primers 
Name 5'-3' sequence Size 
3'-RACE_d(T) GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTT 35 
3'-RACE_adaptor GACTCGAGTCGACATCG 17 
 
6.4.6. Oligonucleotide primers for Isoc1 transcript analysis 
Name 5'-3' sequence Size 
Isoc1_cDNA_Rev TGCACAATTTAAGAATACTTCACCA 25 
Isoc1_cDNA_Fwd CATTAGTGTGGGACAGAGACTGTTGC 26 
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6.4.7. Oligonucleotide primers for Isoc1 intron 5  
Name 5'-3' sequence Size 
Isoc1_Ex5_ampli TCGAGAAGCATGATGGACAG 20 
Isoc1_Ex5_2_Fwd TCCACTCTCTGTGCTTGCAT 20 
Isoc1_Ex5_2_Rev GGGCCCACAGAATCAACTAA 20 
Isoc1_Ex5_3_Fwd GCAGTCCAGTAGGGGGAAG 19 
Isoc1_Ex5_3_Rev ACCTGACCTCACCTGCAGAC 20 
Isoc1_Ex5_4_Fwd GTGCAGTGTCTGCAGGTGAG 20 
Isoc1_Ex5_4_Rev GAGCAGACAAAGTCAGGCAAT 21 
Isoc1_Ex5_5_Fwd GCCAGCTCCCTTTCTTCTTT 20 
Isoc1_Ex5_5_Rev GGGCCTCAGCCATAGACATA 20 
Isoc1Real_6_Fwd GGAACCAGCCTTCCTTTTTC 20 
Isoc1Real_6_Rev TTGAACTTCGGGTGGTCTTT 20 
 
6.4.8. Oligonucleotide primers for genotyping PCR 
Name 5'-3' sequence Size 
Fbn2_FineMap_F AGAAGCACCTTGAGCAGAGC 20 
Fbn2_FineMap_R GCCTTGTTTGGCTATGTTGG 20 
Isoc1Ex5_4_Fwd2 AGGTGATGGTGTGCAGTGTC 20 
 
6.4.9. Oligonucleotide primers for RT-PCR 
Name 5'-3' sequence Size Fluorescent Tag 
18sRNA_Fwd AGATCAAAACCAACCCGGTGA 21  
18sRNA_Rev GGTAAGAGCATCGAGGGGGC 20  
HPRT_QRTPCR_Fwd CTGGTGAAAAGGACCTCTCG 20  
HPRT_QRTPCR_Rev CAAGGGCATATCCAACAACA 20  
SLC27a6_cDNAFwd TGGAATTGGTGGATGTGTTG 20  
SLC27a6_cDNARev CGAAGTTCTCCTGGTCTTGG 20  
 Xbp1_SYBR_Fwd CTGAGTCCGCAGCAGGTG 19  
 Xbp1_SYBR_Rev1 CCAGAATGCCCAAAAGGATA 20  
Xbp-1_Fwd_FAM  TTACGGGAGAAAACTCACGGCC  22 5'-6-FAM   




6.4.10. Oligonucleotide primers for Riboprobe synthesis 
Name 5'-3' sequence Size 
CHX10_T7_Fwd TAATACGACTCACTATAGGGGCAGAGCTGTGATTGGATT 39 
CHX10_T3_Rev AATTAACCCTCACTAAAGGGACAGGTTTGGGGAAGGACT 39 
Isoc1_Fwd_T3 AATTAACCCTCACTAAAGGAACAGATGGGAGTGGTTTGC 39 
Isoc1_Rev_T7 TAATACGACTCACTATAGGAGAGGATTCCCCTCCTTTGA 39 
Fbn2_Fwd_T3 AATTAACCCTCACTAAAGGCAAAAAGGGAAACTCGCTTG 39 
Fbn2_Rev_T7 TAATACGACTCACTATAGGAGGTGTTCCTGCTCAAAGGA 39 
Bip_Riboprobe_Rev_T7  TAATACGACTCACTATAGGTTTCTTCTGGGGCAAATGTC 39 
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